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SUMO, small ubiquitin-like modifier is a versatile protein that modifies a diverse 
spectrum of cellular proteins. SUMOylation is a post-translational modification 
process involves the covalent conjugation of SUMO to its target proteins. 
SUMOylation is found to have critical roles in altering the behaviors of cellular 
molecules, particularly nuclear transport and protein-protein interaction of 
transcriptional factors. It is found to involve in cancer development, which 
prominently demonstrated by its function in maintenance of genome integrity and 
regulation of various cellular processes. Human cervical carcinoma is a major cause 
of death and the second most common among women worldwide, which is found to 
be triggered by human papillomavirus (HPV) infection in over 80% of all cases. The 
disruption of cell cycle and apoptosis control by oncoprotein E6 and E7 is believed to 
be the cause of carcinogenesis in normal cervical epithelium. However, underlying 
mechanism in the host cells during viral infection and after cancer induction remains 
unclear. Involvement of SUMO in cell cycle regulation, apoptosis control and its 
interactions with viral proteins suggest that SUMO may be involved in HPV-positive 
cervical cancers. In order to obtain preliminary insight in how SUMO involves in the 
HPV-induced cancer, the protein expression profiles of HeLa cells are characterized 
iv 
Abstract 
by performing 2-D gel electrophoresis of both the cell lysate conjugated with SUMO 
in vitro and lysate with SUMO overexpressed by transfection. Sixteen potential 
SUMO substrates from the study with in vitro SUMOylation assay; and twenty-one 
related effector proteins from the study with SUMO overexpression in vivo are 
identified with MALDI-TOF MS/MS analysis. 
On the other hand, biarsenical-tetracysteine fluorescent labelling system is a novel 
fluorescent labelling method which allows addition of a small tag on target protein to 
exert specific fluorescence emission. The system can be used in both cellular 
microscopy and in gel electrophoresis investigations, which makes it an ideal method 
in various kinds of SUMO studies, e.g. localization studies and substrate identification 
with SDS-PAGE analysis. However, this system has not yet been utilized in any 

















宮頸癌細胞HeLa細胞的總蛋白進行了試管內SUMO化(h vitro SUMOylation)，以及於 
HeLa細胞內通過過渡性轉染（transient transfection)過度表現SUMO基因°其後以二維 
凝膠電泳（Two-dimensional gel electrophoresis)顯示其與未處理過的HeLa細胞之蛋白質 
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1.1 Small ubiquitin-like modifier (SUMO) and SUMOylation 
Small ubiquitin-like modifier (SUMO) is a family of proteins exerts its effect as a 
post-translational modification by covalent attachment to its target proteins. Owing to 
its analogy of structural and enzymological feature to ubiquitin (Ub), it is classified as 
a member of the ubiquitin-like proteins (Ubl). 
SUMO modification plays important roles in very diverse cellular processes such as 
DNA replication and repair (Hardeland et al., 2002), transcription regulation (Verger et 
al, 2003), nuclear protein transport (Seeler and Dejean, 2003), maintenance of genome 
integrity (Mao et al., 2000), protein subcellular localization (Hamard et al, 2007) and 
cell cycle control (Lee et al., 2006). 
Since its discovery in 1996 simultaneously by several independent investigators 
(Boddy et al, 1996; Mahajan et al., 1997), it has now been developed into a key-topic 
in cancer research arena due to its universal and crucial cellular functions. It acts on 
substrates which are critical in cancer development, such as tumor suppressors p53, 
pRb, c-jun, PML and Daxx. (Muller et al., 2000; Ledl et al, 2005; Kamitani et al, 
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1998; Lalioti et al, 2002) and gives intriguing but still obscure biological functions. 
1.1.1 Ubiquitin，Ubiquitin-like proteins and SUMO isoforms 
Ubiquitin is a 76-amino acid (a.a.) protein conserved among different species, which is 
well known of targeting its substrate protein to degradation through 26S proteasome 
pathway (Hershko and Ciechanover, 1998). Ubiquitin is added to the target proteins as 
a post-translational modification. Post-translational modifications are important for the 
dynamic regulation of protein function or activity, especially when the modification is 
exerted through organic polypeptides, i.e. ubiquitin (lib) and ubiquitin-like proteins 
(Ubl). Ubls are those possess similar protein fold as well as the enzymatic scheme. All 
Ubls share the same enzymatic scheme which consist of a ubiquitin-activating enzyme, 
El, a ubiquitin-conjugating enzyme, E2, and a ubiquitin protein ligase, E3. It 
eventually conjugates the Ubl to its target protein at the 8-amino group of a specific 
lysine residue (Hershko et al, 1983) (Fig. 1.1.2). All Ubls also consist of a regulatory 
system by their deconjugating enzymes, which allows the Ubls be removed from their 
substrates (Yin et al., 2000). This signature feature allows conjugation and 
deconjugation happen in a dynamic mode. Despite of the analogy of three dimensional 
conformation between Ub and Ubl, and the similarity of their enzyme system; all of the 
Ubls do not target their substrates to degradation. They instead convey other kinds of 
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important functional changes regarding transcriptional control, apoptosis, stress 
response and immune responses (Welchman et cd., 2005). Among the Ubls, SUMOs 
are discovered to have the most versatile or universal involvement in cellular 
biochemistry, which makes its identity more ambiguous and intriguing. 
In Saccharomyces cerevisiae and other lowers eukaryotes, SUMO exists as a single 
species (Smt3). It however exists as a family of 4 isoforms in mammals and human: 
SUMO-1, SUMO-2, SUMO-3 and SUMO-4 (Dohmen, 2004). All of the isoforms are 
different in terms of their structures, cellular abundance as well as functions 
(Fig.l.l.l). 
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Figure 1.1.1 Comparsion of three dimensional structure between SUMO-1 and Ubiquitin 
(A) and the primary sequence alignment of Ubiquitin, the three isoforms of human 
SUMOs and Saccharomyces cerevisiae homolog Smt3 (B). (Colour code: Dark blue, residues 
at the position are identical; Light blue, residues at the position are with chemical property 
conserved; Violet, residues at the position are identical in at least three of the SUMO analogs.) 
(Johnson et al.,2004). 
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SUMO-1 is the primitive isoform discovered in mammalian cells which comprising 
only a 18% amino acid sequence homology to ubiquitin (Saitoh et aL, 1997). Despite 
SUMO-1 has a strikingly similar protein fold to Ub, the surface charge topology of 
SUMO is significantly different from that of Ub (Bayer et aL, 1998) (Fig. 1.1.1). It was 
found to localize in the nucleus ubiquitously in different types of cells and generally 
stay in the conjugated form to substrate proteins (Hoege et al., 2002). 
SUMO-2 and SUMO-3 share only a sequence identity with SUMO-1 of -48% and 
�46o/o respectively, however they are very similar to each other in both their amino 
acid sequence (-97%) and protein fold. SUMO-2 and SUMO-3 were found to have 
higher cellular abundance than SUMO-1 and exist as free (non-conjugated) form 
within cells than SUMO-1 (Johnson, 2004). Under different cellular stresses such as 
heat shock and oxidative stress (Saitoh and Hinchey, 2000), SUMO-2 and -3 were 
found shifting from free form to conjugated form. In addition, existing proteomic 
analysis has revealed that the substrate specificity of SUMO-2 and -3 are different 
from SUMO-1 (Vertegaal et al, 2006). 
SUMO-4 has a predicted 86% amino acid homology with SUMO-2. It expresses only 
mainly in kidney, lymph and spleen and is distinct from other three isoforms by an 
amino acid polymorphism M55V (Bohren et al., 2004). It cannot be hydrolyzed to its 
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mature active form by the existing SUMO proteases (Section 1.1.3) and form covalent 
interactions with its substrates, which might instead exert effects through non-covalent 
interaction with its target proteins (Owerbach et al, 2005). 
1.1.2 SUMO cycle 
SUMO's interaction with its substrates has been long compared to the Ub system, 
however, not until recent years have researches put the emphasis on the dynamic nature 
of SUMO-substrate interaction (Dohmen, 2004). 
1.1.2.1 SUMO conjugation consensus sequence 
Like all Ubls，SUMO is covalently linked to a variety of proteins via an isopeptide 
bond between the C-terminal carboxyl group of SUMO and the e-amino group of a 
specific lysine in the substrate. Though analogous, SUMO has a unique enzyme system 
which is completely specific (Desterro et al, 1997). It has long been wondered to have 
a specific consensus amino acid sequence that distinguishes SUMO substrates from the 
‘ h u g e pool of cellular proteins by its specific enzyme system. The most commonly 
agreed consensus sequence is ^KXE, in which 平 represents a hydrophobic residue, 
and X is any residue (Sampson et al,, 2001). This minimal core motif can actually be 
found in over one third of all characterized proteins, suggesting a high chance of false 
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positive prediction, which has also been encountered by different SUMO substrate 
discovery studies (Johnson, 2004). The consensus sequence is sometimes referred to as 
SUMO Binding Motif (SBM). Due to its limited specificity, other possible motifs have 
recently reported (Song et al., 2004; Hietakangas et al, 2006; Yang et al, 2006). 
In SUMO-2, SUMO-3 and SUMO-4, an intrinsic SBM exists which allows 
poly-SUMOylation occur (Tatham et al.’ 2001). In various in vitro studies, 
poly-SUMOylation was observed (Gocke et al, 2005), however the function of poly 
SUMO chain attachment was not well-studied in vivo. On the other hand, SUMO-1 
was found to form polymeric chains recently despite it lacks an intrinsic SBM (Yang et 
al., 2006). 
7.7.2.2 SUMO maturation 
SUMO is synthesized in a precursor form inactivated by a C-terminal tail. It is 
processed by SUMO proteases into mature form with its di-glycine motif near the 
C-terminal exposed for conjugation. SUMO proteases are also responsible for the 
deconjugation of SUMO from their substrates (Section 1.1.2.4). They are regarded as 
SUMO precursor processing enzymes as well as SUMO deconjugation enzymes. It is 
suggested that the maturation step is critical as it determines the level of cellular active 
SUMO available for conjugation which remains to be elucidated. 
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1.1.2.3 SUMO conjugation cascade 
SUMOylation describes the enzymatic conjugation of SUMO to its target substrates. 
As mentioned, SUMO conjugation system consists of a set of enzymes distincts from 
the ubiquitin system. It consists of three types of enzymes, namely SUMO-activating 
enzyme (El), SUMO-conjugating enzyme (E2) and SUMO ligases (E3). 
SUMO El enzyme is a heterodimer consisting of two asymmetric subunits: SAEl 
(Aosl) and SAE2 (Uba2). The C-terminal of Uba2 is of high similarity to the 
ubiquitin-activating enzyme Ubal, however, Ub El cannot activate SUMO, so as vice 
versa (Lois and Lima, 2005). This ATP-dependent enzyme reaction forms a thioester 
bond between a cysteine active site in the subunit of Uba2 and the C-terminus of the 
mature form SUMO (Johnson, 2004). Activated SUMO is then transferred to a cysteine 
in the E2 conjugating enzyme (Ubc9) and forms a SUM0-E2 thioester intermediate. 
This intermediate is acting as the SUMO donor in the reaction in which SUMO is 
transferred to the 8-amino group of a lysine of the substrate. It is worth to note that 
“there is only one single E2 in the SUMO system and thus, the E2 is not redundant as in 
the ubiquitin system. E2 binds directly to the consensus sequence of the substrate 
(Tatham et al., 2003) and also to the SUMO molecule using different binding sites. 
Cys93 is the active site for SUMO thioester bond formation, while residues 
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surrounding Cys93 in the three dimensional structure has been demonstrated to be 
capable of identifying the SUMOylation consensus sequence (Bemier-Villamor et al, 
2002). Therefore E2 is believed to be responsible for substrate identification despite of 
its small size. SUMOylation was found to be achievable with only the participation of 
El and E2 in vitro (Desterro et al., 1999)，however distinct types of SUMO ligases (E3) 
have been discovered recently (Schmidt and Mueller, 2003). These E3s participate in 
the reaction by acting as a dock or platform for the SUMO-E2 complex and the 
substrate, bringing them into closer vicinity and thus lowering down the 
thermodynamic barrier of the whole reaction. It was found to participate in 
coordinating the E2-SUMO-thioester optimally for substrate binding and catalysis. 
These catalytic features make it classified an ligase in SUMOylation (Reverter and 
Lima, 2005). 
There are three distinct types of SUMO E3 ligases: RanBP2/Nup358 domain type 
(Pichler et cd•，2002), Polycomb group protein Pc2 (Shuai, 2000) and the most well 
studied Protein Inhibitor of Activated STAT (PIAS) family (Hochstrasser, 2001). All 
these three classes of proteins were shown to promote the transfer of SUMO from E2 
to substrate in vitro. However, only the PIAS family appears to resemble the 
RING-type ligase in the ubiquitin system (Pichler et al, 2004; Kagey et al, 2003; 
Schmidt and Mueller, 2003) while differ in important aspects. PIAS family has five 
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member isoforms: PIASl, PIASxa, PIASx(3，PIASy and PIAS3. All differs at the 
C-terminal region which involves in substrate binding. E3s can significantly increase 
the efficiency of SUMOylation (Johnson and Gupta, 2001). Several studies 
demonstrated that different PIAS isoforms bind a specific set of SUMO substrates 
(Kahyo et aL, 2001; Miyauchi et al, 2002). Moreover, the PIASx and PIASy subtypes 
are found to have differential tissue expression (Gross et aL, 2001). It is suggested that 
they promote specific SUMO isoforms for their specific substrates (Sachdev et al., 
2001) and are responsible for vital cellular processes such as the p53 pathway, 
transcriptional control and Wnt signalling (Schmidt and Mueller, 2003). 
1.1.2.4 SUMO deconjugation 
Pattern of SUMO conjugates is dynamic and changes in response to different cellular 
stimuli (Sapetschnig et cd., 2002) by the coordination of SUMO ligases and SUMO 
proteases. They enable the cleavage of SUMO from the substrate which allows 
SUMOylation to be reversible. SUMO proteases are hydrolases with dual function: 
- they facilitate the maturation of SUMO by cleavage of C-terminal at the diglycine 
motif; and perform deconjugation, releasing SUMO to the physiological pool. SUMO 
proteases are vital cellular structures in which knockdown studies showed increased 
cell death (Lee et al,, 2006). There are seven discovered SUMO proteases, and all 
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SUMO proteases have a conserved Ulp domain at the C-terminal while being different 
at the N-terminal, in which the difference suggests they might have different substrate 
specificity. Earlier discovered proteases include SENPl (Bailey and O'Hare, 2002) and 
SENP2 (Best et al., 2002) which accumulate in nucleus, while SENP3 localizes in the 
nucleolus (Nishida et al., 2000), SENP5 was recently showed to localize in the 
nucleolus and decrease the level of SUMO conjugates in order to facilitate normal cell 
division process and maintain mitochondrial function (Di Bacco et al., 2006; Zunino et 
al., 2007). SENP6 (SUSPl) on the other hand was shown to localize in cytoplasm and 
interestingly abundant in tissues of reproductive organs (Kim et al., 2000). However, 
the last SUMO protease SENP7 was yet to be characterized. 
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Figure 1.1.2 SUMO conjugation/deconjugation cycle. The figure indicated the dynamic 
nature of SUMO attachment to target proteins. Maturation of SUMO molecule is done by the 
SUMO specific proteases as the first step of the enzymatic cascade. Conjugation is achieved by 
El (SAE1/SAE2), E2 (Ubc9) together with E3 ligases e.g. PIAS, RanBP2. The conjugated 
protein have its function and/or localization altered to mediate downstream effects of 
SUMOylation. The system's regulation is achieved with the SUMO specific proteases by 
detaching SUMO from target proteins. 
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1.1.3 Mode of SUMO action 
SUMO exerts its effect on proteins through mainly three ways: (1) increasing target 
protein's stability through antagonizing the effect of ubiquitination, (2) altering target's 
subcellular localization by modulating its cellular trafficking properties and (3) altering 
target's interactions with its partner proteins (Johnson, 2004). These effects on its target 
protein can be reversed by the deconjugation with SUMO proteases, which offers a 
dynamic nature to SUMOylation. This allows SUMOylation to take place at specific 
time and place to achieve more precise and delicate functions. As a result, the amount 
of SUMOylated proteins is in a dynamic state, depending upon the ultimate 
equilibrium between the rate of SUMO conjugation and deconjugation. However, it is 
interesting to note that for a portion of substrates, the effect of SUMO is permanent 
disregard whether the SUMO is still attaching to the substrate or not. Thus 
consequently biological consequences of SUMOylation inside a cell are not 
proportional to the overall levels of sumoylated proteins (Hay et al, 2005). 
Apart from covalently conjugated to target proteins, SUMO was found to exert effects 
on its "substrates" non-covalently. Non-covalent interaction of SUMO with its target 
partners is necessary for the establishment of the later formed covalent bonding in 
some particular substrates, e.g. Daxx (Lin et al., 2006) and Thymine-DNA glycosylase 
(TDG) (Takahashi et cd” 2005). Thus, non-covalent interaction has been proposed to 
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change the protein conformation for easier conjugation of SUMO (Lin et al., 2006). 
1.1.4 Biological functions of SUMO 
Investigations of how SUMO affects different biological processes develop rapidly in 
recent years. However, some features regarding physiological SUMO's behaviour 
make functional analysis a challenging topic: low levels of modification, severe 
protease activity in native lysates, complicated unknown interactions with different 
proteins, dynamic nature of SUMOylation, and unknown regulation of SUMOylation. 
Experiments used to study the function of SUMOylation including mutagenesis studies 
of SUMOylation sites of target substrates, overexpression or siRNA silencing of 
SUMO or SUMO enzymes in cells. 
The biological function of SUMO is found to be very diverse, generally it modifies the 
function, subcellular localization and the protein-protein interaction of the target 
protein. Taken together the available study reports on SUMO, three general aspects of 
SUMO-mediated consequences can be drawn: (1) SUMOylation diverts signal 
transduction and alters transcription activity and protein cellular level and activity 
(Shaulian and Karin, 2002). It interacts directly with an ever-growing list of 
transcription factors, eg c-jun and c-fos, SRF and Elk-1 (Matsuzaki et al, 2003; Yang 
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et al, 2003; Muller et al, 2000) which modulates the transcription and DNA 
expression level by both coactivation (Um et al., 1998) and corepression eg 
CAAT-enhancer-binding protein C/EBPa (Eaton and Sealy, 2003; Subramanian et al., 
2003). (2) It interacts with nuclear bodies, nuclear import machinery and the 
cy to skeleton which facilitates protein subcellular localization and trafficking, eg 
RanGAPl, key regulator of nuclear import machinery (Matunis et a/., 1996; Mahajan et 
<3/.，1997) and PML nuclear bodies (Muller et al, 1998). (3) It also acts on the DNA 
replication machinery, eg Topoisomerase I (Horie et al, 2002) and DNA repairing 
system, e.g. TDG (Hardeland et al., 2002) and Proliferating cell nuclear antigen 
(PCNA) (Stelter et al., 2003). These evidences consequently make SUMO responsible 
for maintaining the genome integrity and molecular orderliness (Mao et al, 2000). 
In conclusion, the modifier works as a monitor for coordinating and maintaining the 
whole order within a cell. Despite of its diversity of physiological consequences, most 
of the cellular effects discovered up-to-date are nuclear-oriented. 
-1.1.4.1 SUMO in cancer 
Due to the fact that SUMO has intensive interplay between various regulatory cellular 
proteins, it is from the beginning expected to play key roles in the control of gene 
activation, transcriptional control, genome and DNA protection as well as the response 
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to different cellular stresses (Seeler and Dejean, 2003). These roles give SUMO the 
responsibility to be a cancer warrior, which involves in important defence mechanism 
of DNA mutation and cancer formation. Furthermore, the list of SUMOylation 
substrates consists of sets of oncogenes and tumor suppressor genes (Alarcon-Vargas 
and Ronai, 2002). The role of SUMO in cancer formation seems more obvious and 
direct. However, the effects of SUMO inside the cells are complex to conclude a 
general working principle in cancer biochemistry. Despite of the role of SUMO 
appears to be pluripotent, its interaction with viral proteins has been a rising interest in 
the field (Boggio and Chiocca, 2006). 
Whilst one of the effective strategies battling with cancer is to prevent cells from 
undergoing tumorigenesis, efforts have been made in studying the relationship between 
SUMOylation and tumorigenesis process (Kim and Baek, 2006). It is now believed 
that alteration of gene expression of components in SUMOylation system is related to 
tumorigenesis. The mRNA level of Ubc9 was reported to be upregulated in human 
ovarian cancer, adenocarcinomas and prostate cancer (Mo and Moschos, 2005; 
McDoniels-Silvers et cd., 2002, Kim et al, 2006). Furthermore, the protein level of 
Ubc9 and SUMO-1 were found highly upregulated in response to long term low dose 
radiation in premalignant conditions in a clinical study (Romanenko et al., 2006). It 
has also been reported that SUMOylation of p53 with SUMO-2/3 increased premature 
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cell senescence while a mutation of SUMO prevents senescence process (Li et al., 
2006). It is likely that SUMO involves in cancer biochemistry in a very complex way 
with the regulation and participation of various kinds of regulators of cellular processes. 
The elucidation of the upstream signals modulating SUMOylation and its downstream 
effects by genomic and proteomic approaches are important in order to provide more 
comprehensive information of the relationship between SUMO and cancer. 
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1.2 Human cervical cancer and human papillomavirus (HPV) 
Cervical cancer is a major cause of death and the second most common type of 
life-threatening cancer among women worldwide (Behtash and Mehrdad, 2006). There 
are different risk factors contribute to the prevalence of the cancer, e.g. strong family 
history, multiparity, smoking (tobacco), long-term oral contraceptive use (American 
Cancer Society, 2006) and HPV infection. Amongst one of the strongest risk factors is 
infection of HPV (Walboomers et al； 1999). 
HPVs are a group of double-stranded DNA viruses which belong to the family of 
Papillomaviridae. Two main HPV genera are classified at evolutionary level and there 
are over 100 subtypes of HPVs identified according to their specific DNA 
characteristics (Bernard, 2005). Each type of HPV has a unique mode of action and 
causes infection at specific epithelial sites, however generally at mucosal layers of 
gastrointestinal tract, genital tracts and epithelial layers of the skin (Villiers et al, 2004). 
HPVs can further be subdivided into three categories: high risk, low risk and cutaneous, 
-depending on their frequency of causing both squamous cell carcinoma and 
adenocarcinoma type of cervical cancers. More than 30 different HPV subtypes infect 
the epithelium of cervix, amongst HPV-16 and -18 are the most prevalent high-risk 
HPVs. DNA of these high-risk HPVs can be found in more than 99.7% of the 
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carcinoma cells (Doorbar, 2006). 
1.2.1 Infectious cycle of HPV-16 
1.2.1.1 Viral entry 
Infection by HPV is due to wounds in the epithelium which expose basal layer cells to 
possible viral entry. Viral entry is initiated by the interaction of major capsid protein LI 
with heparin sulphate proteoglycans on the cell surface (Shafti-keramat et al, 2003). 
The virion is then internalized through endocytosis via a specific receptor, whose 
identity is currently unknown. The minor capsid protein L2 then disrupts the endosome 
membrane to allow the viral genome import into the host cell nucleus by the carriage 
ofL2 itself (Yang et al., 2003). 
1.2.1.2 Maintenance 
HPVs are nonenveloped viruses that require exploiting the host nuclei for genome 
replication. At the early stage of infection, the viral genome is maintained as an 
episome, acting as a reservoir of copies without integrating into the host genome 
within the basal layer cells (Howley et al., 1996). The initiation of viral DNA 
replication is accomplished with two early proteins El and E2. El binds to the viral 
origin of replication and recruits DNA polymerases and accessory proteins for 
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replication. E2 binds to El to ascot it to the viral origin and it is a transcription factor 
itself for regulating the early promoter, which is crucial for the expression control of 
viral oncogenes E6 and E7. At low level of E2, it acts as an activator for E6 and E7 
transcription; while at high level, it acts as a repressor at the early viral promoter to 
suppress the early gene transcription as a feedback control. The viral genome is 
maintained at a stable copy number within the basal layer cells without triggering 
response of the host immune system (Longworth and Laimin, 2004). 
1.2.1.3 Deregulation of cell cycle 
Cell proliferation is stimulated by the expression of oncogenes E6 and E7 through 
deregulating the cell cycle. In uninfected cells, retinoblastoma protein (pRb) is tightly 
bound to the E2F family of transcription factors. Cell cycle is triggered by the binding 
of external growth to cyclinD/cdk4 complex, which in turn phosphorylates pRb. 
Phosphorylated pRb will detach from E2F and allows E2F to transactivate a group of 
genes e.g. pi6, PCNA，pHArf and cyclin E, which involved in normal S-phase 
progression, p i6 serves a feedback control of the S-phase proteins by regulating the 
level of active cyclin/cdk in the cell. On the other hand, pl4Arf regulates the activity of 
MDM2 ubiquitin ligase, which in turn maintaining sufficient level of p53 for cell cycle 
arrest and apoptosis (Doorbar, 2005). 
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In infected cells, E7 instead of external growth factor triggers the cell cycle 
progression by binding to pRb, persistently releasing the E2F for transactivation of all 
S-phase proteins (Jones et cd., 1997). Feedback control of pi6 is invalid as the 
stimulation is not mediated by cyclin/cdk. Therefore the S-phase proteins are highly 
upregulated. High level pl4Arf causes inactivation of MDM ubiquitin ligase and 
consequently p53 escapes from degradation. The viral E6 protein however further 
counteract this control mechanism by association with E6AP ubiquitin ligase, achieve a 
mass degradation of p53 to prevent the cell from entering senescence, cell cycle arrest 
or apoptotic pathway (Matsumoto et al., 2006) (Fig. 1.2.1). 
1.2.1.4 Amplification and virion release 
Maintenance of virion copies at the basal layer cells will move upwards the layers of 
cells as the cells differentiate. Upregulation of differentiation-dependent promoter 
triggers an increase of expression of viral proteins (Spink and Laimin, 2005). Capsid 
proteins LI and L2 also accumulate after the onset of genome amplification. Viral 
'assembly occurs when E2 enhances the efficiency of encapsidation. (Zhao et al, 2000) 
The packed infectious virion particles are finally released from the comified envelop 
through the disruption of keratin network by E4 protein (Doorbar et al., 1991). 
20 
Chapter I 
High Risk HPV Infection 
/ — — — — — — — — • — — — — — — — — — — — — — — 
/ ？ I � ! 
- " T ^ � ！ 
f r p # I 
I • Trantadivation ! 
j • p i s H ^ ！ 
j PCNA <>••>•• I 
_ ^ dcQTsdlJilion ICI67 • 
MM liMCthrfttion S-phMe ！ 
！ ) 圏 寺 u m “肝 p roQT一 I 
• J Cyctln E | 
j / \ I 
• • Low 17 »«ghE7 j 
I B 激 ^ i 
I |»21. ETand cyol^ n t p2l • E7 form a compl«L| 
I form a complex. C^ cWn E ^ k p21 Inocttvalod. | 
I in«otilv« and pr«Mnt ai CyeNn E/edk Mttva and | 
I Mgh l«v«la praa^nt at low tovvis • 
I CELL C Y C L E S - P I M S E 痛 
I jpWOQRESSION STALUED PWOQWESStOU • 
I • 姆 • 籍 • 麵 • 一 藝 賴 脚 冊 — 面 — 
Figure 1.2.1 Cell-cycle progression dysregulation in HPV-infected cells. In normal cells, 
cell cycle is tightly regulated by the feedback control. MDM2 regulates the cellular level of 
p53 and it is in turn regulated by pl4 ARF. On the other hand, pi6 is responsible to establish 
feedback control on the activity of cyclin/cdk at the beginning of the cell cycle regulation 
cascade. However, in HPV infected cells, the detachment of E2F is not mediated by cyclin/cdk 
complex but by the oncoprotein E7. This disabled the negative feedback control of pRb 
,activation which mediated by pi6 on its inhibiting factor E2F. This results a continuous 
activation of the S-phase proteins in the grey box. On the other hand, E6 oncoprotein mediates 
massive degradation of p53 which causes decrease in the level of MDM2 and destroyed p53 
level regulation (Doorbar, 2006). 
21 
Chapter I 
1.2.2 Viral cancer induction 
1.2,2.1 Integration into the host genome 
The amplification of viral genome is paradoxically a time-point when the virus life 
cycle control is disrupted in which the viral DNA is integrated into the host genome. 
This is not favourable for the vims since this represents the abolishment of production 
of infectious virions. This uncontrolled manner of infection cycle occurs when the 
onset of late events is retarded with unknown signalling mechanism (Middleton et al,, 
2003). Insufficient LI and L2 proteins cannot support sufficiently fast virion packaging 
and might result in a higher chance of host genome integration. The molecular 
mechanism for retardation of late gene expression and viral genome integration into 
the host genome is still unclear. Genome integration intriguingly occurs within the E2 
ORF frequently, which results in a loss of E2 repressive action and confers a 
continuous stimulation of S-phase proteins and thus cell proliferation by E7. As 
p53-mediated DNA repair pathway is blocked by E6, accumulation of aberrations in 




1.2.2.2 Viral oncoproteins E6 and E7 
E6 acts as an anti-apoptotic protein in the viral carcinogenesis. It also mediates 
immortalization through the binding to PDZ motif containing proteins and abolishes 
the cell-cell contact mediated by tight junctions (Nakagawa and Huibregtse, 2000). Its 
ability to activate the catalytic subunit of telomerase hTERT further prevents the 
shortening of telomeres for cell senescence (Klingelhutz et al., 1996). E7 protein 
causes the critical disturbance in the cell cycle control, in addition induces centrosomal 
abnormalities and increases error rate during cell division (Duensing and Munger, 
2004). 
Despite the productions of genome aberrations induced by oncoproteins E6 and E7 
leads to the development of cervical cancer, their expression alone is not considered to 
be sufficient for transformation of a normal cell to an immortal one (Munger et 
a/., 1989). While there are still a lot of questions behind the mechanisms about the loss 
of control of normal viral life cycle and host genome integration, future studies on the 
-carcinogenesis by HPV in cervical tissues are required. 
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1.2.3 SUMOylation and HPV 
1.2.3.1 Known examples of virus-host SUMOylation system interaction 
Viruses have evolved with their strategies to interact with the host cellular systems in 
order to aid their survival. A type of well established interaction is the modulation of 
viral protein function by exploiting the various post-translational modification systems 
in host cells. SUMO has been found to interact with viral proteins in a crucial way 
recently (Boggio and Chiocca, 2006). 
Studies of viral interaction with SUMO revealed the direct SUMOylation of viral 
protein, including the early-immediate proteins (Els) of different types of virus 
affecting viral genome replication and virulence. Cytomegalovirus (CMV) lEs are 
potent transcriptional activators localizing in the nuclear domain 10 (NDIO). The CMV 
IE2 is a classical SUMO substrate. Two SUMOylation sites are found in CMV IE2: 
lysines 175 and 180. An E2 double mutant transfection experiment showed a 5 to 
10-fold reduction of transactivation of CMV promoters (Hofmann et al” 2000). On the 
‘other hand, CMV lEl is a SUMO substrate as well, which its expression 
downregulates the SUMOylation of both NDIO and PML (Muller and Dejean, 1999). 
In bovine papillomavirus (BPV) and HPV, mutation study of the El protein showed 
that El without conjugating to SUMO was not able to accumulate in the nucleus and 
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resulted in a loss of replication capacity (Rangasamy et al., 2000). Its SUMOylation 
site locates at the region which is important for its helicase activity (MacPherson et al., 
1994)，its interaction with E2 and oligomerization (Titolo et al., 1999 and 2000). This 
strongly suggests that SUMO attachment will affect various functions of El in the 
regulation of DNA replication. 
The promyelocytic leukaemia protein (PML), an essential component of NDlOs, is also 
a SUMO substrate. Interestingly, there are some viral proteins reduce the 
SUMOylation of PML. The Epstein Barr virus (EBV) Z protein consists of a 
SUMOylation site and it reduces PML SUMOylation by competitive inhibition 
(Adamson and Kenney, 2001). Whilst the herpes simplex virus (HSV) ICPO protein 
also can downregulate PML SUMOylation, though not by competitive inhibition 
(Parkinson and Everett, 2000). PML SUMOylation is required for the assembly of 
NDIO and the recruitment of other NDlO-related proteins for PML nuclear body (NB) 
formation (Ishov et al, 1999). Intriguingly, PML NB is required for p53 activation and 
nuclear import (Pampin et al, 2006). Obviously the lEs of certain viruses employ the 
nuclear import proteins as a way to trespass the nucleus barrier for their replication and 
survival (Burkham et al., 2001). 
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1.2.3.2 Other possible mode of virus-SUMO interaction 
Apart from being SUMOylated, several viral proteins were found to have SUMO 
protease activity that mimics SENPs. An intriguing example is the YopJ protein of 
Y. perstis (Orth et al, 2000). It is a virulence factor inhibits MAPK pathway. Its 
expression downregulates the level of SUMO conjugates inside the cells. Mutagenesis 
study shows that the inability to downregulate the level of SUMO conjugates results in 
the failure to inhibit the MAPK pathway and consequently the virulence is attenuated. 
Section 1.2.3.1 illustrates that direct SUMO modification of viral proteins can exert the 
effect on their intracellular localization which favours virus survival, subtle interfaces 
can be seen between the viral proteins and the host SUMOylation system, eg PML. 
Besides, there are proteins exist as a common interaction target of SUMO and viral 
proteins, particularly in HPV, e.g. the tumor suppressor p53 (Melchior and Hengst, 
2002), pRb (Ledl et al., 2005) and histone deacetylases (HDACs) (David et al, 2002). 
Viral lEs are critical for its virulence and the ability for it to facilitate productive 
replication, and in the case for high risk HPVs additionally involve in cancer induction 
process. There are still unknown mechanisms behind the onset of delay of late events, 
the synchronization of epithelial cell differentiation and viral life cycle and the exact 




From the current knowledge, the effects of SUMOylation on viral proteins appears to 
be target specific, however, additionally suggest there are subtle and obscure functional 
consequences on the viral life cycle which are worth to be explored. 
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1.3 A novel labelling method: biarsenical-tetracysteine labelling in SUMO 
study 
Biarsenical-tetracysteine labelling system is firstly developed by Tsien and his 
colleagues in 1998 (Griffin et al, 1998). In this fluorescent labelling system, a 
synthesized peptide domain which contains four cysteines organized in a way to 
achieve an ultra high affinity to biarsenical ligands (C-C-P-G-C-C). Arsenicals forms 
reversible covalent bonds with pairs of thiols exist in closely spaced cysteine pairs of 
cellular proteins, which confer fatal toxicity of arsenic compounds. Taking the 
advantage of this binding mechanism, the tetracysteine (4Cys) peptide was designed to 
achieve a higher affinity to the biarsenicals (2As) than both the cellular dithiols and its 
antidote 1,2-ethanedithiol (EDT). 
The biarsencial ligand that used as a dye molecule binding to the 4Cys peptide is a 
modified fluorescein molecule: FlAsH-EDTi. It is natively a non-fluorescent molecule 
when associates with EDT, but becomes brightly fluorescent when its two arsenic 
molecules (2As) bound to the two pairs of thiols in cysteines on the 4Cys peptide 
(Fig. 1.3.2). The fluorescence emission can be detected at 528 nm with excitation at 
508 nm which is observed as a green colour. The 4Cys peptide is a very small peptide 
with only approximately 6-12 amino acids residues. It consists of a motif 
C-C-P-G-C-C, which forms a hairpin loop between the cysteines to achieve a spacing 
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matching the arsenicals of FIASH-EDT2. Its small size enables it to be genetically 
engineered to any recombinant proteins at either the N-terminus or C-terminus and 
even within an a-helix. 
As it is only 6-12 a.a. long, it is far more favourable than the existing fluorescent 
labelling molecule green fluorescent protein (GFP), which is approximately 40 kDa in 
size. The large size of GFP has been along questioned to cause sterical hindrance in 
normal cellular protein-protein interactions if any, which may not reflect the genuine 
physiological phenomena. On the other hand, owing to its engineered properties, 
specificity over the cellular thiols can be achieved. 2As-4Cys system is currently the 
only system that offers single protein specific fluorescent labelling apart from the 
conventional GFP system and the antigen-antibody interaction system. 
^ x p Labelling 
kyj before gel or o x ^ y x o 
SUMO with Non-fluorescent ex Fluorescent 
4Cys tag biarsenical dye 4Cys-biarsenical 
(FIAsh) dye complex 
Figure 1.3.1 Figure illustrating the binding arrangement of 4Cys tag and the biarsenical 
dye. Two arsenic atoms (in red) are present on the biarsenical dye molecule. Two -SH 
molecules (in yellow) on each of the arsenic atom binds to the pair of —SH on the cysteines on 
the tetracysteine tag and forms covalent disulphide bridges. The tag-dye complex can be 
excited by 508 nm laser and eventually emits green fluorescence. 
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Figure 1.3.2 Spectrophotometric properties of the Lumio^M labeling dye. Upper panel, the 
chemical formula of Lumio™ Green (FlAsH) and Lumio™ Red (ReAsH) (Zhang et al, 2002); 
Lower panel, the exitation and emission spectra of both fluorescent dyes (User manual of 
Lumio ™In-cell Labeling Kits 2005 version C 25-0770, Invitrogen ^'^Corp.). 
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1.3.1 Potential use of 2As-4Cys system in SUMO studies 
Study of SUMO since its discovery has been focusing on the elucidation of its 
mechanism of action, the identity and function of its substrate (Seeler and Dejean, 
2003). 2As-4Cys labeling system enables the specific fluorescent tagging of SUMO, 
which allows convenient localization studies by fluorescent microscopy and even 
protein tracking in vivo. On the other hand, the system allows easier substrate 
confirmation by fluorescent visualization in in vitro SUMOylation assays. It is a 
potential labeling system which can apply to two-dimensional electrophoresis which 
resembles the DIGE technology (Section 1.3.2). 
1.3.2 Potential use of 2As-4Cys system in SUMO proteomics 
At present，this labelling system has been applied in fluorescent microscopy and 
real-time protein synthesis monitoring (Rudner et al., 2005; Andresen et al., 2004), 
while its potential use in two-dimensional electrophoresis (2-DE) has not been 
validated. Conventional proteomic studies rely heavily on 2-DE protein separation. 
Alternative methods such as the liquid chromatographic separation of digested protein 
lysates to peptide mixtures (LC/MS), however will need specialization of expensive 
equipments and high computational power machines for analysis purpose. 
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Different methods have been evolved to detect the proteins separated by 2-DE. Usually 
a pool of crude protein lysate will be separated by 2-DE, in which the protein loading 
is restricted from the beginning of the first dimension separation isoelectric focusing 
(lEF). Therefore the sensitivity of detection is demanded at least in the order of 
magnitude of nanogram level. Silver staining is a common method used to achieve this 
detection threshold. Common silver staining protocol offers a threshold of 10 ng 
protein detection. However, ordinary silver staining cannot give its subproteome 
directly. Subproteome can be achieved either by a pre-2-DE immunoprecipitation or a 
post-2-DE western immunoblotting. 
Currently specific labelling on a target protein for 2-DE is restricted to radioactive 
labelling or stable isotopic labelling (Poznanovic et al, 2005; Vertegaal et al., 2006). 
Specific fluorescent labelling has been evolved in the area of cell microscopy after the 
discovery and performance optimization of GFP (Tsien, 1998)，but not in the subject of 
2-DE. Fluorescent labelling in 2-DE to date limited to gel-to-gel differentiation e.g. 
DIGE or is aiming at the improvement of the precision and sensitivity of protein 
detection on the gels. It has not been used to achieve specific labelling of a single 
target protein. Therefore, there are no options available for substrate hunting. 
Nonetheless, specific fluorescent labelling of SUMO in 2-DE proteomics is very 
valuable as it can directly reveal its covalently linked interacting partners in complex 
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cellular extracts. This can minimize the discrepancies aroused by complex 
manipulation before or after 2-DE and at the same time boost up the detection 
precision and sensitivity. Nowadays the proteomics study of SUMO substrates is 
greatly hampered by the native low abundance of such conjugates inside cells and the 
load limit of 2-DE. Fluorescence detection can offer a better sensitivity which 
hopefully can reveal more of SUMO conjugated proteins. The birth of 2As-4Cys 
labelling system which is compatible with electrophoresis condition is an inspiration 
for us to make the attempt to compromise conditions of 2-DE with this specific 
fluorescent labelling system. 
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1.4 Objectives of the present study 
As mentioned in the entire introduction, SUMO plays key roles in the control of gene 
activation, protein localization and responses to cellular stresses, providing adequate 
genome repair and cellular integrity (Seeler and Dejean, 2003). It is also an intriguing 
player in viral cancer formation process in a very complex mechanism with the 
participation of various kinds of cellular regulators. In HPV-induced cervical cancers, 
the oncoproteins pose challenges on the host defence system. Accumulating evidences 
demonstrate the interaction between the viral proteins and the host SUMOylation 
system, however the subtle interplay in between still remains obscure which is worth to 
be elucidated in order to shed new insights on the complex events involved. In long 
term, this is valuable for both expanding the knowledge of the role of SUMO in cancer 
dynamics and determining drug targets towards cancer. For this purpose, a pilot 
proteomic study is performed to achieve the aim of identification of SUMO interacting 
partners in an HPV-infected human cervical carcinoma cell line HeLa. 
Whilst lacking of a direct and robust method for a specific fluorescent labelling in 
SUMOylation study nowadays, we attempted to characterize the use of 2As-4Cys 
labelling system in our study of SUMO to testify its potential use in the SUMO 
research as a part of the research project. 
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Chapter II 
Proteomics investigation of SUMOylation in human 
cervical carcinoma cell line HeLa 
INTRODUCTION 
In order to identify SUMO interacting partners, which are either SUMO conjugating 
substrates or differentially expressed upon overexpression of SUMO in human cervical 
carcinoma cell line HeLa, two-dimensional gel electrophoresis (2-DE) is utilized in 
mapping the protein expression profile therein. HeLa was derived from the cervical 
carcinoma tissue from a young black female (Masters，2002) which provided us the 
source for studying HPV-positive cervical cancer. Here we attempted to use two 
parallel methods to achieve our aim: an in vitro and an in vivo study of SUMO 
interacting partners in the cell line. 
For the in vitro study, we constructed an in vitro SUMOylation system to conjugate our 
recombinant SUMO-1 to the lysate cellular proteins. Direct shifts of protein spots 
visualized in the 2-DE which represents SUMO conjugates. Whilst for the in vivo study, 
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transfection of a SUMO-containing plasmid into HeLa cells is designated to give 
overexpression of SUMO-1 protein in the in vivo system, which is expected to 
stimulate the change of expression level of potential SUMO interacting partners (Li et 
al., 2006). 
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2.1 MATERIALS 
2.1.1 Vectors for expression of SUMO and SUMOylation enzymes in E.coli 
pET28m 
pET28m orginates from pET28a(+) (Novagen) in which the linker region between the 
six polyhistidine (His6)tag and the Nde\ restriction site that contains the thrombin 
cutting site was removed. Transcription of the inserted gene is driven by T7 promoter 
upon induction with isopropyl p-D-thiogalactoside (IPTG). The plasmid possesses a 
kanamycin resistance gene for selection. 
pGEX-6P-l 
Cloning of target gene into pGEX-6P-l (GEHealthcare) allows an expression of 
N-terminal glutathione S-transfease (GST) tagged fusion protein. The GST-tag can be 
removed by digestion with PreScission™ protease recognizing amino acid sequence 
LEVLFQGP located between the tag and the target protein. Transcription of the 
inserted gene is regulated by the lac promoter Piac. The plasmid possesses an ampicillin 
resistance gene for selection. 
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2.1.2 E.coli cell strains 
DH5a 
DH5a (GIBCO) is a common E.coli strain for molecular cloning. The /acZAMlSA 
marker provides complementation of P-galactosidase gene thus allows blue/white 
selection of colonies. Mutation of recKX and endAX provide insert stability and a 
higher plasmid yield respectively. 
BL21 (DE3) pLysS 
BL21 (DE3) pLysS (Novagen) is deficient of ompT and Ion proteases. DE3 means the 
strain is a lysogen of bacteriophage ？iDE3 and thus carries a chromosomal copy of T7 
RNA polymerase gene. pLysS means it encodes T7 lysozyme，which is a natural 
inhibitor of T7 DNA polymerase. The strain produces scarce amount of T7 lysozyme to 
suppress the expression of T7 RNA polymerase prior to induction, hence stabilizing the 
expression of recombinant proteins that might affect cell growth and viability. It carries 
a chloramphenicol resistant gene for selection (Studier and Moffatt, 1986). 
Rosetta 2 (Novagen) 
Rosetta 2 is a BL21 derivative designed to enhance the expression of recombinant 
proteins by presence of tRNAs for seven rare codons AUA, AGG, AGA, CUA, CCC, 
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CGG and GGA on the chloramphenical-resistant plasmid pRARE. The rare codons 
give the strain a more comprehensive translation which is then not limited by the 
codon usage of E.coil (Brinkmann et al., 1989). 
2.1.3 Mammalian cell lines 
HeLa 
HeLa cell line (ATCC, Cat# CCL-2tm) was derived from human cervical 
adenocarcinoma epithelial cells. The cell line was infected with unknown copy number 
of human papillomavirus 18 (HPV-18) and was used as a model cell line for studying 
HPV-infected cervical cancer. It was maintained with RPMI 1640 medium (Gibco, 
Cat#23400-021) supplemented with 10% (v/v) fetal bovine serum (FBS) (Invitrogen, 
Cat# 16000-044) and 1% (v/v) penicillin/streptomycin (P/S) (Invitrogen, 
Cat#l5140-122) at 37�C with 5% CO2. 
C-33A 
‘C-33A cell line (ATCC, Cat# HTB-31tm) was derived from human cervical carcinoma 
epithelial cells. The cell line is HPV-negative and was used as a negative control cell 
line for studying HPV-infected cervical cancer. It was maintained with RPMI 1640 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) 
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penicillin/streptomycin (P/S) at 37�C with 5% CO2. 
2.1.4 E. coli growth mediums 
LB medium 
20 g LB broth (USB, Cat#US75852) was dissolved in 1 L ddH20 and the medium was 
sterilized by autoclave. 
LBA, LBK and LB AC media 
Antibiotics were added to LB medium just prior to use, from stock to a final 
concentration of 0.1 mg/ml, 0.030 mg/ml and 0.034 mg/ml for ampicillin, kanamycin 
and chloramphenicol respectively. 
LB, LBA, LBK and LBAC agar plates 
17.5 g LB agar (USB, Cat#US75851) was dissolved in 500 ml ddHzO and sterilized by 
autoclave. Medium was cooled down to 55 and antibiotics were added (if needed) 
'from stock to a final concentration of 0.1 mg/ml, 0.030 mg/ml and 0.034 mg/ml for 
ampicillin, kanamycin and chloramphenicol respectively. Agar was poured into Petri 
dishes and solidified by resting at room temperature. 
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2.1.5 Mammalian cell growth medium 
Rosewell Park Memorial Insititute (RPMI) 1640 Medium (Gibco, CatU23400-021) 
RPMI 1640 with phenol red, 4 mM L-glutamine and 0.5 mm HEPES was used to 
cultivate both HeLa and C-33A cell lines. The media used were purchased from Gibco 
in powder form and reconstitutions were done following supplier's instructions. A 
packet of powder was dissolved in 1 L of ddH20 and the indicated amount of sodium 
bicarbonate (NaHCOs) was added (2 g/L for RPMI) and the final pH was adjusted to 
7.2 at ambient temperature. The dissolved medium was sterilized through a 0.22 |xm 
Steritop®filter unit (Millipore, Cat#SCGT05RE) in a biosafety carbinet. Sterilized 
medium was stored at 4 until use. Complete medium was prepared by addition of 
10%(v/v) FBS and l%(v/v) P/S to the sterilized plain medium just prior needed. 
2.1.6 Reagents and buffers 
All buffers were prepared by dissolving chemicals in ddH�。； and titrated to suitable 
pH with HCl and NaOH, unless otherwise specified. 
2.1.6.1 Reagents and buffers for molecular cloning 
50x TAE buffer (Tris-Acetate-EDTA) 242 g Tris (USB, Cat#US75825), 57.1 ml 
acetic acid and 100 ml 0.5 M EDTA (USB, Cat#US 15701) were added to ddHsO and 
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brought up to 1 L. Ix working buffer was prepared by dilution with ddHiO. 
1% Agarose gel 1.0 g agarose powder (USB, Cat#US75817) was dissolved in 100 
ml of Ix TAE by microwave oven heat up. After solution was slightly cool down, 1 |il 
EB solution (1 |ag/|al) was added and mixed. 
6x DNA loading dye 3 ml glycerol, 30 mg bromophenol blue and 30 mg xylene 
cyanol FF were dissolved in 10ml ddHsO. Storage at room temperature. 
Ampicillin (100 mg/ml stock) 1.0 g ampicillin (USB, Cat#US11259) was 
dissolved in 10 ml ddH^O or absolute EtOH. Solution was sterilized by filtration with 
0.2 [im filter (Sartorius, Cat# 16532-K) and stored at -20 
Kanamycin (30 mg/ml stock) 0.3 g kanamycin (Invitrogen, Cat#l 1815-032) was 
dissolved in 10 ml ddHzO. Solution was sterilized by filtration with 0.2 i^m filter and 
"stored at-20 
Chloramphenicol (34 mg/ml stock) 0.34 g chloramphenicol (Amersham, 
Cat#US23660) was dissolved in 10 ml absolute EtOH (Merck). Solution was sterilized 
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by filtration with 0.2|Lim filter and stored at -20 
Transformation buffer Tfbl 12 g RbCl，9.9 g MnCl2.4H20 and 1.5 g 
CaCl2.2H20 were dissolved in 700 ml ddH20 with 30 ml IM KOAc and 150 ml 
glycerol added. pH was adjusted to 5.8 with acetic acid and the solution was brought 
up to 1 L with ddHzO and sterilized by filtration. 
Transformation buffer Tfbll 1.2 g RbCl and 11 g CaClrlUiO were dissolved in 
700 ml ddH20 with 150 ml Glycerol added. pH was adjusted to 6.8 with NaOH and the 
solution was brought up to 1 L with ddHzO and sterilized by filtration. 
2.1.6.2 Reagents and buffers for E.coli protein expression 
0.1 M Isopropyl P-D-thiogalactoside (IPTG) 0.23 g IPTG powder (GEHealthcare, 
Cat#US 17886) was dissolved in 10 ml ddHzO. Solution was sterilized by filtration 
with 0.2 |im filter and stored at -20 
lOx Tris-glycine electrophoresis buffer 30.2 g Tris, 188 g glycine and 100 ml 
10 % SDS (w/v) were added to d d H � � a n d brought up to 1 L. Ix working buffer was 
prepared by dilution with ddHiO. 
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6x SDS gel loading dye 30 ml 1 M Tris-HCl (pH6.8), 12 g SDS, 0.6 g bromophenol 
blue and 60 ml glycerol were mixed and brought up to 100 ml with ddHsO to make a 
clear blue solution. 100 |j,l 1 M DTT stock was freshly added to 900 |xl above prepared 
solution before use. 
Coomassie brilliant blue destaining solution 60 ml absolute EtOH, 20 ml 
98% acetic acid and 120 ml ddHsO were added and mixed thoroughly. 
Coomassie brilliant blue staining solution 0.3 g Coomassie� Blue R250 was 
dissolved in 200 ml destaining solution. 
2.1.6.3 Reagents and buffers for mammalian cell culture 
0.25% Trypsin ImM EDTA (Gibco, Cat#25200-072) Trypsin-EDTA was used 
‘ for trypsinization of confluent cells adhered to the culture flask for harvesting or 
subculture. The stock solution was stored at -20°C until use. 
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Phosphate Buffer Saline (PBS) PBS was prepared by mixing 0.272 g KH2PO4, 
0.201 g KCl, 1.42 g Na2HP04 and 8.01 g NaCl in ddHzO and pH was adjusted to 7.4 or 
one bottle of DPBS powder was dissolved directly (Invitrogen, Cat#21600-010) in 1 L 
ddH20, The prepared PBS was autoclaved for sterilization and stored at 4 until use. 
2.1.6.4 Reagents and buffers for Western blot study 
lOx Transfer Buffer (Electroblotting buffer) 29.28 g glycine, 58.14 g Tris-base, 
0.375% (w/v) SDS were mixed and brought up to 1 L. Ix working buffer was prepared 
by dilution with 700 ml ddHzO and 200 ml methanol. 
lOx PBS-Tween 20 (PBS-T) 2.72 g KH2PO4, 2.01 g KCl, 14.2 g NaaHPC^ and 
80.06 g NaCl were mixed and brought up to 1 L. pH was adjusted to 7.4 and 1 ml of 
Tween-20 (USB, Cat#US20605) was added finally. Ix working buffer was prepared by 
dilution with ddHzO. 
“Stripping solution 62.5mM Tris-HCl pH6.8, and 2% SDS were mixed and brought 
up to 200 ml. lOOmM (3-mercaptoethanol was added to the solution prior to use. 
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2.1.7 Reagents and solutions for two-dimensional gel electrophoresis (2-DE) 
and mass spectrometry (MS) sample preparation 
2.1.7.1 Reagents and solutions for 2-DE 
i. 2-DE Sample preparation 
Cells washing buffer 250 mM sucrose and 10 mM Tris dissolved in ddHsO and 
brought up to 500 ml. pH was adjusted to 7.0 and the buffer was stored at 4 
Lysis buffer (LB) 40 mM DTT, 8 M urea or 7 M urea plus 2 M thiourea, 4% (w/v) 
CHAPS were mixed and brought up to 200 ml. The buffer was put to stock as 1.5 ml 
aliquots at -20 
Rehydration buffer (RB) 8 M urea or 7 M urea plus 2 M thiourea, 4% (w/v) CHAPS 
and 0.002% (w/v) bromophenol blue were mixed and brought up to 200 ml. The buffer 
was put to stock as 1.5 ml aliquots at -20 ''C. 1% (w/v) DTT and 1% (v/v) IPG buffer 
(GEHealthcare, Cat#17-6000-x) were freshly added just before use. 
ii. First dimension gel electrophoresis-isoelectric focusing (lEF) 
Bradford protein assay solution Stock reagent was diluted 5-fold for working 
concentration (10% (v/v)) with ddH^O and stored at 4 with aluminium foil cover. 
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iii. Second dimension gel electrophoresis-SDS-PAGE 
Equilibration buffer (EB) 75 mM Tris-HCl pH8.8，6 M urea, 29.3% (v/v) glycerol, 
2% (w/v) SDS were dissolved in 500 ml ddHaO. 40 ml aliquots were made and stored 
at -20�C. 0.002% (w/v) bromophenol blue was added to the buffer upon use. 
Equilibration buffer A (EB-A) 1% (w/v) DTT was freshly added to EB just before 
use. 
Equilibration buffer B (EB-B) 2.5% (w/v) iodoacetamide (lAA) (GEhealthcare, 
Cat#RPN6302) was freshly added to EB just befolre use. 
Agarose sealing solution 0.5% (w/v) agarose and 0.002% (w/v) bromophenol blue 
were dissolved in Ix Tris-glycine electrophoresis buffer. 
iv. Silver staining 
‘See section 2.2.11.4 for the reagent compositions 
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2.1.7.2 Reagents and solutions for mass spectrometry (MS) sample preparation 
i. Destaining of silver stained gel spots 
Silver de-staining solution 30 mM potassium hexacyanoferrate (III) (Sigma, 
Cat#P8131) and 100 mM sodium thiosulphate were dissolved in nano pure water 
separately. Both solution were mixed in 1:1 ratio just before use. Potassium 
hexacyanoferrate (III) solution was stored at 4 with aluminium foil cover. 
ii. Trypsin digestion 
Gel equilibration solution 200 mM ammonium bicarbonate (Sigma，Cat#A6141) was 
dissolved in nano pure water and stored at 4 
Trypsin enzyme (MS grade, Promega, Cat#V5280) The lyophilized enzyme in stock 
vial was dissolved in 25 mM ammonium bicarbonate to a concentration of 40 ng/ml. 
Enzyme solution was put to 100 \i\ aliquots and stored at -20 
‘iii. Peptide extraction 
Peptide extraction solution 100% acetonitrile (ACN) (Sigma, Cat#A3396) and 0.1% 
trifluoroacetic acid (Appliedbiosystems, Cat#400137) were mixed in nano pure water 
just before use. 
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iv. Desalting and concentration of peptide mixture 
Resuspension solution/ziptip^'^ equilibration solution/washing solution [0.1%(v/v) 
TFA] 10% (v/v) TFA stock solution was made and stored in dark at room temperature. 
0.1% (v/v) TFA working solution was prepared with nano pure water just before use. 
ZiptipTM Wetting solution [50% (v/v) ACN] 50% (v/v) was prepared with nano pure 
water just before use. 
Peptide elution solution 50% (v/v) ACN and 0.1% (v/v) TFA was mixed in 1:1 ratio 
in nano pure water just before use. 
a-cyano-4-hydroxycinnamic acid (CHCA) matrix (Fluka, Cat#70900-1G-F) The 
powder form matrix was dissolved in a 50% (v/v) ACN and 0.5% (v/v) TFA until 
saturation and stored at -20 not more than 1 month. 
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2.2 METHODS 
2.2.1 Molecular cloning of SUMO-1 into pET-28m and pHM6 vectors 
The matured form of SUMOs, which were genetically engineered to remove the 
C-terminal fragment behind the G-G diglycine motif were cloned into the selected 
expression vector pET-28m and pHM6 for E.coli bacterial expression and mammalian 
expression. 
2.2.1.1 Design of primers for the cloning of SUMO-1 
To clone SUMO into pET-28m and pHM6, forward and reverse primers were designed 
to suit the restriction sites in the MCS of the expression vector. 
BamHl INotl sites were chosen for cloning into pET-28m as both BamHl and Nod are 
restriction enzymes that both enzymes have no internal cutting sites in SUMO gene. 
Thus, the forward primert was designed with its 3，end complementary to the 5' end of 
‘SUMO and a BamHl site in front of the ATG start codon of the SUMO gene. A GC 
clamp was added at the 5' end of the primer. 
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Another pair of primers十 was designed for the cloning of SUMO into the vector pHM6. 
Kpn\ was chosen as the forward restriction site. 
The reverse primer十 was designed with the 3’ end complemtary to the sequence up to 
the Gly-Gly motif of SUMO in order to make it as a matured form which can be 
conjugated directly to substrate proteins in in vitro SUMO conjugation. A stop codon 
TAG was added to halt the translation after the Gly-Gly motif. 
fAll primers were listed in Appendix 3 
2.2.1.2 DNA amplification by polymerase chain reaction (PCR) 
The SUMO gene was amplified with the following standard PCR reaction mix: 
Table 2.2.1.1 Composition of PCR reaction mix for amplification of SUMO DNA 
Components Volume 
“ lOx PCR reaction buffer 5 
dNTPs mix (2 mM) 2 |il 
Forward primer (10 |iM) 1 |xl 
Reverse primer (10 |aM) 1 |xl 
DNA template (50 ng/^l) 1 i^l 
Expand® High fidelity enzyme mix (3.5 Unit/pi) 1 |a,l 
Autoclaved ddHsO 39 jil 
Total 50 111 
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The PGR buffer and polymerase mix was obtained from Expand® High fidelity PGR 
system (Roche, Cat#ll 732 641 001). The PGR was processed using Thermocycler 
(Eppendorf), equipped with a heating lid preventing evaporation of PGR mix. A 
temperature profile was set up specified for the length of SUMO cDNA and its GC 
content as follows: 
Table 2.2.1.2 PCR reaction profile setting for amplification of SUMO DNA 
Steps Temp. (®C) Duration 
1 Preincubation 94 2 min 
2 Denaturation 95 30 s 
3 Annealing 58 30 s 
4 Extension 72 1 min 30 s 
2-4 Repeated for 30 cycles 
5 Final extension 72 5 min 
6 Cooling and storage 4 oo 
Amplification of SUMO cDNA was verified by running the PCR product with Ix DNA 
loading dye in 1% agarose gel electrophoresis in TAE buffer under 120 V for 20 min. 
The size and existence of amplified cDNA was shown under UV trans-illumination 
(GelDoc) with ethidium bromide staining. 
2.2.1.3 DNA extraction from agarose gels 
QIAquick® Gel Extraction Kit from QIAGEN (Cat#28706) was chosen to perform 
DNA extraction from agarose gels. cDNA amplified with correct size with reference to 
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100 bp-DNA ladder was excised out from the agarose gel with a sterile surgical scalpel. 
For gel slice of 350 mg or smaller, 1 ml QG buffer was added to dissolve the gel by 
incubation at 50 For gel slices larger than 350 mg, slices were trimmed into pieces 
and aliquoted before adding appropriate volume of QG buffer. Gel slices completely 
dissolved in the solution which showed an optimal pH (yellow coloured) was applied 
to the QIAquick columns and centrifuged for 1 min at maximum speed (16,100 x g) in 
Eppendorf bench top centrifuge (Model 5415D). DNA fragments were allowed to bind 
to the columns and the flow-through was discarded. Afterwards 750 |il PE buffer, 
which was an EtOH washing buffer, was added to the column followed by 
centrifugation at 16,100 x g for 1 min. DNA was washed with EtOH. This is to 
precipitate the DNA on the membrane of column. Flow-through was discarded and the 
QIAquick column was centrifuged at same speed for 1 min again to remove residual 
ethanol-containing PE buffer. Finally, 30 autoclaved ddHsO that had pre-warmed at 
70®C was added to the centre of the column membrane and allowed to stand for 1 min 
to ensure complete absorption into membrane. Purified SUMO DNA was then eluted 
by centrifugation at 16,100 x g for 2 min. 
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2.2.1.4 Restriction digestion of vectors and purified PCR products 
Amplified SUMO DNA and our selected vectors pET-28m and pHM6 were subjected 
to double digestion by restriction enzymes BamHl/Nofl or Kpnl/Notl respectively 
using the following reaction profile: 
Table 2.2.1.3 Composition of restriction digestion mixture for construction of 
pHM6-SUMO and pET-28in-SUMO 
^ Volume, ul 
Components 
pET-28m (V) pHM6 (V) SUMO (I) 
lOx NEBuffer 3t M - 5 
IQx NEBuffer 2 卞 - ^ 5^1 
BamHl (20 U/|il)| - 1.5 i^l -
Kpnl (10 U/|Lil)t - 1 [i\ - 1.5 
Not\ (10 U/|al)t 1 i^l 1 1.5 1.5 
lOx BSA (1 mg/ml) 5 |il 5 i^l 5 jal 5 |il 
Vector 10 III lO^U - -
PCR products - - 3 7 3 7 |al 
Autoclaved ddHzO 28 |il 28 i^l - -
Total 50 III 50 i^l 50 i^l 50 pi 
t l x NEBuffer 3: 50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCb, 1 mM dithiothreitol (DTT), 
pH7.9; Ix NEBuffer 2: 10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCb, 1 mM dithiothreitol 
(DTT), pH7.9 
%BamH\ (NEB, Cat#R0136L); Kpnl (NEB, Cat#R0142L); Not\ (NEB, Cat#R0189L) 
The restriction enzyme system was obtained from NEB. The reaction mixtures were 
incubated at 37°C for 3 h. For vector DNA digestions, 1 [l\ of alkaline phosphatase 
(CIP) (lOU) (NEB, Cat#M0290L) was added in the third h of incubation for preventing 
self-ligation of vector itself. After completion of digestion, success of digestion was 
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verified with agarose gel electrophoresis and digested vector and inserts DNA with 
correct size was extracted and purified as described in section 2.2.1.3. 
2.2.1.5 Ligation of SUMO cDNA into expression vector pET-28m and pHM6 
The digested vector and inserts with sticky restriction ends were ligated at a molar ratio 
of 1:6 and 1:8 (vector: insert) with T4 DNA ligase (NEB, Cat#M0202S). Reaction 
(Rxn) was set up as follows and incubated at 16�C overnight (0/N): 
Table 2.2.1.4 Composition of ligation mixture for construction of pHM6-SUMO and 
pET-28m-SUMO 
Volume, 
Components Ligation Rxn (V+I) Negative control 
(V) 
lOx T4 DNA ligase Rxn buffer卞 UU IjU 1 i^l 
Insert 1 |il 1 -
Vector 0.5 )il 0.5 i^l 0.5 
T4 DNA ligase 5 i^l 5 i^l 5 
Autoclaved ddHzO 12.5 i^l 12.5 |al 13.5 
Total 20 i^l 20 i^l 20 [i\ 
卞Ix T4 DNA ligase Rxn buffer: 50 mM Tris-HCl, 10 mM MgCb, 1 mM ATP, 10 mM DTT, 
25 )xg/ml BSA, pH7.5 
JMolar ratio of vector and insert DNA was determined by the relative size of the DNA and 
DNA quantification at OD260. 
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2.2.1.6 Preparation of competent cells 
Preparation of the required competent cells (DH5a, Rosetta2, BL21 (DE3) pLysS) was 
started with frozen glycerol stocks at -80 For DH5a, stock bacteria were streaked 
onto an LB agar plate without antibiotics and while on LBC agar plates for Rosetta2 
and BL21 (DE3) pLysS. Streaked plates were incubated at 3 7 � C for 16 h (0/N). Single 
colonies were picked and inoculated into 5 ml LB medium and cultured at 37 the 
next day for another 16 h (0/N) with constant shaking. 0/N starter culture was then 
transferred to 500 ml flask containing 250 ml blank LB medium and allowed to grow 
at 37 until the OD at 600 nm reaching 0.5. Bacterial cells were then harvested by 
centrifugation with Eppendorf bench top centrifuge (Model 581 OR) at 1,500 x g for 
10 min at 4 while supernatant was discarded. The pellet was resuspended in 83 ml 
Tfbl buffer and chilled on ice for 15 min and centrifuged again at 1,500 x g for 10 min 
at 4 while supernatant was discarded. The pellet was resuspended in 20 ml Tfbll 
buffer and chilled on ice for another 15 min. Cells were then snap frozen in liquid 
nitrogen in 100 aliquots and transfer to -80 until use. 
2.2.1.7 Transformation of ligated mixture into competent DH5a 
Two tubes of 100 }il of E.coli strain DH5a competent cells were thawed on ice for 
10 min without disturbances. Ligation product and negative control were added into 
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each tube of DH5a respectively and mixed gently, followed by incubation on ice for 20 
min. Heat shock was then applied at 42 for 45 s and the mixture was immediately 
cooled on ice for 2 min. Afterwards 1 ml LB medium was added to each tube and the 
cell suspension was incubated at 37 for 1 h for recovery. The bacterial cultures were 
then centrifuged down at 16,100 x g (Eppendorf 5415D) for 1 min. Supematants were 
removed and the transformed cells were resuspended in 100 \i\ medium. Finally, the 
suspensions were spread onto LB agar plates supplemented with 0.034 mg/ml 
kanamycin and incubated at 37 °C 0/N. 
2.2.1.8 Preparation of plasmid DNA 
2.2.1.8.1 Mini-preparation of plasmid DNA 
A single bacterial colony was inoculated into culture tubes with 5ml LB medium and 
appropiate antibiotics (kanamycin) supplemented. The culture was grown at 3TC for 
16 h (0/N) and the cells were harvested by centrifugation at 3230 x g (Eppendorf 
581 OR) for 15 min at 4 The plasmid DNA was isolated using QIAprep® Spin 
Miniprep Kit from Qiagen. 
The pellet acquired was resuspended in 250 \i\ G1 buffer (50 mM Tris-HCl pH8.0, 
10 mM EDTA) with RNase pre-chilled at 250 \i\ G2 cell lysis solution (200 mM 
NaOH, 1% SDS (w/v)) was then added and mixed gently by inversion of tubes for 
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5 times. The mixture was incubated at ambient temperature for 5 min. 350 |il of M3 
neutralizing buffer (5 M potassium acetate solution, pH 4.8) was added. It was mixed 
by inversion for 5 times and immediately put to centrifugation at 16,100 x g 
(Eppendorf 5415D) at ambient temperature for 10 min. The clear supernatant was 
loaded into a spin cartridge of the kit and centrifuged at 16,100 x g for 1 min. The 
flow-through was discarded and the cartridge was then treated with 700 G4 wash 
buffer (70% EtOH, 10 mM Tris-Cl, 1 mM EDTA, pH 7.5). Once again the cartridge 
was spun down at 16,100 x g for 1 min and the flow-through was discarded. A further 
spinning at 16,100 x g for 1 min was applied to remove the residual ethanol. Finally, 
50 |il of autoclaved ddH20 that pre-warmed at 60 was added to the center of 
cartridge membrane. The cartridge was allowed to stand for 1 min for complete eluent 
absorption and centrifuged down at 16,100 x g for 2 min. Recombinant plasmids were 
checked with restriction digestion, PCR amplification. Positive clones were sent to 
DNA sequencing (by TechDragon sequencing service). 
2.2.1.8.2 Midi-preparation of plasmid DNA 
Midi-preparation of plasmid DNA was done in order to obtain a higher DNA quality 
and quantity using HiSpeed® Plasmid Midi Kit from Qiagen (Cat#12643). After 
transformation, single colony was inoculated into 5 ml LB medium with appropiate 
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antibiotics supplemented. Starter culture was grown at 37 0/N. Bacterial cells were 
harvested by centrifugation at 5,400 x g (Beckman, Avanti® J-E 369003) for 
15 min at 4 and the pellet was resuspended in 6 ml pre-chilled PI buffer (50 mM 
Tris-Cl pH8.0, 10 mM EDTA, 100 [ig/m\ RNase A) in a 50 ml Falcon®tube. 6 ml P2 
buffer (200 mM NaOH, 1% SDS(w/v)) was further added for cell lysis and the 
suspension was gently mixed by inverting the tube for 5 times. The lysate was 
transferred to an QIAfilter® cartridge with stopper set and allowed to settle at ambient 
temperature for 10 min. The settled lysate was then forced to pass through the cartridge 
filter by insertion of a plunger. The filtered flow-through was drained through the resin 
of a Hi Speed Midi Tip® by gravity for DNA binding, which had simultaneously 
pre-equilibrated with QBT buffer (750 mM NaCl, 50 mM MOPS pH 7, 
15% Isopropanol (v/v), 0.15% Triton® X-100(v/v)). The tip was washed with 20 ml of 
QC buffer (NaCl, EDTA, Tris-HCl pH 8.0 and EtOH containing) by gravity flow and 
the DNA was then eluted by adding 5 ml QF buffer to the column tip (1.25 M NaCl, 50 
mM Tris-Cl pH8.5, 15% isopropanol (v/v)). 3.5 ml sterilized isopropanol was added to 
the eluted DNA solution for precipitation by incubating at ambient temperature for 5 
min. The precipitated DNA mixture was allowed to pass through a QIAprecipitator® 
using plunger pressure. The precipitator was then washed with 2 ml 70% ethanol and 
made dry by injecting air rapidly for 5 times. Finally, plasmid DNA was eluted in 
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500 |il autoclaved ddHzO pre-warmed at 60°C. The yield and quality of DNA was 
checked by spectrophotometric quantification at 260 nm and with the ratio of OD 
values at 260 and 280 nm respectively. Plasmid DNA was stored at -20 until use. 
2.2.1.8.3 DNA quantification and quality measurement 
Nucleic acid content of DNA from midi-preparation using for transfection purpose was 
measured by spectrophotometric method. OD260 was used for determination of DNA 
concentration while the ratio of OD260 to OD280 was used for determination of DNA 
quality. 
2.2.2 Expression of His6-tagged SUMO, ubc9, TDG, GST-tagged El and 
MBP-tagged Prdx 1 with E. coli 
pET-28m-SUMO, pET-28m-ubc9, pQB80-TDG, pGEX-6P-El and MBP-tagged Prdx 1 
were transformed into desirable E.coli strain (R2 or BL21 (DE3) pLysS ) using the 
procedures described in section 2.2.1.7. Among the recombinant plasmids, El was 
cloned into pGEX-6P vector and is a gift kindly given by Prof Ron Hay, University of 
Dundee, GB，and E2 was cloned into pET-28m vector previously and kindly given by 
Dr. Xu Zheng; while TDG was cloned into pQB80 vector (Qiagen) and kindly given by 
Dr Laurence Pearl, ICR, London. 
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Transformed cells were spread onto LB agar plates supplemented with 17 |ag/ml 
chloramphenicol together with the required antibiotics for each different expression 
vectors as described in section 2.1.1. Colonies were inoculated into LB medium with 
appropiate antibiotics. The bacterial cultures were allowed to grow at 37®C 0/N with 
constant shaking. 
The 0/N cultures were then inoculated in 1:100 (v/v) to 4 L large scale culture with 
appropriated antibiotics and allowed to grow at 37 with shaking until ODeoo reached 
0.5. Cultures were equilibrated at the specific temperature for protein expression 
induction as indicated as follows: 
Table 2.2.2.1 Protein expression temperatures for different recombinant plasmids 
Protein Temperature (®C) Duration 
GST-tagged El ^ ^ 
His6-tagged E2 ^ O ^ 
His6-tagged SUMO ^ O ^ 
His6-tagged TDG O ^ 
MBP-tagged Prdx 1 \il 4 h 
The expression solubility tests were performed by Dr. Xu Zheng, Mr. Man Cheuk-him 
and collaborators at ICR, London as pieces of established usable and repeatable data, 
with the best optimal expression condition which can produce the highest solubility and 
yield listed above. 
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Afterwards 0.1 mM IPTG at a final concentration was added to each culture for protein 
expression induction. The cultures were allowed to grow further with the specific 
temperature and duration as listed above with a constant shaking and finally harvested 
by centrifugation at 5,400 x g (Beckman, Avanti® J-E 369003) for 15 min at 4 
Pellets collected with cells expressing the desired protein were used for protein 
purification or otherwise stored at -80 until use. 
2.2.3 Purification of His6-tagged SUMO, ubc9, TDG, GST-tagged El and 
MBP-tagged Prdx 1 十 
Different liquid chromatographic methods were used for the purification of all fusion 
proteins. Each type of chromatographic resins was packed into XK® 16/20 columns 
(Amersham, Cat#l8-8773-01) except the use of pre-packed HiTrapT^Heparin HP 
(Amersham, Cat# 17-0407-01) affinity column and HiLoad Superdex^M 75 (Amersham, 
Cat# 17-1068-01) gel filtration column. Manual running of chromatographic columns 
were operated with the Peristaltic Pump P-1 (Amersham, Cat#18-1110-91) while 
computational operations were maintained by AKTAprime'^'^ purification system 
(Amersham, Cat#l8-1139-47) and its software PrimeViewTM 5.0. When using the 
AKTAprimeTM system, all buffers and samples were filtered using a 0.22 \im filter 
before use. 0.2 mM PMSF and 0.2 mM benzamidine was added in all the buffers to 
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prevent protein degradation, all protein samples and buffers were kept on ice 
throughout purification processes to minimize protein degradation at the same time. 
All the buffers used in this section is listed in Table 2.2.3.1 and discussed separately in 
the strategy section follows. 
tThis is a protein identified from the in vitro proteomic study by MALDI-TOF MS/MS 
PMF, which was purified for verification purpose. 
Table.2.2.3.1 Composition of buffers used in various chromatography 
Buffer name Buffer consitituents 
(a) Purification ofHis6-SUMO 
Nickel binding buffer 500 mM NaCl，20 mM Tris, 20 mM imidazole, 0.2 mM 
PMSF and 0.2 mM benzamidine, pH7.5 
Nickel elution buffer 500 mM NaCl, 20 mM Tris, 300 mM Imidazole, 0.2 mM 
PMSF and 0.2 mM Benzamidine, pH 7.5 
Q Sepharose binding 50 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM DTT, 
buffer pH 8.0 
Q Sepharose elution buffer 1 M NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM DTT, 
pH8.0 
S75 gel filtration buffer 150 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM 
DTT, pH 7.5 
(b) Purification of His6-TDG 
Nickel binding buffer IsOO mM NaCl, 20 mM Tris, 20 mM imidazole, 0.2 mM 
PMSF and 0.2 mM Benzamidine, pH 8.0 
Nickel elution buffer 500 mM NaCl, 20 mM Tris, 300 mM Imidazole, 0.2 mM 
PMSF and 0.2 mM Benzamidine, pH 8.0 
Heparin binding buffer 150 mM NaCl, 40 mM Tris, 0.5 mM EDTA and 2 mM 
DTT, pH 7.5 
Heparin elution buffer 1 M NaCl, 40 mM Tris, 0.5 mM EDTA and 2 mM DTT, 
pH 7.5 
S75 gel filtration buffer 150 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM 
DTT, pH7.5 
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(c) Purification of His6-ubc9 
Nickel binding buffer IsOO mM NaCl, 20 mM Tris, 20 mM imidazole, 0.2 mM 
PMSF and 0.2 mM benzamidine, pH7.5 
Nickel elution buffer 500 mM NaCl, 20 mM Tris, 300 mM Imidazole, 0.2mM 
PMSF and 0.2mM Benzamidine, pH7.5 
Prescission™ protease 500 mM NaCl, 20 mM Tris, 20 mM imidazole, 0.2 mM 
cleavage dialysis buffer PMSF and 0.2 mM benzamidine, pH 7.5 
S75 gel filtration buffer 150 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM 
DTT, pH 8.0 
(d) Purification of GST-El 
GST Sepharose b ind ingIsOO mM NaCl, 20 mM Tris, 5 mM EDTA and 2 mM DTT 
buffer with 0.2 mM PMSF and 0.2 mM benzamidine, pH7.5 
GST Sepharose elution 10 mM reduced L-glutathione, 150 mM NaCl, 20 mM 
buffer Tris, 5 mM EDTA and 2 mM DTT with 0.2 mM PMSF and 
0.2 mM benzamidine, pH 7.5 
S75 gel filtration buffer 50 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM DTT, 
pH8.0 
(e) Purification ofMBP-Prdxl 
Amylose agarose 500 mM NaCl, 20 mM Tris, 5 mM EDTA and 2 mM DTT 
binding/elution buffer with 0.2 mM PMSF and 0.2 mM Benzamidine, pH 7.0 
S75 gel filtration buffer 150 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM 
DTT 
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2.2.3.1 Affinity chromatography 
2.2.3.1.1 Ni-NTA affinity chromatography 
Ni-NTA (Nickel Nitrilo-triacetic acid) agarose (Qiagen, Cat#30230) was used for the 
affinity purification of His6-tagged proteins. Nickel was embedded on the agarose 
beads for the binding with six histidine residues on the fusion protein, which serve as 
an artificial metal binding domain. 10 ml Ni-NTA beads were packed into the XK16/20 
column and firstly washed with 5 bed volumes of ddHzO to remove the residual 
preservative ethanol and then equilibrated with the specific binding buffer for 5 or 
more bed volumes. DTT and EDTA were not added due to their strong reducing 
property and chelating property respectively. 20 mM imidazole was added to each 
specific binding buffer and pH 7.5 was used universally for minimizing non-specific 
binding. Afterwards, sample loading was performed at a flow rate of 1 ml/min with P-1 
pump on bench at ambient temperature. Sample was kept on ice throughout the process 
to minimize degradation by active proteases in the lysate. After sample loading, the 
resin was washed with the binding buffer until no such unbound protein or impurities 
could be detected with simple Bradford dot test. Finally, elution of the target protein 
was performed with a continuous linear ascending imidazole gradient from 20 mM to 
300 mM at a flow rate of 1 to 2 ml/min by AKTAprime'^'^ system in 10 bed volumes of 
elution buffer. 
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2.2.3.1.2 Heparin affinity chromatography 
5 ml pre-packed HiTrapTMReparin HP (GEHealthcare, Cat# 17-0407-01) affinity 
column was used for affinity chromatography of DNA-binding protein TDG. Heparin 
itself is a glycosaminoglycan (GAG) type of glycoprotein owns binding affinity to 
DNA binding proteins. It also has a mild cationic exchange property therefore proteins 
can be with heparin by ionic strength gradient. It was firstly washed with 5 bed 
volumes of ddHsO and equilibrated with the binding buffer (see table.2.2.3.1) for 
another 5 bed volumes. Sample kept on ice was loaded to the column at a flow rate of 
1 ml/min with P-1 pump on bench followed by washing with binding buffer till no 
protein was detected with Bradford dot test. Finally, elution of the target protein was 
performed with a continuous linear ascending salt gradient from 100 mM to 1M NaCl 
with 10 bed volumes of elution buffer at a flow rate of 1 to 2 ml/min by AKTAprimeTM 
system. 
2.2.3.1.3 Glutathione affinity chromatography 
Glutathione S e p h a r o s e T M 4 Fast Flow (GEHealthcare, Cat# 17-5132-01) was used for 
the affinity purification of GST-tagged proteins. The resin was settled in a Glass 
Econo-Column® (Biorad, Cat#737-2511) and the whole purification process was 
performed on bench. It was washed firstly with 5 bed volumes of ddHzO and 
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equilibrated with the binding buffer for another 5 bed volumes. Protein sample was 
mixed with the equilibrated resin and rocked gently at 4°C for 2 h. The loaded resin 
was washed with the binding buffer by gravity flow until no proteins was detected with 
Bradford dot test. Finally, the target fusion protein was eluted in elution buffer with 
10 mM reduced L-glutathione (Sigma, Cat#G6529) by gravity flow until no proteins 
was detected with Bradford dot test. 
2.2.3.1.4 Amylose affinity chromatography 
Amylose/agarose bead affinity matrix (New England Biolabs，Cat#E8021S) was used 
for the affinity purification of MBP-tagged proteins. The resin was settled in a Glass 
Econo-Column® (Biorad, Cat#737-2511) and the whole purification process was 
performed on bench. It was washed firstly with 5 bed volumes of ddH20 and 
equilibrated with the binding buffer for another 5 bed volumes. Protein sample was 
mixed with the equilibrated resin and rocked gently at 4°C for 2 h. The loaded resin 
was washed with the binding buffer by gravity flow until no proteins was detected with 
Bradford dot test. The MBP-tag was subsequently cleaved on column by incubation 
with PreScission™ protease in the binding buffer at 4 � C 0/N. Finally, the untagged 
proteins were eluted with the binding buffer. 
67 
Chapter II In troduct ion 
2.2.3.2 Ion exchange chromatography 
2.2.3.2.1 Anion exchange chromatography 
Q S e p h a r o s e T M Fast Flow (GEHealthcare, Cat# 17-0510-01) which contains a 
quaternary ammonium bound on the resins as strong anion interacting partner was used 
for the purification of proteins owning a low pi as a further step of purification. Low pi 
proteins can be ionized to an anion by a buffer with a pH higher than its pi. 10 ml Q 
Sepharose beads were packed into an XK16/20 column and firstly washed with 5 bed 
volumes of ddHsO. It was then equilibrated with the specific binding buffer for 5 or 
more bed volumes. Sample kept on ice was loaded at a flow rate of 1 ml/min with P-1 
pump on bench followed by the washing with binding buffer till no protein was 
detected with Bradford dot test. Finally, elution of the target protein was performed 
with a continuous ascending linear salt (NaCl) gradient from 50 mM to 1 M by 
A K T A p r i m e T M system using 10 bed volumes of elution buffer at a flow rate of 
1 to 2 ml/min. 
2.2.3.2.2 Cation exchange chromatography 
SP S e p h a r o s e T M Fast Flow (GEHealthcare, Cat# 17-0729-01) which contains a 
sulphopropyl group attached on the resins as strong cation interacting partner was used 
for the purification of proteins owning a high pi as a further step of purification. High 
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pi proteins can be ionized to a cation by a buffer with a pH lower than its pi. 10ml SP 
Sepharose beads were packed into an XK16/20 column and firstly washed with 5 bed 
volumes of ddHsO. It was then equilibrated with the specific binding buffer for 5 or 
more bed volumes. Sample kept on ice was loaded at a flow rate of 1 ml/min with P-1 
pump on bench followed by the washing with binding buffer till no protein was 
detected with Bradford dot test. Finally, elution of the target protein was performed 
with a continuous ascending linear salt (NaCl) gradient from 50 mM to 1 M by 
AKTAprimeTM system using 10 bed volumes of elution buffer at a flow rate of 
1 to 2 ml/min. 
2.2.3.3 Size exclusion chromatography 
120 ml Pre-packed HiLoad Superdex^M 75 (GEHealthcare, Cat# 17-1068-01) or 200 
(GEHealthcare, Cat# 17-1069-01) gel filtration column was used for size exclusion 
chromatography as a final step of purification depending the size of the target protein. 
The whole operation was done with the AKTAprimeTM system at 4°C. The column was 
firstly washed with 1 bed volume of ddHzO and equilibrated with the gel filtration 
buffer for 1 bed volume. Afterwards a concentrated sample of maximum 1.5 ml was 
injected through the injection valve of the AKTAprimeTM system and finally proteins 
were eluted according to their size by running another 1 bed volume of gel filtration 
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buffer at 1 ml/min. 
2.2.3.4 Purification strategies 
2.2.3.4.1 Purification of His6-tagged SUMO 
Bacterial cell pellets expressing His6-SUM0-1 freshly obtained or thawed from -80°C 
storage were resuspended in lysis and binding buffer containing 500 mM NaCl, 20 mM 
Tris, 20 mM imidazole, 0.2 mM PMSF and 0.2 mM benzamidine, pH 7.5 and then 
lysed by sonication (Sonopuls, Cat#2070) on ice. Soluble fraction was obtained by 
centrifugation of total cell lysate at 48,000 x g at 4 for 1 h. Supernatant containing 
the soluble fraction was filtered by 0.22 |am filters and passed through a 
pre-equilibrated Ni-NTA column. Tagged SUMO was eluted with elution buffer 
containing 500 mM NaCl, 20 mM Tris, 300 mM imidazole, 0.2 mM PMSF and 
0.2 mM benzamidine, pH 7.5 on a linear ascending gradient by AKTAprimeTM system 
and fractions were auto-collected. A final concentration of 0.5 mM EDTA and 2 mM 
DTT was added to the eluted fractions for prevention of protein degradation. Fractions 
containing His6-SUM0 were concentrated to 2 ml using Amicon® ultra-15 (Millipore, 
Cat#UFC9010) by centrifugation at 3,200 x g at 4 °C and further diluted with 20 mM 
Tris, pH 8.0 for lowering down the salt concentration to 50 mM. The partially pure 
His6-SUM0 sample was applied to a second column, the Q sepharose equilibrated 
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with binding buffer containing 50 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM 
DTT, pH 8.0 and eluted with elution buffer containing 1 M NaCl, 20 mM Tris, 0.5 mM 
EDTA and 2 mM DTT, pH 8.0 using linear ascending gradient with AKTAprime'^'^ 
system. Fractions containing the further purified Hise-SUMO were concentrated to 
1.5 ml and injected into the gel filtration column Superdex""^ S75 equilibrated with 
150 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM DTT, pH 7.5 for final 
purification. 
2.2.3.4.2 Purification of His6-tagged TDG 
Pellets expressing His6-TDG thawed from -80°C storage were resuspended in lysis and 
binding buffer containing 500 mM NaCl, 20 mM Tris, 20 mM imidazole, 0.2 mM 
PMSF and 0.2 mM benzamidine, pH 7.5 and then lysed by sonication on ice. Soluble 
fraction was obtained by centrifugation of total cell lysate at 48,000 x g at 4 for 
1 h. Supernatant was filtered by 0.22 |im filters and passed through a pre-equilibrated 
Ni-NTA column. Tagged TDG was eluted with elution buffer containing 500 mM NaCl, 
20 mM Tris, 300 mM imidazole, 0.2 mM PMSF and 0.2 mM benzamidine, pH 7.5 on a 
linear ascending gradient by AKTAprime'^^ system and fractions were auto-collected. 
A final concentration of 0.5 mM EDTA and 2 mM DTT was added to the eluted 
fractions for prevention of protein degradation. Fractions containing His6-TDG were 
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concentrated to 2 ml and further diluted with 20 mM Tris, pH 8.0 for lowering down 
the salt concentration to 150 mM. The partially pure His6-TDG sample was then 
applied to the HiTrap® Heparin equilibrated with binding buffer containing 150 mM 
NaCl, 40 mM Tris, 0.5 mM EDTA and 2 mM DTT, pH 7.5 and eluted with elution 
buffer containing 1 M NaCl, 40 mM Tris, 0.5 mM EDTA and 2 mM DTT, pH 7.5 using 
linear ascending gradient with AKTAprimeTM system. Fractions containing the further 
purified His6-TDG were concentrated to 1.5 ml and injected into the gel filtration 
column SuperdexTM S75 equilibrated with 150 mM NaCl, 20 mM Tris, 0.5 mM EDTA 
and 2 mM DTT, pH7.5 for final purification. 
2.2.3.4.3 Purification of His6-tagged ubc9 
Pellets expressing His6-ubc9 which was freshly obtained or thawed from -80°C storage 
were resuspended in lysis and binding buffer containing 500 mM NaCl, 20 mM Tris, 
20 mM imidazole, 0.2 mM PMSF and 0.2 mM benzamidine, pH7.5 and then lysed by 
sonication on ice. Soluble fraction was obtained by centrifugation of total cell lysate at 
48;000 X g at 4°C for 1 h. Supernatant containing the soluble fraction was filtered by 
0.22 陣 filters and passed through a pre-equilibrated Ni-NTA column. Tagged ubc9 
was eluted with elution buffer containing 500 mM NaCl, 20 mM Tris, 300 mM 
imidazole, 0.2mM PMSF and 0.2mM benzamidine, pH7.5 on a linear ascending 
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gradient by AKTAprimeTM system and fractions were auto-collected. A final 
concentration of 0.5 mM EDTA and 2 mM DTT was added to the eluted fractions for 
prevention of protein degradation. Fractions containing His6-ubc9 were collected and 
put to dialysis against 4L dialysis buffer containing 500 mM NaCl, 20 mM Tris, 
20 mM imidazole, 0.2 mM PMSF and 0.2 mM benzamidine, pH 7.5 at 4 0/N in 
order to perform His6-tag cleavage by Prescission頂 protease. The ubc9-His6-tag 
mixture was applied again to nickel column equilibrated with binding buffer and the 
flowthrough containing the purified ubc9 without His6-tag were concentrated to 1.5 ml 
and injected into the gel filtration column Superdex"*^ S75 equilibrated with 150 mM 
NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM DTT, pH 8.0 for final purification. 
2.2.3.4.4 Purification of GST-tagged El 
Pellets expressing GST-El which was freshly obtained or thawed from -80°C storage 
were resuspended in lysis and binding buffer containing 500 mM NaCl, 20 mM Tris, 
5 mM EDTA and 2 mM DTT with 0.2 mM PMSF and 0.2 mM benzamidine, pH7.5 
and then lysed by sonication on ice. Soluble fraction was obtained by centrifugation of 
total cell lysate at 48,000 x g at 4 for 1 h. Supernatant was filtered by 0.22 [im filters 
and passed through a pre-equilibrated Glutathione Sepharose^'^ column. Tagged El 
was eluted with elution buffer containing 10 mM reduced L-glutathione, 150 mM NaCl, 
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20 mM Tris, 5 mM EDTA and 2 mM DTT with 0.2 mM PMSF and 0.2 mM 
benzamidine, pH 7.5 by gravity. The eluted GST-El were digested with PreScission™ 
protease (GEhealth care, Cat#27-0843-01) at 4°C 0/N and then concentrated to 1.5 ml 
and injected into the gel filtration column Superdex"^ *^  S200 equilibrated with 150 mM 
NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM DTT, pH 8.0 for final purification. 
2.2.1.8.3 Purification of MBP-tagged Prdx 1 十+ 
Pellets expressing MBP-Prdxl which was freshly obtained or thawed from -80°C 
storage were resuspended in lysis and binding buffer containing 500 mM NaCl, 
20 mM Tris, 5 mM EDTA and 2 mM DTT with 0.2 mM PMSF and 0.2 mM 
Benzamidine, pH 7.0 and then lysed aiding by sonication on ice. Soluble fraction was 
obtained by centrifugation of total cell lysate at 48,000 x g at 4°C for 1 h. Supernatant 
was filtered by 0.22 |im filters and passed through a pre-equilibrated amylose column. 
Prdxl was eluted by on column tag cleavage by PreScission™ protease after 
incubating in binding buffer at 4®C 0/N. The partially purified Prdx 1 was then 
concentrated and loaded to SuperdexTM §75 gel filtration column equilibrated with 
150 mM NaCl, 20 mM Tris, 0.5 mM EDTA and 2 mM DTT, pH 7.0 for final 
purification. 
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fThis is a protein identified from the in vitro proteomic study by MALDI-TOF MS/MS 
PMF, which was purified for verification purpose. 
^Molecular cloning of Prdxl into pMAL vector and the expression of protein was 
performed by Mr. Man Cheuk-him, with the best optimal expression condition which 
can produce the highest solubility and yield using BL21 (DE3) pLysS E.coli strain, 
growing at 37�Cfor 4 h. 
2.2.4 HeLa and C-33A cell culturing and protein extraction 
2.2.4.1 HeLa and C-33A cell culturing 
1 ml frozen cell stock of HeLa and C-33A were thawed from liquid nitrogen in 37 
water bath without agitation. Once the cells were thawed to liquid form, they were 
transferred immediately to 7 ml pre-warmed complete RPMI and centrifuged at 
450 X g for 3 min at room temperature. Cell pellets were gently resuspended in 1 ml 
complete RPMI and finally transferred to a 25 cm^ culture flask (Iwaki, 
Cat#IW3123-025x) with 4 ml complete medium. Cells were incubated at 37 in a 
5% CO2, 95% air humidified atmosphere. Cells with 90% confluency were frozen 
using a freezing medium containing 50% FBS, 10% DMSO and 40% plain RPMI and 
dipped frozen in liquid nitrogen for 6 h before long term liquid nitrogen storage. 
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2.2.4.2 Protein extraction for in vitro SUMOylation assay 
For protein extract preparations, 4x10^ cells were harvested by gentle trypsination and 
centrifugation. Total cell extract would be used for the in vitro SUMOylation assay, 
therefore a mild cell lysis buffer was chosen (Lamond Lab Protocol, 2005). The pellet 
was washed with sucrose salt buffer for twice and resuspended in 300 )il of lysis buffer 
containing 20 mM HEPES, 1.5 mM MgCb, 2% glycerol, 420 mM NaCl, 0.2 mM 
EDTA, 1 mM DTT and 0.5 mM PMSF and incubated on ice for 1 h. Syringe pressure 
was applied to the cell lysate for complete cell lysis and the suspension was 
centrifuged at 16,100 x g (Eppendorf 5415D) for 30 min at 4°C. The supernatant was 
collected as the total cell lysate for in vitro SUMOylation purpose. 
2.2.5 Protein quantification with Bradford assay 
Protein concentration of purified proteins and protein extracts were determined by 
Bradford assay. BSA standards of 2.0 |ig, 4.0 \ig, 6.0 |ag, 8.0 \ig and 10 |ig were used to 
establish a standard curve by adding 1 |il protein in 1ml Bradford solution (BioRad, 
Cat#500-0006) using spectrophotometric measurement at OD 595nm. 
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2.2.6 In vitro SUMO conjugation assay 
2.2.6.1 In vitro SUMO conjugation system optimization 
In the in vitro SUMOylation system, only the presence of activiation enzyme (El) and 
conjugation enzyme (E2) were sufficient to facilitate an efficient SUMO conjugation 
(Desterro et al, 1999). In order to test for the efficiency of our existing SUMOylation 
system, a positive control SUMO substrate TDG (Thymine-DNA Glycosylase) was 
utilized. However as the existing protocol only gives a very low SUMO conjugation 
efficiency, parameters of reaction composite (including the reaction buffer composition, 
substrate:enzyme: SUMO molar ratio, reaction duration and temperature) were 
modified and subjected to test with TDG. 
Table 2.2.6.1 Old SUMO conjugation reaction profile (with TDG) 
Reaction component Volume 
ATP (50 mM) 1 
MgCb (50 mM) 1 
DTT (20 mM) 1 
10% Glycerol (v/v) 2 
El (0.1 | ig /�（Mw: 110 kPa) 1 
E2 (ubc9) (5 ^ig/^il) (Mw: 21 kPa) ^ 
SUMO-1 (10 ^ig/^il) (Mw:15 kPa) 0.25 
Substrate TDG (5 |ag/|il) (Mw: 41 kPa) 1 
lOx Rxn Buffer (1.5 M NaCl, 0.5 M Tris-HCl pH 7.5) 2 
ddHzO 10.5 
Total [i\ 20 
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Table 2.2.6.2 Modified SUMO conjugation reaction profile (with TDG) 
Reaction component Volume 
ATP (50 mM) 1 
MgCb (50 mM) 2 
DTT (20 mM) 1 
El (0.1 昭尔 1) 1 
E2 (ubc9) (5 g/[i\) ^ 
SUMO-1 (10 |ag/|il) ^ 
Substrate TDG (5 ^ig/^il) 1 
lOx Rxn Buffer (1.5 M NaCl, NazCOj pH 9.2) 2 
ddHzO 11.2 
Total III 20 
2.2.6.2 In vitro SUMO conjugation of HeLa cell extract 
Reaction mixture of 20 |li1 containing 20 pg of HeLa cell extract was added to the 
SUMO reaction mixture containing 0.4 |ig El (El:Sub molar ratio=l:l501"), 2.6 i^g E2 
(E2:Sub molar ratio=l:4), 5.2 jag SUMO-1 (SUMO:Substrate molar ratio二 1:2) and the 
components listed in table 2.2.6.2. A negative control was set up by excluding 
SUMO-1. The reaction mixtures were incubated for 2 h at 37 After incubation, the 
reactions were terminated by addition of SDS loading dye and heat up at 99 for 5 
min. The reaction mixtures were then run in 15% SDS-PAGE for band shift analysis 
and Western blot analysis. 
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For 2-D gel electrophoresis purpose, the reaction was scaled up with 100 |ag of HeLa 
cell extract and all components in the SUMO conjugation reaction were scaled up 
accordingly. 
fThe value of mole calculated for cell extract was based on an average of Mw of 
cellular proteins, which was about 30-45 kDa, therefore a value of 40 kDa was used. 
2.2.7 Transient transfection of pHM6-SUMO-l into HeLa cells and protein 
extraction from HeLa cells 
2.2.7.1 Transfection with lipofection method 
HeLa cells were seeded on 6-well plates at concentration of 4.0 x 10^  cells per well 
with RPMI medium supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (P/S). Cells were kept at 37 incubator with 5% CO2 and 
95% humidified air O/N or until the cells were 80% confluent. Before adding to the 
wells, for each transfection, 4 jagt pHM6-SUM0-l plasmid DNA was diluted into 
250 i^l Opti-MEM®I Reduced Serum Medium (Invitrogen, Cat#51985-034). On the 
other hand, 8 pi卞 of LipofectamineTM2000 Reagent was diluted into another 250 
Opti-MEM® and incubated at room temperature for 5 min. Afterwards, the two 
solutions were combined, mixed gently and incubated at room temperature for 20 min 
in order to allow DNA-liposome complexes to form. While incubating, the original 
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complete medium on the cells was replaced with 1.5 ml Opti-MEM® reduced medium 
after washing with PBS for once. Upon completion of 20 min incubation, 0.5 ml 
DNA-liposome complexes were added to the wells and the cells with complexes were 
incubated for 4 h j in a 37 incubator with 5% CO2 and 95% humidified air to allow 
the transfusion of complexes into the cells. Finally, the complexes were removed from 
the wells and replaced with 2ml fresh complete RPMI for continued protein expression 
and cell growth for 48 h卞 at 37 incubator with 5% CO2 and 95% humidified air. 
Control was set up by using empty pHM6 plasmid (without SUMO insert) as the DNA 
for transfection. 
f The amount of DNA and Lipofectamine™2000 used were based on the results of 
transfection efficiency optimization with a series of DNA concentration and its ratio to 
Lipofeactamine™2000. Time for incubation of complexes with cells and 
post-transfection cell growth were determined by the extent of effect by toxicity to cell 
viability. 
2.2.7.2 Determination of transfection efficiency 
The transfection efficiency was checked with Western blotting analysis as described in 
section 2.2.10. 
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2.2.7.3 Whole cell protein extraction of transfected cells 
Cells were harvested by gentle trypsination and centrifugation. Cell pellets were 
washed with sucrose salt buffer for twice and resuspended in 50 \il urea lysis buffer 
(LB) for every 5.0x10^ cells. The suspension was incubated on ice for 1 h and further 
lysed by syringe pressure. The lysate was then centrifuged at 16,100 x g (Eppendorf 
5415D) for 20 min and finally the supernatant was collected for assessment of 
transfection efficiency by western blotting analysis. 
2.2.8 Protein quantification with BCA assay 
The protein samples for western blotting analysis and two-dimensional gel 
electrophoresis was quantified and standardized with BCA assay. A BCA assay mixture 
was made by mixing solution A from BCA protein assay kit (Pierce, Cat#23223) 
containing sodium bicinchoninate (BCA) and solution B containing CuS04'5H20 at a 
ratio of 49:1 just before use. The colour of a fresh mixture was appeared pale green. 
Lysate samples subjected to the assay were diluted 10-fold with ddH20. Six samples 
of ' protein standards with different concentrations of BSA (0，2.0, 4.0, 6.0, 8.0， 
10.0 |Lig/|j,l) were prepared. Three replicates of each sample were included in the assay 
for confirmation of accuracy. All the samples were added to wells in 96-well plate. 
200 |al of BCA mixture was then added to the wells and mixed gently. Finally, the 
81 
Chapter II I n t r o d u c t i o n 
96-well plate were incubated at 37 for 30 min and then read by microplate reader 
(BioRad) at 540 nm. 
A standard curve was made with the readings of the protein standards (Fig.2.2.8.1) and 
the equation developed was then used to derive the protein concentration of the test 
samples. 
Result of BCA assay 
0 . 5 0 0 n 
0 . 4 5 0 -
0 . 4 0 0 -
0 . 3 5 0 -
E 0,300 -
§ ^ . . ^ - ' ' ' ' ' • ' y = 0 . 0 3 5 8 X + 0 . 1 0 5 1 s • - ^ ^ 
8 0.200 -
0 . 1 5 0 -
0,100 
0 . 0 5 0 -
0.000 -I 1 1 -I 1 1 1 1 1 —1 1 
0 1 2 3 4 5 6 7 8 9 1 0 
Concentration of BSA protein (mg/ml) 
•• Figure 2.2.8.1 A standard curve of BCA assay. The linear equation obtained was used to 
calculate protein quantity in the lysates. 
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2.2.9 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Mini-Protean 3 cell system (BioRad, Cat# 165-8025) was utilized for slab gel 
SDS-PAGE analysis according to supplier's instructions. Different percentages of 
resolving gels were employed according to the molecular weight of the target protein 
to be examined. 
Table 2.2.9.1 Composition of 5 ml resolving and stacking solution for SDS-PAGE 
Volume (ml) 
Gel component Resolving gel Stacking gel 
^ 1 0 % ^ 5% 
ddH20 1.9 1.6 1.1 1.4 
30% bis-Acrylamide mix 
1.7 2.0 2.5 0.83 
(BioRad) 
Tris (1.5 M，pH 8.8) U 1 3 \ 3 0.63 
IQo/oSDS 0.05 0.05 ^ 0.05 
10% Ammonium persulphate 0.05 0.05 0.05 0.05 
TEMED (BioRad) 0.002 0.002 0.002 0.005 
Total ml 5 
6x SDS loading dye was added to the protein samples and the mixture was heat up to 
99 for 5 min for denaturation. Samples were then loaded to the gel and 
electrophoresed at constant voltage of 220V for 45 min. Resolved gels were stained 
with Coomassie Blue® R250 staining solution for 45 min and destained with the 
detaining solution 0/N. 
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2.2.10 Western blot analysis 
2.2.10.1 Electro-transfer blotting 
Mini Trans-Blot cell (BioRad, Cat# 170-3930) was utilized for wet electroblotting of 
proteins for western blot analysis. A suitable size of 0.45 |Lim Immobilon-P® 
polyvinylidene fluoride (PVDF) membrane (Millipore, Cat#IPVH00010) was activated 
in absolute methanol and immersed in transfer buffer for rehydration. Pieces of 1 mm 
filter paper (Whatman, Cat#3030-917) were soaked simultaneously for padding the 
cassette. The cassette was set up with the following sequence: 
Anode 
Fibre pad 
3x filter paper 
PVDF membrane 
SDS-polyacrylamide gel 
3x filter paper 
Fibre pad 
Cathode 
Figure 2.2.10.1 Regime of transfer cassette. 
Blotting was performed with constant current of 200 mA for 1 h. 
2.2.10.2 Immunoblotting with antibodies 
Membrane blotted with protein was firstly incubated in blocking buffer containing 
10% (v/v) skimmed milk in PBS-T for 45 min at 4°C. Afterwards, the membrane was 
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probed with target-specific primary (1 antibody added in blocking buffer (according 
to the probing ratio (v/v) stated by supplier's protocol) at 4°C 0/N. This was followed 
by washing with PBS-T buffer for 15 min for 3 times. The membrane was then probed 
with HRP-conjugated secondary (2 antibody for 1 h at 4 This was followed by 
washing with PBS-T buffer for 15 min for 3 times and subjected to the enhanced 
chemiluminescence (ECL) assay (GEhealthcare, RPN 2132). 
2.2.10.3 ECL detection 
1 ml of ECL solution A was mixed thoroughly with 0.025 ml of solution B (40:1) on a 
parafilm (Whatman, Cat#9910001) membrane. The immunoblot was incubated with 
ECL solution mixture at room temperature for 4 min to allow the substrate to react 
with HRP on the blot. The blot was then fixed between two pieces of transparency 
plastic and exposed with Fuji RX film (Fuji, Cat#F050.099) in H y p e r c a s s e t t e T M 
(GEmedical system, Cat#RPN11649). The film was finally processed by film 
processor (Kodak). 
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2.2.10.4 Mild stripping for re-probing 
The antibody-bound membrane was incubated in stripping solution at room 
temperature for 15 min with constant shaking. Stripped membrane was washed with 
PBST for 10 times 5 min each to remove the residual stripping solution and was then 
available for re-probing. 
2.2.11 Two-dimensional gel electrophoresis (2-DE) 
2.2.11.1 Sample preparation 
HeLa protein extracts after in vitro SUMOylation for were immediately subjected to 
acetone precipitation for salt and charged detergents that might present in the protein 
sample. The acetone precipitation was performed with 2-D clean up kit (GEhealthcare, 
Cat#80-6484-51) which optimized specifically for 2-DE purpose. 300 |il Precipitant® 
solution was added to each sample and mixed thoroughly with Vortex-genie2® 
(Scientific industries, Cat#G560E). Samples were allowed to settle on ice for 15 min 
and 300 pJ of Co-precipitant® solution was then added to the samples and mixed by 
gentle shaking. Proteins precipitated were then pelleted at 16,100 x g for 5 min at 
4 and supernatants were aspirated out immediately afterwards. Pellets were further 
incubated with another 40 [i\ Co-precipitant® on ice for 5 min and were centrifuged 
again at 14,000 rpm (Eppendorf 5415D) for 5 min at 4 The pellets obtained were 
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resuspended in 25 \i\ ddHsO by vortexing. 1 ml pre-chilled (-20°C) Wash buffer was 
then added to each tube with 5 |al Wash additive solution. The tubes were then 
incubated at -20°C for 1 h, vortexed for 30 s once every 10 min. Afterwards, the tubes 
were centrifuged at 16,100 x g (Eppendorf 5415D) for 5 min at 4"C and supematants 
were decanted. The pellets were left dry in the air for 5 min and then redissolved in 
250 |li1 rehydration buffer (RB). The tubes were finally spun down for removal of 
impure debris and added with 2 |il of appropriate IPG buffer, 
2.2.11.2 First dimension gel electrophoresis-isoelectric focusing (lEF) 
The first dimension gel electrophoresis was performed with the Ettan IPGphor III 
Isoelectric focusing system (GEhealthcare, Cat# 11-0033-64) and Ettan Immobiline^'^ 
drystrip gels (GEhealthcare, Cat# 17-6001). The protein concentrations of samples 
(Experimental and Control) after clean-up procedure were determined again with 
Bradford assay and equal amounts of proteins were applied to Immobiline'^^ Drystrip 
holder (GEhealthcare, Cat#80-6417) without introducing any bubbles. An 
Immobiline™ drystrip was put on the solution by sliding the strip facing down into the 
strip holder. Drystrip cover fluid (GEhealthcare, Cat#l7-1335-01) was applied evenly 
to the top of the strips just sufficient for covering a thin layer for minimizing sample 
evaporation and urea crystallization. Covered strip holders were finally placed on an 
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ethanol wiped EttanTM IPGphor'^^ III Isoelectric focusing unit and allowed to 
rehydrated without voltage application for 12 h at constant temperature of 20 
Afterwards, lEF was allowed to proceed with the following profile卞： 
Table.2.2.11.1 EttanTM iPGphorTM m Isoelectric focusing unit lEF voltage application 
profile for EttanTM 13 cm-Immobiline '^^  drystrip 
Step Voltage mode Voltage (V) Time (h:min) kVh 
1 Step and Hold 500 1:00 0.5 
2 Gradient 0.8 
3 Graident ^ 2:30 11.3 
4 Step and Hold 4.4 
5 Step and Hold ^ ^ 0.4 
Total - 17.0 
t The entire profile was performed at constant temperature of 20 °C and a current limit was set 
to at 50 |xA per strip to avoid unstable current variations. 
2.2.11.3 Second dimension gel electrophoresis-SDS-PAGE 
2.2.11.3.1 Strip equilibration 
Isoelectrically focused strips were equilibrated sequentially with EB-A (containing 1% 
DTT) and EB-B (containing 2.5% lAA) for 15 min each at room temperature with 
gentle rocking. Excessive equilibration buffer was tapped off gently with Kimwipe®. 
2.2.11.3.2 16 X 18cm SDS-PAGE 
SE 600 Ruby™ Standard Dual Cooled Vertical Unit (GEhealthcare, Cat#80-6479-57) 
was utilized for running the second dimension gel. 12% SDS-PA gels were prepared by 
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filling gently the gel solution to the gel cast with 2 sets of 16 x 18cm glass plates and 
1.5 mm spacers. 4 L of Ix Tris-glycine electrophoresis buffer was freshly prepared for 
use. The equilibrated strips were placed on the gels and gently pushed down to the gel 
surface. A piece of filter paper with protein marker (SeeBlue®Plus2; Invitrogen, 
Cat#LC5925) was added and placed at a side. The strips were sealed in place each with 
500 melted agarose sealing solution which could also provide additional contact 
surface between the strip and the SDS gel. The slab gels were attached to the gasket 
and upper chamber was filled appropriate level of electrophoresis buffer. Finally, 
second dimension electrophoresis was performed at a constant current of 15 mA for 
16 h (0/N) or until the bromophenol blue dye front had reached the bottom of the gel. 
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2.2.11.4 Visualization of proteins on SDS-polyacrylamide gel 
2.2.11.4.1 Silver staining 
Proteins were visualized by silver staining when the protein load was 100 ^g or less. 
The procedure adopted (2-D electrophoresis handbook, GEHealthcare) was listed as 
follows: 
Table.2.2.11,2 Silver staining procedure with solution used, volume and duration listed. 
Step Solution used Volume (ml) Duration 
Fixation Fixation solution 
10% (v/v) acetic acid and 45% 400 1 h to O/N 
(v/v)analytical grade ethanol 
Sensitizing 1 Sensitizing solution 1 
. , 20 min for 
35% (v/v) analytical grade 400 . 
twice 
ethanol 
Sensitizing 2 Sensitizing solution 2 
400 2 min 
0.04% (v/v) sodium thiosulphate 
Washing 0.22 ^m filtered ddUjO 5 min for twice 
Silver reaction Silver nitrate solution 
0.4% (v/v) silver nitrate and 250 20 min 
0.2% (v/v) 37% formaldehyde 
Washing 0.22 |im filtered ddEbO ^ 1 min for twice 
Developing Developing solution 
6% (w/v) sodium carbonate, Until spots 
0.2% (v/v) 0.04% sodium 200 appear, visual 
- thiosulphate and 0.14% (v/v) monitored 
37% formaldehyde 
Stopping Fixation solution 
10% (v/v) acetic acid and 45% 400 5 min 
(v/v)analytical grade ethanol 
Storage 0.22 ^m filtered ddHzO 250 Up to 1 month 
at 40c 
90 
Chapter II Methods 
2.2.11.4.2 Coomassie Blue® R250 staining 
Proteins were visualized by Coomassie Blue® R250 staining when the protein load 
was more than 300 |ig. The procedure adopted (Slonczewski and Kirkpatrick, 2001) 
was listed as follows: 
Table.2.2.11.3 Coomassie Blue® R-250 staining procedure with solution used, volume and 
duration listed 
Step Solution used Volume (ml) Duration 
Fixation Fixation solution 
7% (v/v) acetic acid and 50% 400 1 h to 0/N 
(v/v) analytical grade ethanol 
Staining Coomassie blue®-R250 staining 
solution 
0.1 o/o (w/v) coomassie b l u e � 250 20 min 
R-250, 5%acetic acid and 30% 
(v/v) analytical grade ethanol 
Destaining 1 Fixing solution 
7% (v/v) acetic acid and 50% 500 30 min 
(v/v) analytical grade ethanol 
Destaining 2 Destaining solution 0/N or until the 
5% (v/v) acetic acid and 20% 400 background is 
(v/v)analytical grade ethanol clear 
Washing 0.22nm filtered ddHzO ^^^ 5 min for 3 
times 
Storage 0.22|am filtered ddHzO 250 Up to 1 month 
[ at4°C 
The visualized gels were scanned immediately with Image ScannerTM n (GEhealthcare) 
and Lab Scan v.3.0 (GEhealthcare). Gel-to-gel variations were overcome by replication 
of experiments (n=3) and up- or down-regulated protein expression between control 
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and treated cell lysates were evaluated using Progenesis SameSpots™ 2-D analysis 
software (Nonlinear Dynamics). By the software quantifications, spots with differential 
expression difference which were statistically meaningful (p value <0.05) or which 
showed more than a 50% increase or decrease in intensity were defined as up- or 
down-regulated spots. Corresponding gel spots were excised out manually and stored 
at -80 until further processing. 
2.2.12 Sample preparation for mass spectrometry analysis 
2.2.12.1 Destaining and trypsin digestion 
Gel spots were cut into smaller pieces with a gauge needle and destained by incubating 
in 100 |il silver de-staining solution at room temperature with gentle shaking until a 
clear background has attained. Vortex and replacing the de-staining solution with fresh 
ones can accelerate the destaining process as needed. The gel spots were then washed 
with 1 ml nano pure water for 3 times after the yellow colour has been totally removed. 
It was followed by equilibration of the gels with 100 \i\ 200 mM ammonium 
bicarbonate for 10 min for 2 times and then dehydration with 100 \i\ 100% (v/v) ACN 
for 5 min for 3 times. The treated gels were dried under vacuum centrifugation in 
SpeedVac® concentrator (Savant, Cat# SAV-ISS110-220) for 3 min until appearing 
"dust-like". Afterwards, gels were rehydrated in 7 |il trypsin enzyme (40 ng/|il trypsin 
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in 25 mM ammonium bicarbonate) by incubating on ice for 30 min. Finally, 20 \i\ of 
25 mM ammonium bicarbonate was further added to cover the hydrated gel pieces and 
the digestion was carried out at 30 0/N. 
2.2.12.2 Extraction of peptide mixture 
Solutions previously added were transferred to a new tube. Another 20 )il of 25 mM 
ammonium bicarbonate was added to the tubes and the tubes were sonicated for 
10 min followed by brief vortexes. The solution was likewise transferred to the same 
new tube. Extraction was proceeded by sonication with 20 |il 100% ACN / 5%TFA 
solution for 10 minutes for twice, and finally 100% ACN once. All the solutions were 
transferred and combined in a new tube and dried by vacuum centrifugation by 
SpeedVac® for 3 h. 
2.2.12.3 Desalting and concentration of peptide mixture 
Dried peptide samples were resuspended in 10 i^l 0.1% TFA buffer. Purification and 
concentration was achieved with ZipTip® C-18 Pipette Tips (Millipore, 
Cat#ZTC18S096). Firstly the ZipTip was wetted by 10 |al 50% ACN twice. It was then 
equilibrated by aspiration of 10 0.1% TFA twice. The peptides were then allowed to 
bind to the tip by slowly aspirating and dispensing the sample for 20 cycles. 
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Afterwards, the tip was washed with 10 \i\ 0.1% TFA for five times. Finally the 
peptides were eluted in 2 jil 50% ACN / 0.1% TFA solution. The 2 \i\ samples were 
spotted on to a 192 stainless steel MALDI sample plate (Applied Biosystems) 0.5 i^l 
each time and dried by air. Finally, 0.5 \i\ saturated CHCA matrix was loaded to the 
samples and the plate was sent to process by 4700 Proteomics Analyzer equipped with 
the 4700 Explorer softwares (Applied Biosystems)!. 
After data acquisition, combined MS and MS/MS analysis was performed with the 
Mascot based GPS Explorer Software (Applied Biosystems) with appropriate 
exclusion of the contaminant (e.g. skin and hair keratin, trypsin) sample peaks and an 
error tolerance rate for peptide mass set at <50ppm and possible missed cleavage of 
trypsin was set as 1. MALDI peptide mapping was searched within the Swiss-Prot 
(http://ch.expasv.org) and NCBInr (http://ncbi.nlm.nih.gov) databases. 
卞The manipulation of 4700 Proteomics Analyzer was kindly performed by Ms Hellen 
Tsai at Prof. Ice Ngai 's lab of Department of Biology, the Chinese University of Hong 
Kong. 
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2.3 RESULTS 
2.3.1 Construction of recombinant pET-28m-SUMO-l and pHM6-SUMO-l 
SUMO-1 encoding gene was amplified by PCR with the primers containing 
BamHl/Notl and Kpnl/Notl restriction sites for cloning into pET-28m and p H M 6 
respectively (Fig. 2.3.1.1, Fig 2.3.1.3). The SUMO-1 gene with size of 291 bp was 
successfully amplified from the D N A template pGEX-6p-SUM0-1 kindly given by 
Dr. Xu Zheng using the profile described in section 2.2.1.2. Digestions by 
corresponding restriction enzymes were performed and ligation was carried out using 
methods described in section 2.2.1.3-8. Clones were screened by PCR amplification 
(Fig. 2.3.1.2，2.3.1.4). Clones were then sequenced by TechDragon. Ltd.. Using 
ClustalW programme, D N A sequences of positive clones were found to be aligned 
with S U M O genes at the NCBInr database with 100% match scores. 
95 
Chapter II Introduction 
1200 
900 
291 • 300 ^ _ s u m C M 
200 ~ ~ 
100 —— 
Figure 2.3.1.1 PCR products of SUMO-1 gene (291 bp) for construction of 
pET-28m -SUMO-1 recombinant plasmids. Lanes 1 and 2, PCR products; Lane M, 
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Figure 2.3.1.2 Screening of positive pET-28m-SUMO-l recombinant clones by PCR 
amplification. Lanes 1 and 2，positive clones with SUMO-1 gene inserts amplified by PCR; 
Lane M, Portman 100 bp DNA ladder. Analyzed with 1% agarose gel. 
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Figure 2.3.1.3 PCR products of SUMO-1 gene (291 bp) for construction of 
pHM6-SUMO-l recombinant plasmids. Lanes 1 and 2，PCR products; Lane M, Portman 
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Figure 2.3.1.4 Screening of positive pHM6-SUMO-l recombinant clones by PCR 
amplification. Lanes 1 and 2, positive clones with SUMO-1 gene inserts amplified by PCR; 
Lane M, Portman 100 bp DNA ladder. Analyzed with 1% agarose gel. 
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2.3.2 Purification of His6-tagged SUMO, ubc9, TDG and GST-tagged El 
Purification strategies were optimized in order to produce high purity proteins for the 
in vitro SUMOylation. Different combinations of chromatography and buffer systems 
for the purification of His6-SUM0 and T D G were tested, while the purification 
protocol of ubc9 and El was optimized by Mr. Xu Zheng previously. 
2.3.2.1 Purification of His6-SUMO 
Expression vector pET-28m-SUMO was transformed into BL21(DE3) pLysS and 
grown at 20°C overnight after induction by IPTG at ODsoo 0.6. The cells were 
resuspended in nickel column binding buffer and lysed with sonication. The soluble 
fraction was processed through the Ni-NTA resins. Most of the protein impurities 
were able to be removed and came out in the flowthrough. A little amount of protein 
impurities was washed in the post-binding wash. The elution was accomplished with 
120 m M imidazole with approximately 80% purity (Fig.2.3.2.1). Some higher 
molecular weight protein impurities were found when higher concentrations of 
imidazole were used. 
98 
‘ Chapter II Results 
kDa lY FL W 1 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 
250—xm-�-.. 
r i f 
36- M V 
麗 
22 — 
—dl k i i M M t t i ^ M M i i U i i i i i u i i f l N ^—+ h i s s - s u m c m 
8 — 
Figure 2.3.2.1 Purification of His6-SUMO-l by nickel affinity chromatography. Protein 
samples were analyzed by 15% SDS-PAGE. Lane LY, crude lysate of BL21(DE3)pLysS 
expressing His6-SUM0-1; Lane FL, flowthrough after binding Ni-NTA resin; Lane Wl, 
washing (with 20 m M imidazole); Lanes El to ElO, elution of His6-SUMO-l in a gradient of 
120 m M to 300 m M imidazole; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
Partially purified His6-SUM0-1 from fractions El to E5 was loaded to Q anion 
exchange chromatography for further purification. Pure His6-SUM0-1 was able to be 
obtained at elution fraction of 300 m M NaCl, while the higher molecular weight 
protein impurities were successfully removed in higher salt concentrations 
(Fig.2.3.2.2). However, the loss of yield was high using Q anion exchange 
chromatography while an unknown band was observed right above the target band of 
His6-SUM0-1 in fractions E3 to E8. The final purification of the fractions from El to 
E4 was carried out with the size exclusion column SuperdexTM S75. His6-SUM0-1 
was successfully eluted out at a volume of 〜60ml. Fractions E6 and E7 were pooled 
and an approximately 95% pure protein was obtained (Fig.2.3.2.3). 
99 
‘ Chapter II Results 






36- • . • • n i l 
22— .'l^iUlylll^^ ^ ^ ^Igllll 
^ H r HiSg-SUMO-l 
Figure 2.3.2.2 Purification of His6-SUMO-l by Q anion-exchange chromatography. 
Protein samples were analyzed by 15% SDS-PAGE. Lane Ni, pulled fractions of Ni-NTA 
purified His6-SUMO-l; Lane FL, flowthrough after binding Ni-NTA resin; Lane Wl, 
washing (with binding buffer); Lanes El to E8, elution of His6-SUMO-l in a gradient of 
100 m M to IM NaCl; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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Figure 2.3.2.3 Purification of His6-SUMO-l by the gel filtration chromatography. 
Protein samples were analyzed by 15% SDS-PAGE. Lane Q, pulled fractions of Q-Sephrose 
purified His6-SUMO-l; Lane El, fraction eluted at 33 ml; Lanes E2 to E3, fractions eluted at 
40 and 50 ml containing the 36 kDa impurity; Lanes E4 to E8, elution of His6-SUMO-l at 
60-65 ml; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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2.3.2.3 Purification of His6-ubc9 
pQB80-TDG which was kindly provided by Prof. L. Pearl, ICR, London was 
transformed into Rosetta 2 and grown at 16 °C overnight after induction by IPTG at 
OD600 0.6. Cells were resuspended in Nickel column binding buffer and lysed with 
sonication. The soluble fraction was processed through the Ni-NTA resins and eluted 
with high imidazole concentration elution buffer as described in section 2.2.3.4.2. 
Purity obtained was very low, with only approximately 40% purity when eluted with 
100 m M imidazole (Fig.2.3.2.4). Therefore, protein impurities were co-eluted along 
the whole elution spectrum. 
Partially purified His6-TDG from fractions E9 to El9 was loaded to heparin affinity 
column for further purification as T D G was a DNA-binding protein. Higher purity of 
His6-TDG was obtained when eluted with 500 m M NaCl. Purity after heparin 
chromatography was raised to 80% as the major protein impurities were successfully 
eluted at lower concentration of NaCl (Fig.2.3.2.5). The final purification was carried 
out on fractions E7 to ElO with S u p e r d e x ^ M S75 gel filtration column and His6-TDG 
was successfully eluted out at a volume of ~45 ml. Minor bands were observed below 
the target His6-TDG in lanes El to E5 which might be the degraded products of 
His6-TDG. Fractions E2 to E4 were pooled and an approximately 95% pure 
His6-TDG was obtained (Fig.2.3.2.6). 
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Figure 2.3.2.4 Purification of His6-TDG by nickel affinity chromatography. Protein 
samples were analyzed by 12% SDS-PAGE. Lane LY, crude lysate of Rosetta 2 expressing 
His6-TDG; Lanes FLl and 2，flowthrough after binding Ni-NTA resin; Lanes W1 and 2, 
washing (with 20 mM imidazole); Lanes El to El9, elution fractions with His6-TDG in a 
gradient of 20 mM to 300 mM imidazole; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained 
Standard. 
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Figure 2.3.2.5 Purification of His6-TDG by heparin affinity chromatography. Protein 
samples were analyzed by 12% SDS-PAGE. Lane Ni, pulled fractions of Nickel purified 
His6-TDG; Lane FL, flowthrough after binding Ni-NTA resin; Lanes W1 and 2, washing 
(with binding buffer); Lanes El to El9，elution fractions with His6-TDG in a gradient of 
150 mM to 1 M NaCl; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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Figure 2.3.2.6 Purification of His6-TDG by gel filtration chromatography with 
Superdex 顶 S75. Protein samples were analyzed by 12% SDS-PAGE. Lane Q, pulled 
fractions of Q-Sephrose purified His6-TDG; Lanes El to E5, elution fractions at -45 ml 
containing His6-TDG with >90% purity; Lanes E6 to 7，elution fractions at 65 ml containing 
the 22 kDa impurity; Marker - Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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2.3.2.3 Purification of His6-ubc9 
pTwoE-ubc9 was transformed into BL21(DE3)pLysS and grown at 22 overnight 
after induction by IPTG at ODeoo 0.6. Cells were resuspended in Nickel column 
binding buffer and lysed with sonication. The soluble fraction was processed through 
the Ni-NTA resins and eluted with the high imidazole concentration elution buffer as 
described in section 2.2.3.4.3. Most of the impurities were removed at a lower 
concentration of imidazole while His6-ubc9 was eluted with - 7 0 % purity at 90 mM 
imidazole (Fig.2.3.2.7). The partially purified His6-ubc9 was processed by 
PreScissionTM protease to cleave the His6-tag to enable studies on non-covalent 
interactions by nickel pull-down. The cleavage product ubc9 was further purified by 
passing through nickel column. The flowthrough was collected and concentrated for 
gel filtration purification. 
The final purification was carried out with Superdex™ S75 gel filtration column and 
ubc9 was successfully eluted out at a volume of 〜65ml (Fig.2.3.2.8). Fractions E8 to 
El2 were pooled and an approximately 9 8 % pure protein was obtained. 
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Figure 2.3.2.7 Purification of His6-ubc9 by the nickel affinity chromatography. Protein 
samples were anylzed by 12% SDS-PAGE. Lane LY, crude lysate of BL21(DE3)pLysS 
expressing His6-ubc9; Lanes FLl and 2, flowthrough after binding Ni-NTA resin; Lanes W1 
to 3, washing (with 20 mM imidazole); Lanes El to El8, elution fractions with His6-ubc9 in a 
gradient of 50 mM to 300 mM imidazole; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained 
Standard. 
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Figure 2.3.2.8 Purification of ubc9 by the gel filtration chromatography. Protein samples 
were anylzed by 12% SDS-PAGE. Lane Ni, pulled fractions of Ni-NTA purified His6-ubc9; 
Lane El, fraction eluted near the end of void volume of column (33 ml); Lanes E2 to E3, 
eluted fractions at 40 and 45 ml containing the 50 kDa impurity; Lanes E4 to E6, eluted 
fractions at 50-60 ml containing the 36 and 22 kDa impurity; Lanes E7 to El2，elution 
fractions ~65 ml containing ubc9 with a >90% purity; Marker, Invitrogen SeeBlue® Plus 2 
Pre-Stained Standard. 
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2.3.2.3 Purification of His6-ubc9 
pGEX-6p-l-El was transformed into BL21(DE3)pLysS and grown at 37。C for 3 h 
after induction by IPTG at ODeoo 0.6. Cells were resuspended in GST column binding 
buffer and lysed with sonication. The soluble fraction was processed through the 
glutathione Sepherose™ resins and eluted with reduced L-glutathione elution buffer 
as described in section 2,2.3.4.4. Efficacy of purification was low with only -50% 
purity. A lot of impurities were co-eluted with GST-El (Fig.2.3.2.9). The GST-tag was 
successfully removed by PreScission™ protease after the elution of GST column. The 
partially purified El protein was processed further by Superdex tm S200 gel filtration 
column and El was successfully eluted out at a volume of 〜55ml (Fig.2.3.2.10). 
However, impurities were observed which is possibly via non-covalent interactions 
with the target protein and thus co-eluted (Fig.2.3.2.10). Final purity was 
approximately 55%, and a low yield (only 3 m g from 4 L of E.coli cells) was 
obtained. 
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Figure 2.3.2.9 Purification of GST-El by GST SepheroseTM affinity chromatography. 
Protein samples were analyzed by 15% SDS-PAGE. Lane LY, crude lysate of 
BL21(DE3)pLysS expressing GST-El; Lane FL, flowthrough after binding glutathione 
sepherose resin; Lanes W1 and 2, washing (with binding buffer); Lanes El to E7, elution of 
GST-El in 10 mM reduced L-glutathione; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained 
Standard. 
kDa GT E1 E2 E3 E4 E5 E6 E7 E8 E9 E10E11 
2 5 0 一 广 . 
148 一 i 'k . , , 
AO . BtiNliJi'lf'^ f''‘奶丨'1 iitiiiilM Vt U Mil Ifr- IwA ….—"晰 
® . , ~100kDa 
64—-w r!^? v. 
5 。 - , ， — . … ： 
务嚇、•^参..... 
36—\ f}y ,.。 
V^yitM ... 
( - ‘.  
I 
)• . . V:" , , 
Figure 2.3.2.10 Purification of El by gel filtration chromatography. Protein samples 
were analyzed by 15% SDS-PAGE. Lane GT, pulled fractions of GST purified GST-El; Lane 
El, fraction eluted near the end of void volume of column (33 ml); Lanes E2 to E3, fractions 
eluted at 40 ml containing the 40 kDa impurity; Lanes E4 to E7, fractions eluted at 55 ml 
containing the El protein; Lanes E7 to El l , fractions eluted at 65 ml containing the 60 kDa 
impurity; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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2.3.3 In vitro SUMO conjugation assay 
2.3.3.1 Optimization of in vitro SUMO conjugation system 
The in vitro S U M O conjugation system was optimized to achieve 100 % 
SUMOylation of T D G protein. T D G was utilized as a positive control which has been 
as it has been shown to be a well-known S U M O substrate (Hardeland et al., 1999). A 
S U M O conjugation reaction profile was formulated previously by Dr. Xu Zheng. 
However, it was not attempted to get optimized. 
T D G had a size of -50 kDa. When it was conjugated with a S U M O molecule, a 
bandshift to about 66 kDa in SDS-PAGE would be observed (Fig. 2.3.3.2). The 
optimization was carried out in three parameters as shown in fig. 2.3.3.1: (1) the 
physical parameters, (2) the chemical parameters and (3) the enzymatic parameters. 
From the result shown in Fig.2.3.3.2, it was observed that the best S U M O conjugation 
efficiency could be achieved in a reaction mix with a molar ratio of 
E2:SUMO-1:Substrate of 1:2:4 and final concentrations of 5 m M ATP, 10 m M MgCb, 
,2 m M DTT, 150 m M NaC^in Na2C03 buffer at pH 9.2 (a final pH equal to 7.7t) at 
y f C for 2 h. The optimized reaction condition was used in the subsequent in vitro 
SUMOylation assays. 
fThe difference in pH caused was due to the pH altering property of ATP. 
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Figure 2.3.3.1 Illustration of the three parameters of in vitro SUMOylation assay profile. 
In vitro SUMOylation system was composed of three major sets of parameters: 1. physical 
parameters, including the reaction time and temperature; 2. chemical parameters, the 
concentration of different chemicals used in the reaction profile and 3. enzymatic parameters, 
the molar ratio among SUMO, SUMO enzymes and its substrate. The optimization was 
carried out by screening in different variation of conditions in these three criteria to maximize 
the efficiency of SUMOylation. 
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Figure 2.3.3.2 Optimization result of SUMO conjugation assay. Analyzed in 15% 
SDS-PAGE. (A) Optimization of pH: Lane 1, TDG added with El and E2; Lane 2, SUMO; 
Lane 3, TDG SUMOylation (TDG-S) at pH 7.7; Lane 4, TDG-S using the original condition 
(Tris-HCl pH 7.0, 5 mMATP, 5 mM MgCh, 2 mM DTT, 1% glycerol, 150 mMNaCl, 30 min 
at 37°C, E2:S:Substrate=l:l:iy, Lane 5，TDG-S at pH 7.4. (B) Optimization of reaction 
temperature and reaction time: Lane 6, TDG-S using the original condition; Lane 7, TDG-S 
at 3(rc for 1 h; Lane 8，TDG-S at 37°C for 1 h; Lane 9，TDG-S at 37�C for 1.5 h. (C) 
Optimization of chemical parameters: Lane 10, TDG-S using the original condition; Lane 
11, TDG-S without glycerol; Lane 12, TDG-S without DTT; Lane 13, TDG-S with 2-fold ATP; 
Lane 14, TDG-S with 2-fold MgCh. (D) Optimization of enzymatic parameters: Lane 15, 
TDG-S with E2:SUMO:TDG 2:1:2; Lane 16, TDG-S with E2:SUM0:TDG 1:5:10; Lane 17, 
TDG-S with E2:SUM0:TDG 1:2:4; Lane 18, TDG-S with E2:SUM0:TDG 4:1:2. (E) TDG-S 
using the optimized parameters (NaiCOs, pH 9.2, 5 mMATP, 10 mM MgCl2, 2 mM DTT, 
150 mMNaCl, 2 h at 37 V, E2:S:Substrate=l:2:4) 
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2.3.3.2 In vitro SUMO conjugation of HeLa cell protein extract 
2.3.3.2.1 Protein extraction for in vitro sumoylation assay 
Ordinary extraction of proteins from mammalian cells composed of stringent 
detergents like e.g. SDS, ND-40, Triton®-X-100 or degradation agent like urea. 
However these will interfere with the SUMOylation assays. Nonetheless, a survey of 
both SUMOylation efficiency and lysis efficiency was carried out with five buffer 
recipes adopted from online protocol sites in the attempt to obtain the best lysis buffer 
system for SUMOylation assays in HeLa cell lysates (Table 2.3.3.1). 
In order to determine the efficiency of S U M O conjugation, 6 |xl of each buffer was 
added to T D G and S U M O conjugation assay was performed as described in section 
2.2.6. Result was shown in Fig. 2.3.3.3 and the efficiency comparison was listed in 
Table 2.3.3.2. 
Lanes C and E showed no sign of S U M O conjugation to TDG, suggesting that buffer 
C and E inhibit SUMOylation. On the other hand, lanes A and D showed a dramatic 
decline of S U M O conjugation efficiency. The highest SUMOylation efficiency was 
achieved with lysis buffer B, though only approximately 50% of conjugation 
efficiency was retained. Lysis buffer B was used in the subsequent experiments as it 
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was the best lysis buffer among the five lysis buffers accounting for both the S U M O 
conjugation efficiency and cell lysis efficiency (Table 3.2.3.2). 
Table.2.3.3.1 List of lysis buffer in the survey of in vitro SUMOylation efficiency. 
Lysis Composition References 
buffer 
A 10 mM Hepes pH 8.0，1.5 mM MgCb, 10 mM KCl, Protocol from 
1 mM DTT Lamond's labt 
B 20 mM Hepes pH 8.0, 1.5 mM MgClz, 2% Glycerol, Protocol from 
420 mM NaCl, 0.2mM EDTA, ImM DTT, 0.5mM Lamond's labt 
PMSF 
C 50 mM Tris pH 7.5, 0.5 M NaCl, 1% Triton-X, 1% DOC, Protocol from 
0.1% SDS, 2mM EDTA, 0.5mM PMSF Howe's lab丰 
D 20 mM Tris pH7.4, 150 mM NaCl, 1% Triton-X, 1 mM Athie-Morales et al, 
Na2V03’ 20 mM N-ethylmaleimide, 1 mM EDTA, 2004 
200 ^ iM lAA, 1 m M PMSF 
E 50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton-X, Protocol from 
1% DOC, 0.1% SDS, 1.0% NP40, 2 mM EDTA, Howe's labt 
1 mM PMSF, 1 mM DTT 
n.b. Italics represents the detegent components in the buffer receipe 
Lamond's lab, the University of Dundee (http://www.lamondlab.com/f7pwtocols.htm) 
^Howe 's lab, the University of Vermont (http://www.uvm.edu/~akhowe/HoweLabProtocols3.html) 
Table.2.3.3.2 Comparison of the SUMO conjugation efficiency and cell lysis efficiency 
among the five lysis buffer. 
Lysis buffer SUMO conjugation efficiency (% of Cell lysis efficiency卞 
OG) (obtained protein concentration in 
mg/ml) 
A ^ 2.02 
B S m 3 M 
C 0% n.a4 
D ^ 7.03 
E 0% 
卞cell lysis efficiency was determined by lysis of 1x10^ cells in 50 …corresponding buffer and 
measured the O D at 595 n m with Bradford assay 
Jdue to total loss of S U M O conjugation efficiency, cell lysis efficiency was not measured. 
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Figure.2.3.3.3 Selection of lysis buffer compatible with in vitro SUMOylation. Analyzed 
in 15% SDS-PAGE. Lane T, TDG protein as negative control; Lane S, SUMO protein as 
negative control; Lane OG, in vitro SUMOylation in original reaction buffer; Lane A, 
SUMOylation in Lysis buffer candidate A; Lane B, SUMOylation in Lysis buffer candidate B; 
Lane C, - SUMOylation in Lysis buffer candidate C; Lane D, SUMOylation in Lysis buffer 
candidate D; Lane E, SUMOylation in Lysis buffer candidate E; Marker, Invitrogen 
SeeBlue® Plus 2 Pre-Stained Standard. 
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2.3.3.2.2 In vitro SUMOylation of HeLa cell lysate 
The optimized reaction profile was applied to in vitro S U M O conjugation of HeLa 
cell protein extract obtained with lysis buffer B as described in section 2,2.4.2. Three 
control reactions were set in parallel to the experimental reaction: (1) S U M O 
conjugation system only (including S U M O , El, E2)，（2) T D G with S U M O 
conjugation system; and (3) lysate protein without S U M O conjugation system. All of 
the reactions were treated with the same reaction buffer. Control 1 allowed us to 
distinguish bands resulted from the S U M O conjugation of its own enzyme system 
components e.g. S U M O conjugation of ubc9. Control 2 was a positive control of 
S U M O conjugation to ensure the conjugation efficiency was optimal. 
As the reaction contained total lysate, visualization by C o o m a s s i e T M blue staining was 
incapable to reveal the difference in between. Therefore, immunoblotting was 
performed with monoclonal anti-SUMO antibody (Fig. 2.3.3.4.). By comparing the 
controls and the reaction sample lanes, extra bands at around 60-70 kDa and 36 kDa 
could be observed. The bands were resulted by the exogenous in vitro S U M O 
conjugation as they were not observed in the lane 3, which was loaded with control 
lysate, where the level of endogenous S U M O conjugates was too low to be detected 
under a short exposure time. 
114 
‘ Chapter II Results 
A B 
1 2 3 4 1 2 3 4 kDa 
M l J E i 
TDG-SUMO _ ^ ^ - 4 t . 一 64 
U" — 50 
1 » -丨 _ _ 丨 
UBC9-SUMO ~ ~ H H ^ ^ ^ P I iff 
， ？ m 
— P H i i ^ fe 
Figure 2.3.3.4 In vitro SUMO conjugation assay of HeLa total protein extract [short 
exposure]. Proteins samples were analyzed on a 12% SDS-PAGE, followed by 
immunoblotting with anti-SUMO-1 antibody (A) or CoomassieTM blue R250 staining (B). 
Lane 1，(Control) in vitro SUMOylation of TDG; Lane 2，(Control) in vitro SUMOylation 
system; Lane 3，(Control) HeLa lysate only; Lane 4，in vitro SUMOylation of HeLa lysate, 
ubc9-SUMO cannot be observed as clear in lane 2 due to enzymatic competition by massive 
amount of substrates in the lysate; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
Extra bands resulted from the in vitro SUMOylation of HeLa lysate are boxed. 
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2.3.4 Differential proteomes of control and in vitro SUMOylated HeLa total 
cellular extract 
One of our aims is to identify SUMOylation substrates by performing 
two-dimensional gel electrophoresis (2-DE) on the HeLa total cellular proteins which 
have been processed with and without in vitro SUMOylation. Upon in vitro S U M O 
conjugation, the potential SUMOylation substrates in the total lysate would be 
attached in the presence of extra El, E2 and S U M O . The proteomic study on S U M O 
substrates was from the beginning greatly hindered by the low percentage of S U M O 
conjugated proteins present in cells in vivo (Rosas-Acosta et al., 2005). Various 
strategies were developed to overcome the problem. Single-stage affinity purification 
was widely utilized to enrich the quantity of SUMOylated proteins, including fusion 
tag purification or immunoprecipitation (Vertegaal et al., 2006). However, these 
methods encountered the problem of non-specific affinity interactions. Fusion tag 
purification often causes high background produced by non-specific interactions. 
Immunoprecipitation is difficult to manipulate as this is very dependent on the quality 
of antibody and the conditions in the immunoprecipitation experiments. When 
proteins obtained from these two methods are subjected to 2-DE analysis, 
false-positives are easily produced. 
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Therefore, here we attempted to utilize the advantage of in vitro SUMOylation system 
to identify potential SUMOylation substrates. This was often used as a means to carry 
out validation experiments on proteins identified by the MALDI-TOF MS/MS P M F 
matching in proteomics research. In this approach, in vitro SUMOylation was carried 
out in a parallel of two reactions. One was a lysate sample supplemented with the in 
vitro SUMOylation system (SUMO, El and E2); the other one was a control 
"placebo" reaction, with only lysate sample. Both reactions were performed in the 
optimized buffer at 37 Both reaction mixtures were collected after the reaction and 
subjected to sample clean-up procedure and subsequent 2-DE analysis (section 
2.2.11). 
Totally 100 |ig (for silver staining) or 300 |ag (for Coomassie stain) of lysate protein 
was used for in vitro SUMOylation and 80% was recovered from the clean-up 
procedure. Both silver staining and Coomassie staining were adopted to visualize the 
gel patterns after the electrophoresis process. Fig.2,3.4.1 illustrates the proteome gel 
pattern after 2-DE separation. Using Progenesis™ analysis software quantifications 
(Nonlinear Dynamics), spots with differential expression difference which were 
statistically meaningful (p value <0.05) or which showed more than a 1.5-fold 
increase or decrease in intensity were defined as up- or down-regulated spots 
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(Fig.2.3.4.1-2). According to this definition, 37 differential spots were found in the in 
vitro SUMOylated HeLa lysate and localized in pi 3-10 and molecular masses ranging 
from 10 to 120 kDa (Figure 2.3.4.3). 
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Figure 2.3.4.1 2-D gel alignment in the Progenesis SameSpot^"^ Software . (A) Gel images 
were aligned with SameSpot™ software. Magenta represents the control gel, and green 
represents the reaction gel; (B) Vectors in red colour were drawn by putting the cursor on a 
specific spot. The marker spots would be used for the alignment analysis by the software. 
Aligned gels provided the precision of gel-to-gel comparison by correlating the same spot 
from 2 or more gels. 
119 
‘ Chapter II Results 
oroiifis^  V 一 n^tmmuiua nonlin6Qr 
ft.v<«wSpots I ^ imct I I OM«.r | qtimu | CX幼[•Quro^ | | 
i k^ fau . mctJMf jWw jJ 
- 1,1 ^ AM... CH'^ ifl 
城 一 “ J I ^ . f r r ^ r ~ ^ 
MM - ‘ 
MM. — 
- “ •J 战… ^八 
3eJ» - i.S fcj • 
MO - fcj MO... 
- ^ M ) ^ taLu 
06*2 - 1.» …zl 
^ {rcMM) tQ< in r«nlti 4 m»rti«d 
X p ： — ,_H. ^ 1 • 
•• p “ 
、•； • l . i ^ 
• . 
• -
；• r • • • � 
_ • . .J. 
iVbrtiM一.Mrxi ~tS.「•TIT ,J 
^ S«<t»n Cwnptvt* .•». 
Figure 2.3.4.2 Spots review in the Progenesis SameSpot^"^ Software. The aligned gel was 
then processed by the spot detector and analyzer. The figure displayed the spot comparison in 
the blue square indicated in the overview panel at the bottom right comer. Spots from both 
gels were shown in the centre of the window. The graph at the bottom centre indicated the 
variations detected as a downregulated spot. In the red circle was the fold of change between 
































































































































































































































































































































































































































‘ Chapter II Results 
2.3.4.1 Mass Spectrometric identification of differential protein candidates 
The spots with significant differential intensity were sent to peptide mass fingerprint 
(PMF) analysis by matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS/MS). In an overview, a total of 16 proteins (5 
upregulated/ 2 shifted position/ 9 downregulated) from triplicated experiments (Fig. 
2.4.1.1) were annotated with the Mascot program embodied in the GPS ExplorerTM 
software by performing protein database search against NCBInr with the P M F raw 
data. Parameters were set to filter the M S and MS/MS peaks which were due to 
background noises e.g. skin keratins and trypsin. This could prevent the devastating 
effect of the noise peaks on the actual peptide peaks of the protein sample 
(Fig.2.3.4.4-5). 
The accuracy of a protein matched was determined by the Protein Score and the 
Protein Score C.I. % (confidence interval) (Fig.2.3.4.6). These were included in the 
-- report of Mascot search reflecting the Probability Based Mowse Score (PBM Score) 
of each sample. The Score represent the statistical confidence of accuracy of the 
identifications. The list of proteins with respective identities and reported functions 
were tabulated in Table 2.4.1.1 and discussed in section 2.4. 
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Figure 2 . 3 . 4 . 4 Peak filtering settings for the protein identity search through NCBInr 
with P M F obtained from M A L D I - T O F M S / M S analysis. (A) M S peak filtering setting; (B) 
MS/MS peaking filtering settings. Setting aimed at excluding noise peaks caused by trypsin 
and skin keratins which are abundant in the protein samples 
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Figure 2.3.4.5 The search criteria for the protein identity search through NCBInr with 
PMF obtained from MALDI-TOF MS/MS analysis. Search was limited in the human 
database，maximum missed cleavage of 1, carbamidomethyl and oxidation as variable 
modifications, MS/MS fragment toleration of 0.1 Da and peptide charges 1+. 
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Figure 2.3.4.6 MASCOT search results display in the GPS ExpIorer^ M Software . (A)The 
spots were identified in each well in the MALDI plate, the green wells represents protein 
identification has a high confidence of correctness, in the centre is the protein list ranked by 
%C.I.; (B) The raw M S peak profile obtained with the raw PMF data and a list of peak 
centroid mass with the peak specific information. 
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2.3.5 Overexpression of SUMO-1 in HeLa cells by transient transfection 
Overexpression of SUMO-1 was induced by transiently transfecting pHM6-SUM0-l 
into HeLa using lipofection method. This was in the attempt to mimic the 
upregulation of S U M O protein level in vivo which was reported in various kinds of 
stressed conditions (Shinbo et aL, 2006; Manza et al., 2004). Transfection efficiency 
trials were performed with a series of post-transfection incubation durations, D N A 
concentration and amount of Lipofectamine® reagent. Overexpression of SUMO-1 
was readily detected when cells were lysed 48-h post-transfection with 2-4 }xg of 
plasmid and a Lipofectamine® ratio of 1:2 (Fig.2.3.5.1) 
1 2 3 4 5 6 7 
kDa 
— 2 5 0 
… —148 
( — 98 
SUMO-1 • 
Figure 2.3.5.1 Overexpression of SUMO-1 by transient transfection of pHM6-SUMO-l 
in HeLa cells. Cell lysates of 48 h post-transfection were analyzed by 12% SDS-PAGE and 
immunoblotted with anti-SUMO-1 antibody. Lane 1, control without transfection; Lane 2, 
control transfecting with empty pHM6 vector; Lanes 3 to 6, transfection with different 
concentrations of plasmid (Lane 3，1 昭；Lane 4，2 fig; Lane 5, 3 (xg; Lane 6, 4 p,g); Lane 7, 
purified SUMO-1 protein as positive control; Marker, Invitrogen SeeBlue® Plus 2 
Pre-Stained Standard (on membrane only). All lanes had protein quantity normalized with 
BCA assay. 
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2.3.6 Differential proteomes of total cellular protein extract from control and 
SUMO-1 transfected HeLa cells 
The other aim in our study was to identify downstream S U M O effect proteins, which 
was achieved by performing two-dimensional gel electrophoresis (2-DE) on the HeLa 
total cellular protein with and without transfection of pHM6-SUM0-l plasmid. 
Transient transfection was carried out in order generate the stress-induced 
upregulation of S U M O protein level in vivo. Proteomic studies of SUMOylation were 
mainly focused on getting a SUMOylation substrate proteome from various kinds of 
cell type (Rosas-Acosta et al., 2005). This ordinary approach commonly used can 
provide the information of potential SUMOylation substrates. Recently, S U M O was 
found to interfere with the function of other proteins by means of non-covalent 
interactions (Kaukinen et al., 2003). The biological effects of S U M O conjugation to 
its substrates cannot be revealed by merely a list of S U M O substrates, thus limiting 
our knowledge of the roles of S U M O in the network of signalling pathways and cell 
cycle regulation. In our experiment, the upregulated S U M O protein level in the cells 
would promote the downstream effects. N-ethylmaleimide, a potent S U M O protease 
inhibitor was intentionally not added to the lysis buffer, which would be assumed to 
prevent S U M O from substrate deconjugation by the active S U M O protease in the cell 
lysate. This was originally a challenge for the proteomic study of S U M O substrates. 
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However, it was an advantage for our purpose to filter out the possibility of getting 
S U M O substrates in our differential proteome investigation. By comparing gels with 
and without the overexpression of S U M O , the differential protein spots would 
represent the proteins regulated by an increased level of S U M O protein. 
1 X 10^  cells with and without pHM6-SUM0-l plasmid transfection were lysed in the 
urea lysis buffer. Totally 100 ^ ig of each cellular lysate protein extract was processed 
with clean-up procedure with 80% recovery. Silver staining was adopted for the 
visualization of gel patterns after the electrophoresis. Fig.2.3.6.1 illustrates the 
proteome gel pattern after 2-DE separation. Analyses were performed as the same as 
described in section 2.3.3. According to the same criteria of spot selection as in the in 
vitro investigation, among the 52 protein candidates found, 31 proteins were 
up-regulated and 21 proteins were down-regulated in the SUMO-1 transfected cell 



















































































































































































































































































































‘ Chapter II Results 
2.3.6.1 Mass Spectrometric identification of differential protein candidates 
The spots with significant differential intensity variation were sent to peptide mass 
fingerprint (PMF) analysis by matrix-assisted laser desorption ionization 
time-of-flight mass spectrometry (MALDI-TOF MS). In an overview, a total of 21 
proteins were annotated with the M A S C O T program assigned for protein database 
search with the P M F raw data (Fig.2.5.1.1); The list of proteins with respective 
identities and reported functions were tabulated in Table 2.5.1.1. Their respective 
identities and reported functions were separately discussed in section 2.5. 
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2.4 Proteins identified in pwteomic study with in vitro SUMOylation -
Analysis of protein candidates 
In this section, a detailed report about the proteins identified in the proteomic study 
with in vtiro SUMOylation, including their putative functions and possible relations to 
S U M O was discussed. On the other hand, peroxiredoxin 1 (Prdxl) was selected for 
further verification by in vitro SUMOylation. In the verification，Prdx 1 was 
confirmed to be a S U M O substrate candidate. 
2.4.1 Proteins identified from the in vitro investigation 
In the list of 16 proteins annotated with the M A S C O T program assigned for protein 
database search with the P M F raw data, 6 of them were upregulated, 9 of them were 
downregulated and another 1 of them was found to have a shift of position in the in 
vitro sumoylated HeLa lyasate. List of zoom images of the differential spots were 
presented in Fig.2.4.1.1. The identity of proteins with a summary of functions were 
listed in Table 2.4.1.1. The fidelity of assignments were supported by the Mascot 
score of % Confidence Interval (C.I.) of >80% or a number of peptide match > 4. The 
6 up-regulated proteins in in vitro sumoylated HeLa lysate compared to untreated 
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lysate were cyclophilin A，nm23A, CTIO, vimentin, TSA and the ubc9 which was 
added extrinsically. The 9 downregulated proteins were DJ-1 protein, enolase 1，heat 
shock protein 27 and 70; phosphoglycerate mutasel, stress-induced phosphoprotein 1, 
triosephosphate isomerase, annexin I and aldolase A. The 1 protein found with 
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In vitro In vitro 
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JT^^ ^ " ^ ira-xr- 1 
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a. v-crk CTIO; B. TSA c. D M protein (Downregulated) 
yd 〔 溻 T j 
d. nm23A protein e. Vimentin 
^ p ^ � I 
f. Cyclophilin A g. Ubiquitin conjugation protein Ubc9 
h. Heat shock protein 70 (Downregulated) i. Stressed induced phosphoprotein 1 
(Downregulated) 
i n ^ F ‘ _ ； 
^ I 編 u li .-
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In vitro In vitro 
CONTROL 
CONTROL SUMOylated SUMOylated 
I: V . i v ： 
I. Aldolase A (Downregulated) m. Heat shock protein 27 
(Downregulated) 
^ t e . : ， -
n. Phosphoglycerate mutase 1 o. Triosephosphate isomerase 
(Downregulated) (Downregulated) 
。：.。: ： • ‘ 」 . ： f c O 
p. Peroxiredoxin 1 q. Peroxiredoxin 1 
(Downregulated) 
Figure 2.4.1.1 Comparison of the protein level in HeLa cell lysate with and without in 
vitro SUMOyaltion. Image analysis of the stained 2-D gels was performed using the 2-D 
analysis software Progenesis^ *^  SameSpot. Spots unless specified were upregulated after in 
vitro SUMOylation. The differential spots were indicated by point arrows. Identities (a 一 q) 
were matched with SWISS-PORT and NCBI non-redundant databases. 
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2.4.2 Verification of putative SUMO substrate Prdx 1 
Verification of peroxiredoxin 1 was performed by the in vitro SUMOylation of 
purified recombinant peroxiredoxin 1 expressed in E.coli. 
2.4.2.1 Purification of Prdx 1 
pMAL-c2p-Prdxl was transformed into BL21(DE3)pLys and grown at 37 for 4 h 
after induction by IPTG at OD600 0.6. Cells were resuspended in amylose column 
binding buffer and lysed with sonication. The soluble fraction was processed through 
the amylose resins and eluted by on-column PreScission™ protease cleavage of the 
MBP-tag yielding Prdxl protein. After purification, a 〜85% purity was achieved 
(Fig.2.4.2.1). Some background impurities were co-eluted at low molecular weights. 
The partially purified Prdxl protein was processed further by SuperdexTM §75 gel 
filtration column and Prdxl was successfully eluted out at a volume of 〜55ml (Fig. 
2.4.2.2). However, the M B P protein remained co-eluted with Prdxl. Attempts had 
been taken to reload the cleaved eluate on the amylose column again to remove the 
M B P tag, however, null improvement was could be achieved. There might be 
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non-covalent interactions between the tag with the Prdxl and thus co-eluted even after 
the size exclusion separation. Eventually, 90% pure Prdxl was obtained. 
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Figure 2.4.2.1 Purification of MBP-Prdxl by amylose affinity chromatography. Protein 
samples were analyzed on 12% SDS-PAGE. Lane LY, crude lysate of BL21(DE3)pLysS 
expressing MBP-Prdxl; Lanes FLl and 2, flowthrough after binding amylose resin; Lane Wl, 
washing (with binding buffer); Lanes Rel and 2, resin with residual MBP-tagged Prdxl 
remained uncleaved; Lane E, elution fraction of Prdx 1 protein by on-column cleavage of 
MBP-tag with PreScission™ protease; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained 
Standard. 
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Figure 2.4.2.2 Purification of Prdx 1 by Superdex^'^ S75 Gel filtration chromatography. 
Protein samples were analyzed on 12% SDS-PAGE. Lane Am, pulled fractions of Amylose 
resin purified Prdxl with detached MBP; Lanes El and 2，elution fraction near the end of 
void volume of column (-33 ml); Lanes E3 to E7, elution fractions at -40 ml containing the 
40 kDa MBP tag; Lanes E8 to E l l , elution fractions at ~55ml containing Prdxl protein 
remained contaminated with MBP; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained 
Standard. 
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2.4.2.2 In vitro SUMOylation of Prdx 1 
In vitro SUMOylation of Prdx 1 was performed with the protocol modified in section 
2.3.3.1. A routine optimization was performed to make sure the upshifting band 
representing SUMO-1-Prdxl could be clearly seen. E2:Prdxl molar ratio of 8:1 was 
found to be the best condition according to the result shown (Fig. 2.4.2.3). 
Validation was then performed with reactions were set up with controls. S U M O , T D G 
and prdx 1 only were set up to demonstrate the sizes and band positions of these 
3 proteins. Another control was made consisting of SUMO-1, El and E2 for 
comparison of background bands produced by the self-SUMOylation of El and E2 in 
the conjugation enzyme system. On the other hand, a control comprising T D G 
SUMOylation was set up to validate the activity of SUMOylation enzymes. 
From Fig. 2.4.2.4, an extra band was found around 40 kDa as indicated in the black 
box was believed to be the band of SUMO-1-Prdxl conjugate. Western analysis was 
performed by firstly probing against anti-Prdx-1 antibody (Abeam, Cat#abl5571) at 
1:25000 and then reprobed against anti-SUMO-1 antibody at 1:500 after mild 
stripping (section 2.2.10.4) for comparison of the western results. A band at around 
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40 kDa which was the same position seen in the Coomassie™ stained gel could be 
probed in both western analysis，implying that the band was composed of both 
SUMO-1 and Prdx-1, Mass spectrometry analysis will be performed in the future in 
order to provide more evidence for the identity of the band. 
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Figure 2.4.2.3 In vitro SUMOylation assay of Prdxl. Protein samples were analyzed in 15% 
SDS-PAGE. Lane 1, Marker (Invitrogen SeeBlue® Plus 2 Pre-Stained Standard); Lane 2, 
SUMO only as a control; Lane 3, comparative control with the SUMOylation enzymatic 
machinery; Lane 4, control with TDG protein only; Lane 5, control reaction proving the 
capability of El and E2 enzymes; Lane 6, Prdxl only as control; Lanes 7-10, SUMOylation 
test on SUMO:Prdxl molar ratio; Lanes 11-12，SUMOylation test on E2:Substrate molar ratio; 
Lanes 13-15, SUMOylation test with chemical parameters. (Black rectangle - the shifted band 
ofSUMO-Prdxl conjugate) 
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Anti-Prdx 1 Anti-SUMO-1 
_墜 
1 2 3 4 5 6 7 8 9 10 11 12 
Figure 2.4.2.4 Western analysis after in vitro SUMOylation assay of Prdxl. Probing 
against SUMO-1 and Prdxl on the same PVDF membrane using primary antibody with 
ratio 1:500 and 1:25000 respectively. Lanes 1 and 7，SUMO-1 only as a control; Lanes 2 
and 8, comparative control with the SUMOylation enzymatic machinery (SUMO-1, El, E2); 
Lanes 3 and 9’ control with TDG protein only; Lanes 4 and 10’ control TDG reaction proving 
the capability of El and E2 enzymes; Lanes 5 and 11, Prdxl only as control; Lanes 6 and 12, 
SUMOylation of Prdxl. Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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2.4.3 Highlights of the proteins identified 
2.4.3.1 DJ-1 protein 
It was reported that DJ-1 protein was associated with Parkinson's disease and cancer 
(Clements et al” 2006). It is related to cancer by having a role in stabilizing Nrf2, a 
master regulator of antioxidant factor transcription. DJ-1 underexpression in response 
to oxidative stress resulted in decreased phosphorylation of Akt, leading to increased 
cell death (Kim et al., 2005). DJ-1 was on the other hand shown interacting with p53 
to restore its transcription activity from inhibition (Shinbo et al., 2005). It was very 
recently found to be a novel SUMOylation substrate last year (Shinbo et al.，2006). 
2.4.3.2 nm23A 
This is a protein well-known involving in cell cycle regulation and differentiation 
(Lombardi et al., 2001)，and D N A repair (Postel, 2003). It was found to have aberrant 
expression in cervical carcinogenesis (Wang et al, 2003). Another study reported that 
nm23 interacts with HPV-16 E7 protein, resulted in drastic downregulation of 
transcription coupled with increased protein degradation. This was believed to be an 
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important feature in the strategy of H P V promoting cell transformation and tumor 
progression (Mileo et al., 2006). 
2.4.3.3 v-crk protein of CTIO 
v-crk protein is an oncogene product of CTIO sarcoma vims, v-crk was found to 
activate the PDK/Akt pathway and thus promote cell transformation, Activated Akt 
involves in suppression of apoptosis and cell cycle progression (Akagi et al, 2002). It 
was reported to transform PTPIB, protein-tyrosine phosphatase IB which originally 
suppress cell proliferation by binding to tyrosine kinases. PTPIB was found to be 
SUMOylated and SUMOylated PTPIB has shown to have counter effects on the 
transformation by c-vrk (Dadke et aL, 2006). 
2.4.3.4 Annexin I 
Annexin I was described as a steroid-regulated protein which involves in 
anti-inflammatory response. Downregulation of annexin I was frequently found in 
cancers (Silistino-Souza et cd., 2007). It was found to suppress carcinogenesis by 
inhibition of cyclin D1 expression and cell proliferation through the E R K pathway 
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(Alldridge et al., 2003). It was found to have implication in TRAIL-induced apoptosis 
(Petrella et al., 2005). 
2.4.3.5 Enolase 1， aldolase A， triosephosphate isomerase (TIM) and 
phosphoglycerate mutase 1 
All these four enzymes were involved in the cellular metabolism and particularly in 
the glucose metabolism. In which both aldolase and PG mutase was found to be 
upregulated in cancers (Taguchi et cd., 2001; Durany et al, 1997). Enolase 1 is a 
cytoplasmic enzyme involved in glycolysis and was recognized as a tumor antigen in 
lung cancer by its downregulation (He et al., 2007) while was found to have an 
elevated expression in HPV16 E7 transfected C33A cells (Lee et al, 2004). Its 
interaction in cancer formation and progression is unknown and waited to be 
elucidated. It was suspected that the increased production of ATP regulates the levels 
of enzymes involved in ATP-dependent reactions (Ando et al., 2001). However, it 
should also be reminded that these proteins are a group of abundant proteins found in 
cellular extracts, the authenticity of their identity as SUMOylation substrates should 
be verified by in vitro SUMOylation. 
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2.4.3.6 Cyclophilin A (CypA) 
Cyclophilin A is a peptidyl prolyl isomerase performing cis/trans isomerization of 
praline peptide bands and was found to interact with gag in HIV infection and help in 
achieving the maximal infectivity (Towers, 2007). It might be a candidate protein 
which interacts with viral proteins of H P V as well which have to be elucidated. 
2.4.3.7 Stress induced phosphoprotein 1 (Stip 1) 
It is an Hsp70/90 organizing protein which has been found to be upregulated after 
Ras-activated oncogenic transformation of NIH3T3 fibroblast cells (Ji et al., 2007). It 
has been known that an elevated level of phosphorylated Akt is essential in Ras 
transformation (Kim et al, 2005). The localization of Stipl was translocated the 
nucleus from Golgi in transformed cells. The nuclear translocation might suggest 
possible relationship with S U M O . 
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2.4.3.8 TSA and peroxiredoxin 1 (Prdx 1) 
TSA and peroxiredoxin 1 are two thiol-specific antioxidant proteins found in human 
cells. TSA was found to be a putative S U M O substrate in a yeast-two hybrid study 
(Hannich et al” 2005). Prdx 1 is another antioxidative protein which remove ROS in 
the cells. It has been found to be elevated in various human cancers which believed to 
be due to the hypoxic environment of the tumors. It was recently shown to be a 
responsive gene of Nrf2 (Kim et al, 2007) downregulating JNK signalling and 
apoptosis in lung cancer cells (Kim et al., 2006). H D A C inhibitor drugs was shown to 
activate Prdx 1 expression and subsequent apoptosis induction with Prdx 1 in 
esophageal cancer cells (Hoshino et al., 2005). On the other hand, Prdx 1 was also 
demonstrated to interact with c-Myc transcriptional regulator, modulating its function 
and inhibiting c-Myc transformation. Increased oxidative damages were found in 
knockout mice and malignancies were formed (Egler et al., 2005), suggesting a tumor 
suppressor activity of Prdx 1. 
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2.5 Proteins identified in proteomic study with overexpression of SUMO-1 in 
HeLa cells -Analysis of protein candidates 
In this section, a detailed report about the proteins identified in the proteomic study 
with overexpression of SUMO-1 in HeLa cells, including their putative functions and 
possible relations to S U M O was discussed. On the other hand, keratin 17 (Kit 17) was 
selected for further verification by Western analysis. In the verification, keratin 17 
was confirmed to show upregulation under overexpression of SUMO-1 in HeLa cells. 
2.5.1 Proteins identified from the in vivo investigation 
In the list of 21 proteins annotated with the M A S C O T program assigned for protein 
database search with the P M F raw data, 19 of them were upregulated and 2 of them 
were downregulated which were in HeLa cells. List of zoom images of the differential 
spots were presented in Fig.2.5.1.1. The identity of proteins with a summary of 
functions were listed in Table 2.5.1.1. The fidelity of assignments were supported by 
the Mascot score of % Confidence Interval (C.I.) of >80% or a number of peptide 
match > 4. The 19 up-regulated proteins in HeLa cell overexpressed with SUMO-1 
compared to control HeLa cells were heat shock protein 60, Actinyl, cytokeratin 18, 
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keratin 8, 17; 14-3-3o (SFN protein), tubulin|32, calreticulin precursor, ISG15 
Ubiquitin-like modifier, PR02619, hepatocyte graoth factor isoform 4 (HGF4), 
ubiquitin specific protease 11 (USPll), La4.1 protein, XIAP-1, carnitine translocase, 
PDZ-RGS3, Ubiquitin associated domain 1 and a hypothetical protein. The two 
downregulated proteins in HeLa cells overexpressed SUMO-1 were heat shock 
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CONTROL TRANSFECTED CONTROL TRANSFECTED 
H H ^ I H I 
a. PR02619 B. PDZ-RGS3 • • • • 
c_ Cytokeratin 18 d.HGF4 • • • • 
e. XIAP-1 f. Calreticulin precursor 
- g. Heat shock protein 60 i. Hypothetical protein 
h. Tubulin beta 2 
• • • • 
j . ISG15 Ubiquitin-like protein k. Heat shock protein 70 (downregulated) 
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CONTROL TRANSFECTED CONTROL TRANSFECTED • • • • 
I. Keratin 17 m. Actin gamma 1 • • • • 
n. Keratin 8 o. carnitine/ acylcarnitine translocase • • • • 
p. La 4.1 protein q. unnamed protein product • • • • 
r. SFN protein s. Cytokeratin 18 
t. Ubiquitin associated protein 
I H M H m • • • 
U. XIAP-1 V. Keratin 1 (downregulated) 
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Figure 2.5.1.1 Comparison of the protein level in HeLa cell lysate with and without 
overexpression of SUMO-1 by transient transfection of pHM6-SUMO-l. Image analysis 
of the stained 2-D gels was performed using the 2-D analysis software Progenesis"^ "^ SameSpot. 
Spots unless specified were upregulated after an exogenous overexpression of SUMO-1 by 
transient transfection. The differential spots were indicated by point arrows. Identities (a - v) 
were matched with SWISS-PORT and NCBI non-redundant databases. 
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2.5.2 Verification of upregulation of keratin 17 
Verification of upregulation of keratin 17 was performed by immunoblotting analysis 
of the control and SUMO-1 transfected HeLa total lysate. 
2.5.2.1 Immunoblotting against keratin 17 
In order to verify the upregulation of keratin 17 obtained from M S analysis, 
immunoblotting against keratin 17 using anti-keratin 17 antibody (LabVision, 
Cat#MS489S) was performed. Same quantity of lysate proteins from the control 
without SUMO-1 transfection (transfected with empty pHM6 vector) and that with 
SUMO-1 transfection were loaded on 10% SDS-polyacrylamide gels and transferred 
to PVDF membrane as illustrated in section 2.2.10.1. The PVDF membrane was 
probed against Anti-Keratin antibody at 1:500 reprobed against anti-actin antibody at 
1:5000 after mild stripping (section 2.2.10.4) for normalization of the western results. 
A band probed at around 50 kDa with the correct size of keratin 17 protein was 
observed (Fig.2.5.2.1). The gel orientation was the same on the 2-D gel (Fig.2.3.6.1). 
An > 2-fold upregulation of Keratin 17 could be observed in the SUMO-1 transfected 
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cell lysate, which matched with the results obtained from the 2-D gel study 
(Fig.2.3.6.1). Therefore the result suggested that Keratin 17 was upregulated in HeLa 
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5 0 — A n t i - K e r a t i n 
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| | | | m + Anti-Actin 
Figure 2.5.2.1 Western analysis of keratin 17 in HeLa cells with and without 
overexpression of SUMO-1. Probing against Anti-keratin 17 antibody at 1:500 after 
analysis on 10% SDS-PAGE. Lane 1, lysate of H e L a cells without S U M O - 1 transient 
transfection; Lane 2, lysate of H e L a cells with S U M O - 1 transient transfection; Marker, 
,Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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2.5.3 Highlights of the proteins identified 
Among the proteins identified, significant relationship with tumorigenesis and 
dysregulation of cell cycle and cell proliferation could be observed. 
2.5.3.1 Heat shock proteins (Hsp 60, 70 and 27) 
Two heat shock proteins were identified一the heat shock protein 60 and 70 (Hsp60, 
Hsp70). Heat shock proteins are a family of chaperone mitochrondrial 
matrix-associated protein. They are responsible for the chaperoning and folding of 
proteins and to eliminate the adverse effects caused by various cellular stresses, 
including those are acute and chronic, e.g. oxidation, tumor induction. Many key 
components of survival and apoptotic pathways are regulated by interactions with 
chaperones (Mosser and Morimoto, 2004). Heat shock proteins promote cell recovery 
from stress either by repairing the damaged proteins by refolding or by degrading 
them. Thus, they are upregulated upon cellular stresses. On the other hand, if the cell 
damage is too severe to be repaired, Hsps will render the cells to go through 
apoptosis. 
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Hsp 60 It has been reported that the Hsp60 protein was both a pro-apoptotic and an 
anti-apoptotic protein, which promotes caspase-3 maturation by acting as a chaperone 
to procaspase-3 (Xanthoudakis et al., 1999) while on the other hand promotes Bax 
degradation (Arya et al., 2007). It was found that to be overexpressed in the 
exo-cervix carcinogenesis (Cappello et cd., 2003), which confers an example of its 
role as an oncoprotein. Increased expression of Hsp 60 was also reported in other 
malignancies e.g. breast carcinoma, ovarian and prostate carcinoma (Cappello et al,, 
2003). Its functional role being a chaperone of procaspase-3 might be dysregulated 
during the carcinogenesis of cells, however, the mechanism behind remains unknown. 
Hsp 70 Hsp 70 is as an anti-apoptotic protein, which is abundantly expressed in 
different human cancers (Kaur et al., 2000). It promotes cell survival by inhibition of 
caspase activation, recruitment of procaspase 9 and 3; and the assembly of functional 
apoptosome which significantly increased the tumorigenic potential of cells. As cells 
which possess aberrant D N A transcription and translation are kept survive, forced 
overexpression of Hsp70 was reported to increase cellular transformation and tumor 
formation (Samali et al” 1999) owing to its transformation of oncogenes e.g. p53. It 
has become a marker of prostate cancer recently (Johansson et al., 2006). It is 
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interesting to note that overexpression of Hsp 70 was found with a number of viral 
induced carcinogenesis process by interacting with SV40 T antigen and the El A 
protein of adenovirus (Sawai and Butel, 1989). 
Hsp 27 Hsp 27 is another anti-apoptotic chaperone which downregulates the 
apoptosis by binding to Akt and activate it (Rane et cd., 2003). On the other hand, Akt 
phosphorylates Hsp27 to dissociate it from complex. Phosphorylated Hsp27 will form 
dimers which interact with Daxx to prevent it from activating Askl protein in the 
FasR-stimulated apoptosis (Charette et al., 2000). Overexpression of Hsp27 was also 
reported in different tumors (Fuller et al., 1994; Ciocca et al., 1993). It has shown to 
be upregulated in primary carcinoma of vagina and C33A cell transfected with 
HPV16 E7 gene (Lee K A et al, 2004). 
2.5.3.2 14-3-30 protein (SFN protein) 
14-3-3 protein is a family of proteins which binds targets at phosphoserine/threonine 
site to participate in signal transduction and cell cycle regulation (Urano et al., 2004). 
Decreased expression of 14-3-3a has been reported in different types of carcinomas 
including breast cancer (Ferguson et al., 2000), ovarian cancer (Akahira et al., 2004), 
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hepatocellular carcinoma (Iwata et al, 2000), prostate cancer (Lodygin et cd., 2004), 
etc. It is a negative regulator of cell cycle in response to D N A damage, by 
sequestering the cyclinBl-cdc2 complexes to achieve G2/M arrest in cytoplasm. It is 
on the other hand a p53 stabilizer and exerts positive feedback on p53 by retaining the 
p53 protein in the nucleus for degradation by means of locking p53 and M D M 2 
together (Lee and Lozano, 2006). Therefore it exhibits potent tumor suppressor 
function. In tumors, it is downregulated by hypermethylation of promoter or 
over-degraded by proteasome complex. 14-3-3cr antagonizes Akt by inhibiting its 
activation and neutralizing its outcome. 14-3-3o has a strong negative regulatory role 
in the cell cycle during tumorigenesis. 
2.5.3.3 PDZ-RGS3 
PDZ-RGS3 is also reported to have an upregulated m R N A expression in p53 related 
tumors recently (Ooe et cd., 2007). It is a regulator of G-protein signalling which 
enhances the rate Gai and Gaq hydrolyzing GTP to GDP and is shown to bind Gpiy2 
and prevent it from inducing the production of IP (inositol phosphates), the activation 
of Akt and M A P K pathway (Shi et cd., 2001). This might be due to the fact that RGS3 
interacts with phosphoserine-binding protein 14-3-3 (Niu et al, 2002), being 
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responsible for keeping RGS3 from localizing into the nucleus. 14-3-3 protein itself is 
an Akt antagonist. (Urano et al, 2004) The downregulation of Akt activity will then 
downregulate another cell growth signalling pathway m T O R and also stabilizing p53. 
Therefore, upregulation of RGS3 level promote cell death to occur. 
2.5.3.4 Keratins 8，17 
Keratins are abundant proteins in epithelial cell type functioning as intermediate 
filaments (IF). IFs contribute to the cytoarchitecture and additionally modulate 
different cellular responses to stress, pro-apoptotic signals (Coulombe and Wong, 
2004). Keratin 8 and 17 were found to be upregulated in cervical cancer cells and 
were defined to be tumor markers of cervix carcinoma (Carrilho et al., 2004). It was 
recently shown to have cell growth regulatory function by binding to the adaptor 
protein 14-3-3o (Kim et al., 2006). This binding occurs after Akt phosphorylated 
keratin 17. The binding retain 14-3-3o in the cytoplasm for stimulation of m T O R 
pathway. However, the upregulation is limited by the negative feedback of 14-3-3o on 
Akt. 
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Keratin 8 was found to exist as pairs with keratin 18 (K8/18). Their upregulation was 
believed to contribute to the cancer cells motility and invasiveness since they are 
responsible for the adhesiveness of cells (Hendrix et al, 1997). On the other hand, 
overexpression of K8/18 confers resistance to Fas-mediated apoptosis and has a 
negative regulation on Akt through the interaction of intergrinpi (Galameau et al, 
2007). 
2.5.3.5 XIAP-1 
XIAP-1 is known as the X-linked inhibitor of apoptosis. It interferes the apoptotic 
pathway by suppressing both caspase-3 and caspase-9 (Bratton et al., 2002). 
Overexpression of XIAP-1 was reported in hepatocellular carcinomas (Sakemi et al., 
2007). 
2.5.3.6 ISG15 
ISG15 was discovered as an interferon-stimulated gene, and was later found to be an 
ubiquitin-like protein. ISG15 mediates IFN activity and thus confers an anti-tumor 
effect. At the same time, ISGylation of protein phosphatase 2CP suppresses its activity 
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and thus inhibiting N F - K B signalling (Takeuchi et al.’ 2006). I S G 1 5 is a responsive 
gene of p53 and downregulation of ISG15 was reported to be associated with 
immortalization of primary cells (Polyak et al., 1997; Andersen and Hassel, 2006). 
Coincidently, it was found to modify 14-3-3o, however the significance behind has 
yet to be elucidated (Zou and Zhang, 2006). Finally, ISG 15 was reported to have 
relationship to innate immunity against viral infection (Ritchie et al, 2004). 
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2.6 DISCUSSION 
Over the past decade, extensive studies on SUMOylation have revealed the versatility 
and universality of S U M O in cellular context. It has been found to be involved in 
regulatory processes including transcriptional control (Verger et cd., 2003), signal 
transduction modulation (Utsubo-Kuniyoshi et al., 2007), protein localization 
(Hamard et al., 2007) and cell cycle control (Lee et al., 2006). These lead to 
researches linking S U M O to the pathogenesis of various types of cancer and viral 
infection (Boggio and Chiocca, 2006). With accumulated amount of evidences, the 
underlying mechanism was waiting to be elucidated. In our study, proteomic method 
has been adopted to conduct a pilot investigation on SUMOylation in HeLa cervical 
carcinoma cells. Our aims are to identify (1) potential S U M O substrates in cell lysate 
with in vitro SUMOylation and (2) putative S U M O interacting partners in cells with 
overexpression of S U M O . In the in vitro study, a total of 16 proteins were identified 
(Table 2.4.1.1); while in the in vivo study, another 21 proteins were identified (Table 
2.5.1.1). 
Potential S U M O substrates were found by conducting in vitro SUMOylation on HeLa 
cell lysates. The reaction conditions of in vitro SUMOylation were optimized to 
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achieve a higher reaction efficiency for SUMOylation of cell lysates. Reaction 
components (El, E2 and SUMO-1) were accordingly purified with both high yield 
and purity, with the only exception El. As El was added in a very insignificant 
quantity (0.075 |ig), its purity would not cause any negative effects on the SDS-PAGE 
analysis of S U M O conjugates. In addition, the activity of El was not affected under 
such purity. Higher purity of reaction component proteins can give a better resolution 
of the S U M O conjugates in both SDS-PAGE and two-dimensional gel electrophoresis 
and thus is of a significant importance. On the other hand, a trial was done on the lysis 
buffer used to prepare total protein extracts from the HeLa cells. This is considered to 
be critical as an inappropriate lysis buffer would lead to a significant drop or even 
inhibition of in vitro SUMOylation. This can happen when the lysis buffer contains 
detergents or solubilization chemicals, which conventional lysis buffer often 
constitute of. Our results have shown that even a small amount of detergents can 
disrupt in vitro SUMOylation (Fig.2.3.3.3) and thus finally a lysis buffer with no 
detergents was selected (Lamond et al., 2005), which gave considerably satisfactory 
yield and lysis efficiency. Endogenously modified SUMOylation substrates were not 
of our concern, as deSUMOylation occurs readily upon cell lysis by active S U M O 
proteases in the cell lysate (Vertegaal et al, 2006). Nonetheless, the total cell protein 
extracts were attempted to treat with SENPl for in vitro deSUMOylation prior to in 
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vitro SUMOylation. However, the presence of SENPl protease remained in the 
extract greatly impaired the subsequent in vitro SUMOylation even when SENPl 
inhibitor N-ethylmaleimide was added. Therefore, the native total cell extracts 
obtained was straightly utilized to perform in vitro SUMOylation eventually. 
Through in vitro SUMOylation of HeLa cell lysates, potential S U M O substrates 
which were not SUMOylated endogenously at a particular cell status during lysis 
could be attached with S U M O by exogenous enzymatic forces. The subproteome of 
S U M O conjugates are specific at different times, upon different cellular events 
(Gocke et al., 2005). However, in vitro SUMOylation can give a universal proteome 
of the S U M O conjugates. 
Significant changes were made in the optimization of in vitro SUMOylation including 
the increase of reaction time and the ratio between E2, SUMO-1 and the substrate 
protein. In particular the ratio between the reaction components are considered to be 
critical, as dramatic efficiency differences were observed (Fig.2.2.3.2D). It was found 
that a higher SUMO:substrate ratio will cause an impairment of reaction efficiency 
(Fig.2.2.3.2D). The reduction of reaction efficiency upon an increase of 
SUMO:substrate ratio might imply that the S U M O binding site on E2 has been 
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saturated when S U M O is too abundant which is not favourable to either the binding of 
substrate to E2 or the transfer of S U M O to the substrate (Tatham et aL; 2003). Further 
improvement of the efficiency of in vitro SUMOylation can be achieved by 
supplementing El and E2 into the reaction mixture once an hour (Xu, 2005). While 
on the other hand, studies has shown the importance of S U M O E3 ligases in the in 
vitro SUMOylation was neglected in the past (Weger et al., 2005; Kirsh et aL, 2002; 
Miyauchi et al. 2002), the efficiency of in vitro SUMOylation can possibly be 
enhanced with a specific type of E3 ligase. 
The resulting reaction mixture which represents a more complete S U M O substrate 
subproteome was processed by 2-DE, followed by staining with silver nitrate and 
Coomassie blue® R250 method. Subsequent MALDI-TOF MS/MS studies showed 
that the efficiency of peptide mass fingerprinting was unexpectedly low with the use 
of silver nitrate staining. This was due to a low signal-to-noise ratio in the m/z (mass 
to charge) data which caused by contamination of M S samples during sample 
preparation step before M A L D I ionization. M S sample preparation was a challenging 
process which consisted of limits of the sample purity due to environmental 
contaminations particularly skin and hair keratin contaminations (Gingras et al., 2005). 
Preventive measures to minimize the contaminations such as wearing gloves, labcoats 
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and mouth masks have been taken. Automation of spot picking could be considered 
when possible. M S sample preparation in a closed fumehood can be considered in the 
future for improvement. At the same time, the effect of contamination materials can 
be minimized by increasing the quantity of sample materials. This can be achieved by 
loading more protein sample in the 2-DE analysis and visualizing gels with 
Coomassie blue⑧ R250 stain. Efficiency of MALDI-TOF MS/MS peptide mass 
fingerprinting was significantly increased with more M S samples giving a high 
confidence value in peptide sequence identification. As Coomassie blue® R250 
staining with a three-fold increase of protein loading has not affected the resolution of 
protein separation in 2-DE, it is highly recommended in conducting future 
MALDI-TOF MS/MS proteomic studies. 
By the proteomic study on in vitro SUMOylated HeLa cell lysates, 16 differentially 
expressed proteins were identified with P M F (Table 2.4.1.1). The difference between 
gels loaded with controls and SUMOylated samples were due to shifting of protein 
properties which caused by attachment of S U M O . In principle, S U M O could be 
identified in the P M F in the ideal case, however its smaller protein size and a 
relatively lower peptide mass quantity made the identification difficult. This may be 
achieved by manipulation of the raw mass spectrum by appropriately increasing the 
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background noise tolerance. As this is a very technical work needs expertise, it was an 
aim to be fulfilled in the future follow-up works. This limitation can also be 
compensated by verification of in vitro SUMOylation on each identified protein 
which was a practical way to prove the authenticity of the protein's identity as 
SUMOylation substrates. The present list of proteins thus represents the potential 
S U M O substrates which yet need to be verified, but nevertheless are discussed here. 
The 16 identified proteins comprised a large group of stress response proteins 
including the chaperones (Hsp70 and Hsp 27)，chaperone associated protein (stress 
induced phosphoprotein 1)，anti-oxidative proteins (DJ-1, TSA and peroxiredoxin 1)， 
metabolic related proteins (aldolase A, enolase 1, phosphglycerate mutase 1 and 
triosephosphate isomerase) and cell cycle regulation proteins (nm23A). On the other 
hand, proteins involved in carcinogenesis were identified including an oncoprotein 
(v-crk CTIO) and a tumor suppressor protein (annexin I). Finally, a protein involving 
in virus infectivity and cellular immunity (cyclophilin A) and an intermediate filament 
protein (vimentin) were identified. 
Details of each identified protein were briefly discussed in section 2.4.1. The stressed 
related proteins were found respectively to be expressed differentially in cancers 
(Refer to section 2.4.1). As the stress response is responsible for either genetic or 
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protein-wise cellular repairs; or leading to increase apoptosis if the cell damage is 
considered to be severe (Faried et al., 2004), aberrant stress response will lead to 
cancer formation or progression. Tumor suppressors like annexin I are another type of 
stress response specific in the inhibition of cell proliferation during tumorigenesis. 
Oncoproteins works in the same way to suppress the cell cycle progression as seen in 
the example of v-crk CTIO. No transcription factors were identified in our present 
study possibly due to their very low abundance in cells and the detection limit of our 
system. Nevertheless, there are other studies has specifically aimed at identifying 
transcription factors using the approach stable-isotope labeling by amino acids in cell 
culture (SILAC) (Vertegaal at el., 2006). 
The list of proteins identified does not tell about the effect of S U M O attachment, if 
authentically exists. S U M O attachment was known to mediate different types of 
effects as stated at the beginning of this section. Physiological effects of 
SUMOylation are of great interests to be carried out on the substrate candidates. From 
-the list of identified proteins, candidates with totally antagonistic functions exist, e.g. 
tumor suppressor and oncoprotein. This can often be seen in S U M O proteomic studies 
(Guo et al, 2006). Upon this observation, our data suggests that SUMOylation 
probably mediates a network of cellular events to achieve the repair of cellular defects, 
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rather than exerts effects on specific proteins only. 
To address on the possible relationship between H P V infection and S U M O in HeLa 
cell line model observed from the proteins identified by in vitro SUMOylation, it is 
interesting to note that nm23 was reported to interact with HPV-16 E7 protein and as a 
result downregulated in HPV-positive cancer (Mileo et al., 2006). It is of potential 
importance and is worth to verify if it is an authentic S U M O substrate. On the other 
hand, cyclophilin A was found to have a role of innate immunity towards virus. It was 
a protein overcome by HIV-1 gag protein which utilizes it in achieving higher 
infectivity (Tower, 2007). It is not known if same situation happens in H P V infection, 
nevertheless worth to be investigated in the future. 
Proceeding from the list of identified proteins, verifications has been begun on 
peroxiredoxin 1 (Prdxl). Results show that Prdxl can be SUMOylated in vitro, while 
the case in vivo is yet to be verified. Immunoprecipitation (IP) trials have been 
-performed, however large quantities of non-specific bandings prevented us from 
drawing a conclusion from the result of IPs. This will remain to be a part of future 
work together with verifications of other proteins on the list. Prdx 1 was found to 
interact with c-Myc, a potent transcriptional regulator of cell cycle progression to act 
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as a tumor suppressor within the cells (Egler et al., 2005). The effect of SUMOylation 
of Prdx 1 remained as a work with great interest to be done in the future. Based on the 
known effects of sumoylation, SUMOylation of this anti-stress protein could be a 
protective mechanism against intracellular stress by: (1) stabilizing key anti-stress 
proteins by antagonizing the effect of ubiquitination; (2) targeting these proteins to 
specific subcellular organelles for processing excessive ROS resulted from cellular 
stress. S U M O might also alters its affinity to c-myc and thus assist in its tumor 
suppressor activity. Experiments can be designed to elucidate these predictions. 
Another part of the study was searching S U M O interacting partners by 
overexpression of SUMO-1 in HeLa cells. Overexpression of S U M O mediated by 
transient transfection of pHM6-SUM0-l into HeLa cells would promote its 
downstream effects by mimicking an upregulation of S U M O protein level in cells 
during stress conditions (Shinbo et al., 2006; Manza et al., 2004). Overexpression of 
S U M O enzymes is another way to promote in vivo SUMOylation, however was not 
‘used in our study. Nonetheless, this has been considered to be a novel way to study 
the effect of SUMOylation in cell line models (Lee et al., 2005). Approach commonly 
used to in proteomic study of S U M O can obtain a list of SUMOylation substrates. 
However, this is deficient in revealing the complex and versatile downstream effects 
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of S U M O via both conjugation and non-covalent interaction with target proteins. 
Therefore in this study, the differentially expressed proteins upon overexpression of 
S U M O were identified to give a broader insight into the downstream effect of S U M O 
interaction. S U M O deconjugation occurs during cell lysis under normal conditions 
due to the exposure of cellular proteins to S U M O proteases which were originally in 
different cellular compartments (Vertegaal et al., 2006). Therefore exclusion of 
N-ethylmaleimide in the cell lysis buffer would allow S U M O deconjugation occurs. 
This protocol was utilized in our investigation in order to discriminate our identified 
proteins from being a SUMOylation substrate. 
By 2-DE and MALDI-TOF MS/MS analysis on HeLa cell lysate overexpressing 
SUMO-1, 21 differentially expressed proteins were identified by peptide mass 
fingerprinting (PMF) (Table 2.5.1.1). Since silver nitrate staining was chosen as the 
visualization method, a relatively low PMF identification efficiency was resulted. Due 
to the limit of M S PMF identification, the 21 identified proteins were all with a 
‘relatively high cellular content and thus gave larger protein spots to be identified. The 
detection limit hampered the identification of protein spots in relatively lower 
quantities in our experiments (e.g. some downregulated proteins). This can be 
significantly improved when more protein sample was loaded in 2-DE and stained the 
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gel with Coomassie Blue® R250 as discussed above. 
The 21 identified proteins comprised a large group of apoptosis-related proteins and 
cell cycle regulators including Hsp60 and 70，keratin 8 and 17，XIAP-1, ISG15, 
PDZ-RGS3 and 14-3-3a protein. On the other hand, proteins reported to have 
dysregulation of protein level in cancers were identified including actinyl (Guo et al., 
2005), tubulinp (Rosas-Acosta et cd., 2004), hepatocyte growth factor 4 (Desiderio, 
2007), PR02619 (Chahed et al, 2005) and keratin 1 (Bae et al, 2005). A brief 
summary of their relationship with apoptosis and cancer is shown in Table 2.6.1. 
Other identities with no direct link to apoptosis and cancer are calreticulin precursor 
La4.1, carnitine/acylcarnitin translocase and Ub specific protease 11. Details of each 
identified protein were briefly discussed in section 2.4.1. Here, a few interesting 
observations among those apoptosis-related proteins can be drawn. 
Firstly, all of the proteins shown in Table 2.6.1 have aberrant expression in cancers. 
‘They are either upregulated or downregulated to affect the apoptotic pathway and are 
cell-type specific. The pro-apoptotic proteins were downregulated in cancers while the 
anti-apoptotic proteins were upregulated instead. The exception is PDZ-RGS3 
pro-apoptotic protein, was however upregulated in p53-mutated tumors (Ooe et al., 
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2007). The mechanism of how S U M O modulates on these proteins is unknown, but 
from our results, overexpression of S U M O seems upregulated both the pro-apoptotic 
and anti-apoptotic proteins. Future studies on the effect of S U M O on these proteins 
are worth to be conducted. Secondly, all of the proteins are involved in NF-KB activity 
regulation (Table 2.6.1). NF-KB is a well-known transcription factor which regulates 
cell cycle gene expression and is an activator of anti-apoptotic gene expression. 
Dysregulation of NF-KB has been found in cancers (Karin, 2006). S U M O is on the 
other hand linked to NF-KB by modification of its inhibitor IKBOI and prevents IKBCX 
from degradation (Desterro et al., 1998). S U M O is further linked to the NF-KB 
regulation by modification of N E M O (iKKy), the regulatory subunit of IkB Kinase. 
SUMOylation of N E M O leading to its degradation by ubiquitination and thus 
activates NF-KB by suppressing IKBCX (Mabb et al., 2006). Therefore, NF-KB pathway 
would likely be a central pathway which S U M O involved in the regulation of 
apoptosis and cell cycle control. Thirdly, except Hsp60 and ISG15, all of the proteins 
are involved in the Akt signaling pathway. Akt pathway is a very versatile signal 
‘transduction mediator which involves in apoptosis regulation and cell cycle control, 
thus is a critical regulator of cell survival and proliferation (Song et al., 2005) 
(Appendix 5). It is also called the protein kinase B (PKB) which acts as a 
serine/threonine protein kinase. Akt activity is highly regulated by the identified 
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proteins (Table 2.6.1) which finally lead to different apoptotic outcome. There are no 
present studies on the relationship between SUMOylation and Akt signaling, which 
worth to be investigated in the future. 
To address on the possible relationship between HPV infection and S U M O in HeLa 
cell line model observed from the proteins identified under S U M O overexpression, it 
is interesting to know that an upregulation of Hsp70 was reported to be essential in 
the survival of virus in the host. It was observed that Hsp70 can be utilized by the 
virus to escape from the cellular surveillances and preventing apoptosis (Mosser and 
Morimoto, 2004). 14-3-3o was on the other hand found to express in keratinocytes 
prominently, which the inactivation of 14-3-3 a leads to immortalization of the 
keratinocytes. This happens in the early transformation stage of the keratinocytes 
during differentiation which is currently unknown for its mechanism (Section 1.2.1.4). 
Therefore, this protein might possibly have a role in the events which is worth to be 
elucidated in the future. Keratin 17 is a protein aberrantly upregulated in 
‘HPV-positive cervical carcinomas which has been used as a tumor marker (Carrilho et 
al, 2004). Overexpression of keratin 17 is further found under S U M O overexpression 
in our study. Interestingly keratin 17 allows binding of 14-3-3o (Kim et al, 2006)， 
thus relationship behind the proteins may further provide clues in the relationship 
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between S U M O and HPV-mediated cancers. Finally, ISG15 was amazingly found to 
modify 14-3-3a by ISGylation and its protease USP18 was reported to have a role in 
the innate cell immunity against viral infection (Ritchie et al., 2004). Possible 
utilization of ISG15 on the ISGylation of 14-3-3a might have a role in the 
HPV-mediated cancers. All of these results are valuable as a starting point for further 
investigations in the relationship between SUMOylation and viral cancer. 
Proceeding from the list of identified proteins, verifications has been begun on keratin 
17. Our results show that keratin 17 is upregulated in vivo under the overexpression of 
S U M O with western analysis. Further studies can be done in the future to characterize 
the molecular mechanism and biological significance of its upregulation upon 
overexpression of S U M O . The m R N A level of keratin 17 can be measured by 
RT-PCR to determine whether the regulation is at m R N A level. On the other hand, 
S U M O gene silencing by RNAi can be performed to observe the change in keratin 17 
protein expression level. The effect of S U M O regulation on keratin 17 can be 
‘explored by investigation of expression level change of Akt in attempt to address a 












































































































































































































































































































































































































































































































































































































































































































































Chapter III Introduction 
Chapter III 
Characterization of a novel fluorescent labeling method: 
Biarsencial-tetracysteine labeling in SUMO study 
INTRODUCTION 
Specific fluorescent labeling is highly favourable and valuable for the study of 
interaction of S U M O with other cellular proteins. In the past, the green fluorescent 
protein (GFP) was extensively utilized in protein-protein interaction study (Zhang et 
al., 2002). However, its size (〜40 kDa) is not suitable for labeling small proteins, 
which may severely affect the physiological function or cellular localization of the 
protein. The advance of biarsenical-tetracysteine labeling system shed lights on the 
development of fluorescent tagging with its satisfactory small size (〜6-12 amino acids). 
The 2As-4Cys system is currently the only system that offers single protein specific 
‘ fluorescent labelling apart from conventional GFP system and the antigen-antibody 
interaction system. 
On the other hand, study of S U M O since its discovery has been focusing on the 
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elucidation of its mechanism of action, the identity and function of its conjugation 
substrate. The 2As-4Cys labeling system enables the specific tagging of S U M O for 
convenient localization studies by fluorescent microscopy, substrate confirmation by in 
vitro SUMOylation assay, and is a potential labeling system which can apply to 
two-dimensional electrophoresis resembling the DIGE technology (Section 1.3.1). 
W e attempted to characterize its potential use in research of SUMOylation by creating 
a recombinant 4Cys-SUM0. Different aspects of S U M O researches utilizing the 
recombinant 4Cys-SUM0 including its competency in labelling in vitro S U M O 
conjugates, in cell labelling of overexpressed S U M O and the efficacy of fluorescence 
in two-dimensional gel electrophoresis were studied. 
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3.1 MATERIALS 
3.1.1 Molecular cloning, protein expression and purification of 
pET-28m-4Cysl-SUMO-l and pET-28m-4Cys2-SUMO-l 
The materials, reagents and buffers were listed in section 2.1.1, 2.1.2, 2.1.4 and 2.1.6. 
3.1.2 Mammalian cell culture and transient transfection of 
pHM6-4Cysl-SUMO-l and pHM6-4Cys2-SUMO-l into HeLa cells 
The materials，reagents and buffers were listed in section 2.1.3, 2.1.5 and 2.1.6. 
3.1.3 Reagents and buffers 
3.1.3.1 Reagents and buffers for Lumio^ "^ in-gel labeling 
LumioTMGreen Detection Kit (Invitrogen, Cat#LC6090) All in-gel biarsenical 
labeling in this study was conducted with the assay kit purchased from Invitrogen. 
-个Preparation of reagents and solutions for SDS-PAGE please see Section 2.1.6.2 and 
2.2.9.. 
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3.1.3.2 Reagents and buffers for Lumio^ "^ in cell labeling 
LumioTMGreen In-Cell Labeling Kit (Invitrogen, Cat#12589-057) All in-cell 
biarsenical labeling in this study was conducted with the assay kit purchased from 
Invitrogen. 
10 mM 1,2-Ethanedithiol (EDT) 4.2 of EDT (Sigma-Aldrich, Cat# 398020) 
was added to 5 ml dimethyl sulfoxide (DMSO)t and mixed gently. 
fit is added inside a chemical fumehood as EDT is neural toxic. 
90 mM Calcium chloride (lOOx) 0.1 g calcium chloride was dissolved in PBS and 
brought up to 10 ml. 
Opti-MEM® I reduced serum medium, without phenol red (Gibco，Cat#11058) 
Opti-MEM reduced serum medium without phenol red was used as the medium during 
‘Lumio™ in-cell labelling. The media as purchased from Gibco in sterilized solution 
form and stored at 4 until use. 
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3.1.3.3 Reagents and buffers for immunostaining 
Fixing solution [4% paraformaldehyde (USB, Cat#19943)] This solution 
was purchased directly from the supplier in the form of 4 % in PBS. 
Blocking solution 10 % horse serum (Invitrogen, Cat# 16050-144) was freshly 
added in PBS just before use. 
Hoechst 33342 staining solution 10 mg/ml stock solution (lOOOOx) was 
prepared by dissolving 0.01 g Hoechst dye powder (Invitrogen, Cat#H-1399) in 1 ml 
ddH20. The stock solution was kept in dark at 4°C. Working solution was prepared by 
10-fold dilution of the stock in ddHaO. 
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3.2 METHODS 
3.2.1 Molecular cloning of tetracysteine-tagged SUMO (4Cys-SUMO) into 
pET-28m and pHM6 vectors 
The tetracysteine tag was attempted to genetically engineered to the N-terminus of 
matured S U M O for expression of the fluorescent tag as a recombinant protein. 
3.2.1.1 Design of primers and oligonucleotides encoding tetracysteine tag 
3.2.1.1.1 For4Cysl-SUMO-l 
The D N A sequence encoding tetracysteine (-C-C-P-G-C-C-) motif 
A R E D C C P G C C A R R was modified from the original sequence of 
E A A A R E A C C P G C C A R A (Adams et al, 2001) was introduced into the forward 
primer just behind the restriction site and prior to the A T G start codon of S U M O gene. 
- Nde\ and Hindlll were chosen for pET-28m and p H M 6 respectively. 
The reverse primer used was the same as the one in section 2.2.1.1 containing a stop 
codon and a Notl restriction site. 
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3.2.1.1.2 For 4Cys2-SUMO-l 
On the other hand, the newest modified tag with a sequence of F L N C C P G C C M E P 
(Martin et al., 2005) was adopted in the middle of the research. New tag was not 
introduced to the primers. In this method, a pair of complementary linkers containing 
the tag with appropriate restriction site overhangs were designed. The linkers were 
ligated into a plasmid containing S U M O , which had prepared in section 2.2.1.5. 
For pET-28m, an Ndel overhang was added at the 5' end of the sense strand, while a 
BamHl overhang was added at the 5' end of the antisense strand. The tag sequence was 
designed to be in frame with the S U M O gene that follows: 
Amino acid sequence 
Ndef overhang ^ L N C C P G C C M E P 
Fw: 5'-TATGCA TTC CTG AAC TGT TGT CCC GGC TGC TGC ATG GAG CCT 
Rv: 3'- ACGT A AG GAC TTG AC A ACA GGG CCG ACG ACG TAG CTC GGA 
- -> SUMO 
Fw: G-3" GATC C ATG... 
Rv: C CTAG -5' G TAC 
BamHl overhangs 
Figure 3.2.1.1 4Cys2-oligonucleotide pair for NdeUBamHl cloning. 
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For pHM6, an Hind\\\ overhang was added at the 5' end of the sense strand, while a 
Kpn\ overhang was added at the 3’ end of the sense strand. The tag sequence was 
designed to be in frame with the S U M O gene that follows: 
Amino acid sequence 
Hindlll overhang F L N C C P G C C M E P 
Fw: 5'-AGCTTG TTC CTG AAC TGT TGT CCC GGC TGC TGC ATG GAG CCT 
Rv： 3_-AC AAG GAC TTG ACA ACA GGG CCG ACG ACG TAC CTC GGA 
Kpnl overhangs > ^^^^^ 
Fw: G G TAC-3" C ATG 
Rv: C-5' C ATG G TAC..... 
Fig.3.2.1.2 4Cys2-oIigonucleotide pair for HindlWKpnl cloning. 
Both designed sequences were sent to nucleotide synthesis (Invitrogen) (referred later 
in the chapter as 4Cys-01igos). 
3.2.1.2 DNA amplification of 4Cysl-SUMO-1 by polymerase chain reaction 
(PCR) 
- T o construct the plasmid of pHM6- and pET-28m-4Cys 1 -SUMO-1, the 
tagged-SUMO-1 gene was amplified with the following PCR reaction mix: 
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Table 3.2.1.1 Composition of PCR reaction mix for amplification of 4Cysl-SUMO-l 
Components Volume 
1 Ox PCR reaction buffer 5 ^ il 
dNTPs mix (2 m M ) 2^1 
Forward primer (10 jaM) 1 |xl 
Reverse primer (10 |aM) 1 i^l 
D N A template (50 ng/|il) 1 |il 
Expand® High fidelity enzyme mix (3.511/^ 1) 1 |xl 
Autoclaved ddHiO 39 
Total 50 \x\ 
A different temperature profile was set up specified for the unusually long length of 
4Cys-SUM0 primer and its G C content as follows: 
Table 3.2.1.2 PCR reaction profile setting for amplification of 4Cysl-SUMO-1 
Steps Temp. (®C) Duration 
1 Preincubation 94 2 min 
2 Denaturation 95 30 s 
3 Annealing 60 45 s 
4 Extension 72 1 min 45 s 
2-4 Repeated for 30 cycles 
5 Final extension 72 5 min 
6 Cooling and storage 4 oo 
Amplification of S U M O cDNA was verified by analysis the PCR product with in 1 % 
agarose gel electrophoresis in TAE buffer under 120 V for 20 min. The existence and 
the size of amplified cDNA was visualized under U V trans-illumination 
(Alphamanager^"^, Alphainnoctech) with ethidium bromide staining. The D N A 
bandings was extracted from agarose gel as described in section 2.2.1.3 
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3.2.1.3 Restriction digestion of vectors and purified PCR products of 
4Cysl-SUMO-l 
Amplified 4Cys-SUM0 D N A and our vector pET-28m and p H M 6 were subjected to 
double digestion by restriction enzymes Nde\ and Not\\ or HindlU and Notl 
respectively using the following reaction profile and proceeded as described in section 
2.2.1.4: 
Table 3.2.1.3 Composition of restriction digestion mixture for construction of 
pHM6-4Cysl-SUMO-l and pET-28m-4Cysl-SUMO-l 
^ Volume, ul 
Components 
pET-28m (V) pHM6 (V) 4Cysl-SUMO-l (I) 
lOx NEBuffer 3卞 ^ - ^ 
lOx NEBuffer 2卞 - ^ 5 ^ il 
Ndel (20 U/^ l)j： \jd - 1.5 ix\ -
Hindlll (20 - 1 - 1.5 
Notl (10 1 III 1 III 1.5 ^il 1.5 ul 
1 Ox BSA (1 mg/ml) 5 \i\ 5 ^il 5 ^il 5 
Vector 10 10 \i\ - -
PCR products - - 37 |il 37 |il 
Autodaved ddH20 28 [i\ 28 |il - -
Total 50 50 50 ^il 50 
tlx NEBuffer 3: 50 m M Tris-HCl, 100 m M NaCl, 10 m M MgCb, 1 m M dithiothreitol (DTT), 
pH7.9; Ix NEBuffer 2: 10 m M Tris-HCl, 50 m M NaCl, 10 m M MgCb, 1 m M dithiothreitol 
(DTT), pH7.9 
tNdel (NEB, Cat#R0111L); HindlU (NEB, Cat#R0104L); Notl (NEB, Cat#R0189L) 
3.2.1.4 Ligation of 4Cysl-SUMO into expression vector pET-28m and pHM6 
The ligation reaction was set up as described in Section 2.2.1.5. and successful clones 
were mini- or midi-prepared as described in Section 2.2.1.8. 
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3.2.1.5 Restriction digestion of pET-28m-SUMO and pHM6-SUMO for ligation 
with 4Cys2 oligos 
For the construction of pHM6-4Cys2-SUMO-l and pET-28m-4Cys2-SUMO-l, the 
S U M O plasmids prepared as described in the previous chapter (Section 2.2.1.5) were 
subjected to double digestion by restriction enzymes Nde\ and Bam HI', or HindlW and 
Kpnl respectively using the following reaction profile: 
Table 3.2.1.4 Composition of restriction digestion mixture for construction of 
pHM6-4Cys2-SUMO-l and pET-28m-4Cys2-SUMO-l 
Volume, 
Components 
pET-28m-SUMO (V) pHM6-SUMO (V) 
IQx NEBuffer 3t ^ -
lOx NEBuffer 2 卞 - ^ 
Ndel (20 U/^ il) -
BamHl (20 U/|il) 1 ^il -
Hindlll (20 U/|^ l) - 1 
Kpn\{\()\JI\i\) - 1 III 
10xBSA(l mg/ml) 5 5 |il 
Vector 10 ^il 10^1 
Autoclaved ddHzO 28 28 
Total 50 III 50 
tlx NEBuffer 3: 50 m M Tris-HCl, 100 m M NaCl, 10 m M MgCb, 1 m M dithiothreitol (DTT), 
pH7.9; Ix NEBuffer 2: 10 m M Tris-HCl, 50 m M NaCl, 10 m M MgCb, 1 m M dithiothreitol 
(DTT), pH7.9 
The restriction digestion was carried out sequentially as efficiency of double digestion 
was unsatisfactory. For pET-28m-SUMO, the plasmid was firstly digested with Ndel 
for 3 h at 37 The second enzyme BamHl was then added and allowed to digest for 
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another 2 h, finally CIP was added and incubated for 1 h. For ligation to pHM6-SUM0, 
the digestion was done in the same manner, with HindiW followed by Kpn\. 
After completion of digestion, success of digestion was verified with agarose gel 
electrophoresis and digested vector and inserts D N A with correct size was extracted 
and purified as described in section 2.2.2.3. 
3.2.1.6 Ligation of 4Cys2 oligos to the digested pET-28m-SUMO and 
pHM6-SUMO plasmids 
3.2.1.6.1 Self-annealing of the 4Cys2 oligonucleotides 
A mixture containing same quantity of the complementary oligonucleotides were 
allowed to self-anneal by incubating at 98 for 1 min followed by incubation at 58°C 
for 10 min. The annealed oligos (ds 4Cys2 oligos) were cooled on ice and the stock 
mixture was stored at -20°C. 
3.2.1.6.2 Phosphorylation of ds 4Cys2 oligos and ligation to the plasmids 
‘ The digested plasmids were put to ligation with the tag in different V:I molar ratios 
(1:4-10). Due to the difficulties in obtaining recombinant clones, ligation volume was 
reduced to 10 [il, as a smaller volume of ligation can enhance the ligation efficiency: 
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Table.3.2.1.5 Composition of ligation mixture for construction of 
pHM6-4Cys2-SUMO-land pET-28m-4Cys2-SUMO-l 
Volume, fil 
Components Ligation Rxn (V+I) 
Negative control (V) 
1:6$ 
IQx T4 D N A ligase Rxn buffer卞 1 )al 1 pi 
Insert 2 ^il -
Vector • 0.5 |xl 0.5 |il 
T4 D N A kinase 1 |il 1 |xl 
T4 D N A ligase 1 1 i^l 
Autoclaved (1啦0 4.5 6.5 |il 
Total 10^1 10 
卞Ix T4 DNA ligase Rxn buffer: 50 m M Tris-HCl, 10 m M MgCb, 1 m M ATP, 10 m M DTT, 
25 |ig/ml BSA, pH7.5 
JMolar ratio of vector and insert DNA was determined by the relative size of the DNA and 
DNA quantification at OD260. 
Since the 4Cys2 oligos was small in size (36 bp), it was prone to spontaneous 
concatamer formation. Therefore, during the ligation, the mixture containing the 
plasmid and 4Cys2 oligos was heat at 65 for 10 min prior to adding the ligase. This 
was suggested to prevent non-specific V-V and I-I self-ligation. 
Afterwards, T4 kinase with the T4 ligase buffer was added to the mixture and 
incubated at 37 for 30 min for the phosphorylation of the 5' ends of ds 4Cys2 oligos. 
Finally, T4 ligase was added and the mixture was incubated at 16 0/N. 
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The ligation reaction mixture was transformed into DH5a as described in 
section 2.2.1.7 and single colonies were picked for an 0/N culture. PCR clone check 
was performed using the sense strand 4Cys2 oligo as the forward primer and the 
original SUMO-1 reverse primer with Not\ restriction site. The 0/N culture as a D N A 
template and the PCR products were run on a 2 % agarose gel for checking the success 
of tag ligation. Positive clones were sent to D N A sequencing (by TechDragon 
sequencing service) for verification and the confirmed clones were mini- or 
midi-prepared as described in Section 2.2.1.8. 
3.2.2 Expression and purification of pET-28m-4Cysl-SUMO-1 and 
pET-28m-4Cys2-SUMO-l in E.coli expression system 
pET-28m-4Cys 1 -SUMO-1 and pET-28m-4Cys2-SUMO-l were respectively attempted 
to expressed in E.coli using the same conditions as pET-28m-SUMO as described in 
sections 2.2.2 and using the same purification strategy for pET-28m-SUMO as 
described in section 2.2.3.4.1. 
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3.2.3 Immunohistochemistry (IHC) staining of endogenous SUMO in HeLa cells 
HeLa cells were seeded on 4-well plates (NUNC, Cat# 176740) with cover slips at 
concentration of 2.0 x 10 cells per well with RPMI 1640 medium supplemented with 
10 % (v/v) FBS and 1 % P/S. Cells were kept at 37 °C，5 % CO2 and 95 % humidified 
air until the cells were 70 % confluent. On the next day, cells were fixed with 200 \i\ 
40/0 (v/v) paraformaldehyde per well for 2 h at room temperature and afterwards 
washed with 300 |il PBS for 5 min for 3 times. The cells were then incubated with 
200 1^1 blocking solution (10% horse serum in PBS) for 1 h at room temperature 
shielded from light. Next, cells were incubated with primary antibody rabbit 
anti-SUMO-1 (Cell Signalling, Cat# 4972) in volume ratio 1:300 in 150 blocking 
solution for overnight at 4 covered with aluminium foil. On the third day, cells 
were washed with 300 )il PBS for 5 min for 3 times and subsequently incubated with 
Cy3-labelled goat anti-rabbit secondary antibody in volume ratio 1:5000 in 150 |j,l 
blocking solution for 1 h at room temperature in the dark. Next, cells were washed 
again with 300 pi PBS for 5 min for 2 times. Finally, cells were stained with 0.2 i^l 
‘ Hoechst 33342 working solution for 1 min in 200 |il PBS and washed with fresh PBS 
for 5 min twice. Procedures after adding the secondary antibody were all performed 
without ambient light exposure. 
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After the staining procedures, the cover slips with stained cells were dipped dry on 
Kimwipe® and put on glass slides that dripped with 10 90 %(v/v) glycerol with the 
cells face-downwards. Slides were taken to view under Nikon® TE2000-U inverted 
research microscope with the RFP and UV/DAPI filter sets (Spectrum characteristics 
see Appendix 4). 
3.2.4 In-cell labeling of 4Cysl/2-SUMO with LumioTM Reagent 
Lumio™Green In-Cell Labeling Kit (Invitrogen, Cat# 12589-057) was utilized to 
facilitate in-cell biarsenical labeling of the tetracysteine tagged S U M O . It is used to 
detect the presence of 4Cysl/2-SUMO and tested against its potential for displaying 
proteins having interaction with S U M O (both covalently and noncovalently) upon 
overexpression of 4Cys tagged S U M O in vivo. LumioTM reagent is 
membrane-permeable and was thus able to facilitate live cell imaging. 
3.2.4.1 Preparation 
- HeLa cells were seeded on 4-well plates (NUNC, Cat# 176740) at concentration of 
2.0 X 103 cells per well with RPMI 1640 medium supplemented with 10 % (v/v) FBS 
and 1 % P/S. Cells were kept at 37 5 % CO2 and 95 % humidified air until the cells 
were 70 % confluent. The cells were transfected as described in Section 2.2.7.2 with 
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0.4, 0.8 and 1.2�昭 pHM6-4Cysl/2-SUMO plasmid D N A together with 0.8, 1.6 and 
2.4 of L i p o f e c t a m i n e T M 2000 Reagent which were respectively diluted into 50 \i\ 
Opti-MEM® I reduced serum medium without phenol red (Invitrogen, Cat#l 1058-021) 
for each well. A control was set up by transfecting empty pHM6 vector into the cells. 
3.2.4.2 In-cell LumioTM labeling 
Transfected cells were washed with PBS for twice in order to remove trace of the 
serum containing medium prior the labeling. Next, for 4-well plates staining, 1 |xl of 
LumioTM Reagent was diluted in 1 ml Opti-MEM®I reduced serum medium without 
phenol red (Invitrogen) (1000-fold dilution) to make a 1.0 ^ M working concentration 
for labeling. At the same time, 2 of Disperse Blue® 3 (DB3) was diluted in another 
2 ml reduced medium (1000-fold dilution) to make a 20 m M working concentration for 
background reduction. To start the labeling process, PBS was removed from the wells 
and 150 \i\ of the labeling solution containing Lumio reagent was added to the wells, 
with 10 |liM 1,2-dithiol reagent EDT for blocking the endogenous pairs of thiols that 
- cause high noise background signals. Cells were incubated with the solution at room 
temperature for 15-30 min and then discardedt. Finally, 300 }il DB3 solution was 
added to each well and not removed from the wells during the detection by fluorescent 
microscope. 
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fLumio reagent containing solutions were to be carefully disposed as carcinogenic 
arsenic compounds according to University 's instructions. 
3.2.4.3 Detection and imaging of the labeled cells 
Labelled cells were visualized with fluorescent microscopy utilizing 
Nikon(DTE2000-U inverted research microscope. FITC filter was used (Spectrum 
characteristics in Appendix 4) and images were recorded with the equipped C C D 
camera with equal exposure time and gamma indices. Long exposures were avoided 
which might cause significant photobleaching of the dye complex. 
3.2.5 In-gel labeling of 4Cysl/2-SUMO with LumioTM Reagent 
3.2.5.1 LumioTM in-gel labelling 
LumioTMGreen Detection Kit (Invitrogen, Cat#LC6090) was utilized to facilitate in-gel 
biarsenical labeling of the tetracysteine tagged S U M O . The fluorescent system was 
used to detect the presence of 4Cysl/2-SUMO and S U M O conjugates from in vitro 
- SUMOylation. T D G protein was used as the positive control and in vitro SUMOylation 
of T D G and HeLa lysates obtained by whole cell protein extraction (Section 2.2.4.2) 
was carried out as described in section 2.2.6. 
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After the in vitro SUMOylation reaction, the reaction mixtures were immediately 
cooled on ice. For 15 reaction mixture, 4 |il LumioTM Gel Sample Buffer卞（4x) was 
added and thoroughly mixed. The tube was then added with 0.2 [i\ LumioTM Green 
Detection Reagentt and incubated at 70 for 10 min. Afterwards, the sample was 
cooled down on ice for 2 min. Sample cooled was next centrifuged briefly at 
16,100 X g for 30 s and added with 2 i^l LumioTM in-Gel Detection Enhancerf, mixed 
well and incubated at room temperature for 5 min. Finally, the sample was analyzed 
with SDS-PAGE as described in Section 2.2.9, the gel tank was covered with 
aluminium foil to minimize exposure to possible ambient light excitation. 
fAll reagents were stored at -20�C immediately after use to prevent degradation of 
chemicals. 
3.2.5.2 Visualization and imaging of the labeled gel 
(a) UV illumination at 302 nm 
After SDS-PAGE, the gel was preserved in ddHiO and immediately visualized under 
- U V exposure at 302 nm in the Alphamanager® (Alphalnnotech). The image was taken 
using the intrinsic C C D camera of the gel documentation equipment through the 
ethidium bromide filter using 4-10 seconds exposure. After imaging, the gel was 
stained with Coomassie Blue®R250 as described in section 2.2.9. 
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(b) Typhoon Trio '^^Laser-scanning at 5S2 nm 
After SDS-PAGE, the gel was preserved in ddHsO and immediately brought against 
fluorescent scanning by TyphoonTM Trio scanner (GEHealthcare). Acquisition of image 
was done by choosing the desired grid area in the computer equipped with 
ImageQuant® TL. Excitation was conducted with the 532 nm laser beam and 555 nm 
band-pass filter (555 BP 20) was chosen as the emission filter. The pixel size was set to 
be 200 \im and a P M T voltage of 600 V was selected. The resulted image was exported 
in bitmap file format. After imaging, the gel was stained using silver nitrate method as 
described in section 2.2.11.4.1. 
3.2.5.3 Detection limit of fluorescent 4Cys2-SUMO-l in SDS-PAGE 
Fluorescence detection limit of 4Cys2-SUMO-l with Lumio™ labelling was 
performed by loading the following concentrations of purified 4Cys2-SUMO-l with 
2-fold serial dilution: 6 |ag, 3 1.5 )ig, 0.75 |ig, 0.38 |ig, 0.14 \ig and 0.06 |ig. The gel 
was stained with Lumio™ in-gel labelling kit as described in section 3.2.5.1. 
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3.2.5.4 In-gel labelling in two-dimensional electrophoresis (2-DE) 
3.2.5.4.1 Modification of equilibration buffer before SDS-PAGE 
It has been reported by the Tsien's group (Adams et al., 2001) that a high concentration 
of 1,2-dithiols will cause disintegration of tag-dye complex by competition of the dye 
molecule. High concentrations of 1,2-dithiols were used as the elution reagent. On the 
other hand, iodoacetamide (lAA) was well-known as the alkylation agent of cysteine 
residues to prevent cysteine modification during the SDS-PAGE. Therefore，the 
Immobiline™ strip equilibration step before second dimension gel, which involved 
DTT and lAA isage was optimized in order to accommodate LumioTM labelling. 
In the optimization experiments, purified 4Cys2-SUMO-l was used to illustrate the 
results. Different concentrations of DTT: 20, 8，3 mg/ml and lAA: 5, 15, 5 mg/ml were 
added to the purified 4Cys2-SUMO-l with LumioTM Gel Sample Buffer. LumioTM 
labeling was carried out as described in section 3.2.5.1. The mixture was analyzed by 
SDS-PAGE and detected as described in section 3.2.5.2. 
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3,3 RESULTS 
3.3.1 Adoption of old version of 4Cys-tag (4Cysl) in SUMO study 
3.3.1.1 Construction of recombinant pET-28m-4Cysl-SUMO-1 and 
pHM6-4Cysl-SUMO-l 
The SUMO-1 gene incorporated with the 4Cysl sequence (4Cysl-SUMO-1) at the 
N-terminal was amplified successfully from the D N A template SUMO-1 -pGEX-6p 
kindly given by Mr. Xu Zheng, with a forward primer containing the tetracysteine 
sequence A R E D C C P G C C A R R and a reverse primer with stop codon added behind the 
S U M O gene (Appendix 3) using the PCR profile described in section 3.2.1.2. 
Restriction digestions of the PCR products were performed {NdeVNotl for pET-28m 
vector; HindWUNotl for p H M 6 vector) and ligation was carried out as described in 
3.2.1.3-4. Clones were screened by PCR amplification. All the positive clones were 
sent to D N A sequencing (TechDragon). The D N A sequences of the positive clones 
‘ were validated with the NCBInr database sequences and shown to have 100% match 
scores by ClustalW program. 
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Figure 3.3.1.1 PCR products of 4Cysl-SUMO-l (327 bp) for construction of 
pHM6-4Cysl-SUMO-l and pET-28m-4Cysl-SUMO-1 recombinant plasmids. Lanes 1 and 
2，PCR products for HindWUNotl restriction digestion; Lanes 3 and 4，PCR products for 
NdeMNotl restriction digestion; Marker, GeneRuler Ikb D N A ladder. Analyzed in 1% agarose 
gel. 
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3.3.1.2 In vivo HA-4Cysl-SUMO-1 LumioTM labelling 
To observe the effect of LumioTM labelling in vivo, pHM6-4Cys 1 -SUMO-1 was 
transfected into HeLa cells as described in section 3.2.4.2. A separate well of cells 
transfected with 4Cysl-SUMO-1 was brought to lysis for a western blot analysis to 
show the transfection efficiency (Fig.3.3.1.2A). The remaining wells of cells were 
labelled by LumioTM in-cell reagent as described in section 3.2.4.3. Results showed 
that when 10 |iM E D T was added to the labelling mixture, background was 
successfully reduced. However, comparing with the control experiment in which the 
cells were not transfected with pHM6-4Cys 1 -SUMO-1, bright fluorescence was still 
observed (Fig. 3.3.1.2). Technical support of I n v i t r o g e n T M was consulted and 
accordingly, addition of EDT and using labelling medium without phenol red were all 
adopted into the labelling system. Significant difference of fluorescent intensity was 
observed between the control and transfected samples. However, the background 
problem generated could not be solved completely. 
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Figure 3.3.1.2 In cell HA-4Cysi-SUMO-1 LumioTM labelling in HeLa cells. (A) 
Transfection efficiency determination by western analysis probing with anti-SUMO-1 antibody. 
PVDF membrane transferred from 12% SDS-PAGE: Lane 1, control; Lane 2 and 3, 
transfection with 0.8 fig pHM6-4Cys 1 -SUMO-1 DNA. (B) Green fluorescence detected from 
Lumio™ dye-4Cysl tag complex by FITC/GFP filter set of Nikon TE2000 fluorescent 
microscope. 
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3.3.1.3 Immunohistochemistry (IHC) staining of endogenous SUMO in HeLa 
cells 
IHC staining of S U M O in HeLa cells was performed using anti-SUMO-1 antibody and 
anti-rabbit Cy3 secondary antibody. Endogenous SUMO-1 protein was labelled with 
Cy3 and thus appeared as red fluorescence. IHC staining result was served as a 
labelling efficiency control that can be compared by LumioTM labelling. IHC staining 
showed that endogenous SUMO-1 was localized mainly inside the nucleus and were 
very abundantly shown in the subnuclear structures. (Fig. 3.3.1.3) 
Hoec|jst 33342 of ihc of endogenous Lumio^'^staining of 
^ S U M O ° r SUMO-1 4Cys1-SUMO-1 • • • 
60x 
. Figure 3.3.1.3 Comparison of IHC staining of endogenous SUMO-1 and in cell 
HA-4Cysl-SUMO-l LumioTM labelling in HeLa cells. Left panel, IHC staining of SUMO-1 
with rabbit anti-SUMO-1 Ab in 1:300 and anti-rabbit Cy3 Ab in 1:5000 (White arrows 
indicating the pronounced subnuclear structures), viewed with the RFP filter set of Nikon 
TE2000; Right panel, Lumio™staining of 4Cysl-SUMO-1 with Lumio''" Green in-cell 
labelling kit, viewed with the FITC filter set of Nikon TE2000. 
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3.3.1.4 Expression and purification of His6-4Cysl-SUMO-1 
Expression plasmid pET-28m-His6-4Cysl-SUMO-1 was transformed into 
BL21(DE3)pLyS and grown at 20。C overnight after induction by IPTG at ODeoo 0.6. 
The cells were lysed and the His6-4Cys 1 -SUMO-1 was purified as described in section 
2.2.3.4.1. Most of the impurities in the background could be removed after the nickel 
column. The elution of His6-4Cys 1 -SUMO-1 with approximately 75% purity was 
accomplished with 120 m M imidazole (Fig. 3.3.1.4). 
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Figure 3.3.1.4 Purification of His6-4Cys 1 -SUMO-1 by Nickel affinity chromatography. 
Protein samples were analyzed by 15% SDS-PAGE. Lane TL, total lysate of BL21(DE3)pLysS 
expressing His6-4Cys 1 -SUMO-1�； Lane FL, flowthrough after binding Ni-NTA resin; Lane W, 
washing (with 20 mM imidazole); Lanes El to Ell , elution fractions of His6-4Cys 1 -SUMO-1 
in a gradient of 120 mM to 300 mM imidazole; Marker, Invitrogen SeeBlue® Plus 2 
Pre-Stained Standard. 
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Partially purified His6-4Cysl-SUMO-1 from fractions E5 to Ell were subjected to 
desalting and loaded to Q anion exchange column for further purification. Purification 
efficiency was low since impurities bound retained when compared with the result of 
nickel chromatography (Fig.3.3.1.5). Large amount of His6-4Cys 1 -SUMO-1 was 
eluted at a low concentration of NaCl and only fractions E2 and E3 were pooled and 
concentrated for final purification with SuperdexTM S75 size exclusion column. 
His6-4Cys 1 -SUMO-1 was successfully eluted out at a volume of ~60 ml. Fractions E9 
to El3 were pooled and a final purity of 95% has been achieved (Fig.3.3.1.6). 
His6-4Cys 1 -SUMO-1 was found to have very similar biophysical properties as 
His6-SUM0-1 in the identical purification scheme. While the Q sepharose did not give 
significant improvement of recombinant protein purity, it was removed from the 
purification scheme in the later SUMO-1 purification experiments. DTT concentration 
in column buffers can be raised to 10 m M in order to prevent the dimer formation in 
His6-4Cys 1 -SUMO-1 purification as significant major band around 36 kDa, which was 
-believed to be a dimer form of His6-4Cysl-SUMO-1 (Fig.3.3.1.4, 3.3.1.5). 
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Figure 3.3.1.5 Purification of His6-4Cysl-SUMO-1 by Q anion-exchange chromatography. 
Protein samples were analyzed by 15% SDS-PAGE. Lanes Wl to W2, washing (with binding 
buffer); Lanes El to E8, elution fractions of His6-4Cys 1 -SUMO-1 in a gradient of 100 m M to 
IM NaCl; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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Figure 3.3.1.6 Purification of His6-4Cysl-SUMO-l by gel filtration chromatography with 
SuperdexTM S75. Protein samples were analyzed by 15% SDS-PAGE. Lanes El to E2, 
fractions eluted out at 33 ml; Lanes E3 to E7, fractions eluted at 40-55 ml containing 30 kDa 
impurity; Lanes E8 to El3，fractions eluted at 60 ml containing His6-4Cysl-SUMO-1 with 
95% purity; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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3.3.1.5 Validation of 4Cysl-SUMO-1 conjugate by LumioTM in-gel labeling 
The successfully purified His6-4Cysl-SUMO-1 was then used to validate the 
robustness of LumioTM in-gel labeling of 4Cysl-SUMO-1 conjugated proteins. T D G 
was adopted as the model substrate protein for SUMOylation. In vitro SUMOylation 
reaction was carried out on T D G as described in section 2.2.6.1 and the reaction 
mixture was labeled with in-gel LumioTM reagent as described in section 3.2.5.1 
immediately after the reaction. SDS-PAGE gel obtained was viewed under U V 
illumination and a clear fluorescent band at -64 kDa was observed which corresponded 
to the size of 4Cys 1 -SUMO-1 -TDG conjugate (Fig.3.3.1.7). Labeling was then further 
applied to in vitro SUMOylated lysates. However, no significant fluorescent signals 
could be obtained. 
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Figure 3.3.1.7 In gel His6-4Cysl-SUMO-1 LumioTM labelling in 15% SDS-PAGE (A) UV 
excitation at 302 nm (B) Coomassie® R250 staining after LumioTM labelling. Lane 1, 
purified TDG; Lane 2, purified His6-SUM0-1; Lane 3, product of TDG SUMOylation with 
His6-SUMO-l; Lane 4，purified His6-4Cysl-SUMO-1; Lane 5, product of TDG SUMOylation 
with His6-4Cysl-SUMO-1; Lane 6, product of 10 |xg HeLa cell lysate SUMOylation with 
His6-4Cysl-SUMO-1; Lane 7，10 ^ g HeLa cell lysate; Marker, Invitrogen SeeBlue® Plus 2 
Pre-Stained Standard. 
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3.3.2 Adoption of a modified version of 4Cys-tag (4Cys2) in SUMO study 
At the time we attempted to optimize the labeling performance, Martin et al； 2005 
reported a new 4Cys tag giving intense fluorescence signal upon LumioTM dye binding. 
Construction of libraries for a massive screening of the tag motifs revealed that tag 
sequence F L N C C P G C C M E P gave a 20-fold increase of fluorescent intensity with a 
reduced background. This new 4Cys motif (4Cys2) was adopted for our later 
experiments. 
3.3.2.1 Construction of recombinant pET-28m-4Cys2-SUMO-l and 
pHM6-4Cys2-SUMO-l 
The S U M O plasmids generated in section 2.2.1 were used for the construction of 
pET-28m-4Cys2-SUMO-1 and pHM6-4Cys2-SUMO-l. They were digested with 
corresponding restriction enzymes (Fig. 3.3.2.1) as described in section 3.2.1.6 and 
' were used as "vectors" for ligation with the 4Cys2 tag. 
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Figure 3.3.2.1 Restriction digestion of pHM6-SUMO-l with HindVlUKpnl and 
pET-28m-SUMO-l with Ndel/BamHl. Lane 1, linearized pHM6-His6-SUMO-l at -5.4 kbp; 
Lane 2, linearized pET-28m-His6-SUMO-1 at -5.3 kbp; Marker, GeneRuler 1 kb D N A ladder. 
Analyzed in 1% agarose gel. 
214 
Chapter III Results 
4Cys2 was obtained by self-annealing of complementary oligonucleotides and mixed 
with the linearized SUMO-1 plasmid in appropriate ratios (1:4, 1:6 and 1:8). 
Phosphorylation of 4Cys oligonucleotides was done in the same reaction mixture prior 
to addition of T4 D N A ligase (section 3.2.1.7). Concatamer formation was successfully 
prevented as seen from the 2% agarose gel (Fig. 3.3.2.2). Successful clones were 
identified as -50 bp upshifted bands. The optimal molar ratio of vector to insert was 
determined to be 1:6. Positive clones were sent to D N A sequencing (TechDragon Ltd.). 
D N A sequence of the positive clones was found to be aligned with SUMO-1 gene in 
NCBInr database with an in-frame 4Cys2 tag fused at the N-terminal of the SUMO-1 
gene. 
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Figure 3.3.2.2 Clone check PCR of pHM6-4Cys2-SUMO-l (A) pET-28m- 4Cys2-SUMO-l 
(B) in 2% agarose gel. Clone check was performed by PCR with the sense strand 4Cys2 
oligonucleotide as the forward primer and the original SUMO-1 reverse primer with Not\ 
restriction site. The vector to insert ratio is indicated in the figure as shown. Marker, Portman 
lOObp DNA ladder. 215 
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3.3.2.2 In vivo HA-4Cys2-SUMO-l LumioTM labelling 
The constructed pHM6-4Cys2-SUMO-1 plasmid was then transfected into HeLa cells 
as described in section 3.2.4.1 for testing the efficiency of 2As-4Cys labelling with the 
new 4Cys2 motif. Results showed that fluorescent intensity of 4Cys2 labelled cells was 
able to be distinguished from the background, which has been drastically reduced 
(Fig.3.3.2.3). The labelled HA-4Cys2-SUMO-l was found in the nucleus, which 
resembled the results obtained from the IHC staining in section 3.3.1.2 (Fig.3.3.2.4). 
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Figure 3.3.2.3 In cell HA-4Cys2-SUMO-l LumioTM labelling in HeLa cells. (A) Western 
analysis of transfection efficiency probing with anti-SUMO-1 antibody on PVDF membrane 
transferred from 12% SDS-PAGE: Lane 1, control; Lane 2, transfected with 0.8 fig 
pHM6-4Cys2-SUMO-l DNA; Lane 3, transfected with l.lfig pHM6-4Cys2-SUMO-l DNA. 
(B-D) Green fluorescence detected from LumioTM dye-4Cysl tag complex by FITC/GFP filter 
set of Nikon TE2000 fluorescent microscope. Panel B, Control; Panel C, transfected with 
transfected with 0.8 fig pHM6-4Cys2-SUMO-l DNA; Panel D, transfected with 1.2 jxg 
pHM6-4Cys2-SUMO-l DNA. 
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Figure 3.3.2.4 Comparison of IHC staining of endogenous SUMO-1 and in cell 
HA-4Cys2-SUMO-l LumioTM labelling in HeLa cells. Left panel, IHC staining of SUMO-1 
with rabbit anti-SUMO-1 Ab in 1:300 and anti-rabbit Cy3 Ab in 1:5000 (White arrows 
indicating the pronounced subnuclear structures), viewed with the RPP filter set of Nikon 
TE2000; Right panel, Lumio^ ''staining of 4Cys2-SUMO-l with Lumio" Green in-cell 
labelling kit, viewed with the FITC filter set of Nikon TE2000. 
218 
Chapter III Results 
3.3.2.3 Expression and purification of His6-4Cys2-SUMO-l 
Expression plasmid pET-28m-His6-4Cys2-SUMO-1 was transformed into 
BL21(DE3)pLyS and grown at 20°C overnight after induction by IPTG at OD600 0.6. 
The cells were lysed and His6-4Cys2-SUMO-1 was purified with the identical method 
described in section 2.2.3.4.1. Most of the impurities could be removed after the nickel 
column. However, large amount of the His6-4Cys2-SUMO-1 came out in the 
flowthrough and washing which should be due to overloading of crude lysate. Protein 
impurities were eluted at higher concentration of imidazole in fractions E7 to Ell. The 
elution of His6-4Cys2-SUMO-1 with approximately 85% purity was accomplished 
with 120 m M imidazole (Figure 3.3.2.5). 
The His6-4Cys2-SUMO-1 with relatively high purity from fractions E2 to E6 were 
pooled and concentrated for final purification with SuperdexTM §75 size exclusion 
column directly. His6-4Cys2-SUMO-1 was successfully eluted out at a volume of 
~60 ml. Fractions E4 to E6 were pooled and a final purity of 95% was achieved 
(Fig. 3.3.2.6). 
4Cys2 tagged His6-SUM0-1 was again shown to possess very similar biophysical 
properties as His6-SUM0-1 in the identical purification scheme. 
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Figure 3.3.2.5 Purification of His6-4Cys2-SUMO-l by nickel affinity chromatography. 
Protein samples were analyzed by 12% SDS-PAGE. Lane TL, total lysate of BL21(DE3)pLysS 
expressing His6-4Cys2-SUMO-1 ； Lane FL, flowthrough after binding Ni-NTA resin; Lane W, 
washing (with 20 m M imidazole); Lanes El to Ell，elution fractions of His6-4Cys2-SUMO-l 
in a gradient of 120 m M to 300 m M imidazole; Marker, Invitrogen SeeBlue® Plus 2 
Pre-Stained Standard. 
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Figure 3.3.2.6 Purification of His6-4Cys2-SUMO-1 by gel filtration chromatography with 
SuperdexTM S75. Protein samples were analyzed by 12% SDS-PAGE. Lane Ni, pulled 
fractions from Nickel column elution; Lanes El to E2, fractions eluted out at 33 ml; Lanes E3 
to E6, fractions eluted at 60-65 ml His6-4Cys2-SUMO-l with 95% purity Lanes E7 to ElO, 
fractions eluted at 70-80 ml containing a lower molecular weight impurity; Marker, Invitrogen 
SeeBlue® Plus 2 Pre-Stained Standard. 
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3.3.2.4 Validation of 4Cys2-SUMO-l conjugate LumioTM in-gel labeling 
The successfully purified His6-4Cys2-SUMO-1 was then used to validate the 
robustness of Lumio™ in-gel labeling of 4Cys2-SUMO-l conjugated proteins by in 
vitro SUMOylation of T D G and HeLa cell lysates as described in section 2.2.6. 
SUMOylated mixture was labeled with in-gel Lumio™ reagent as described in section 
3.2.5.1 immediately after the reaction. The experiment was done with a control using 
pure His6-4Cys 1 -SUMO-1, in order to compare the fluorescent intensity of the old and 
new versions of the 4Cys tag. SDS-PAGE gel obtained was viewed under U V 
illumination. Results showed that 4Cys2 achieved a much stronger fluorescent 
intensity than 4Cysl under the same labeling condition and with the same quantity of 
SUMO-1 protein (Fig.3.3.2.7). Labeling of SUMO-1-TDG conjugate could be clearly 
seen as a fluorescent shifted band corresponding to the Coomassie staining image 
(Fig.3.3.2.8). On the other hand, the labeling of SUMOylated conjugates in HeLa 
lysate showed a better fluorescent intensity with 4Cys2 which was not achieved using 
- 4Cysl as the tag (Fig.3.3.2.8). 
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Figure 3.3.2.7 Comparison of in gel LumioTM labelling between the fluorescent 
performance of His6-4Cysl-SUMO-1 and His6-4Cys2-SUMO-l (A) under 302 nm UV 
excitation and (B) Coomassie® Blue R 250 staining after Lumio^'^ labelling. Lane 1, in 
vitro S U M O conjugation system with His6-4Cys2-SUMO-1 ； Lane 2, I S U M O conjugation 
system with His6-4Cys 1 -SUMO-1 ； Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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Figure 3.3.2.8 In gel His6-4Cys2-SUMO-l LumioTM labelling in 12% SDS-PAGE (A) UV 
excitation at 302 nm (B) Coomassie® R250 staining after Lumio^'^ labelling. Lane 1, 
purified TDG; Lane 2, purified His6-SUM0-1; Lane 3, product of TDG SUMOylation with 
His6-SUMO-l; Lane 4, purified His6-4Cys2-SUMO-l; Lane 5, product of TDG SUMOylation 
with His6-4Cys2-SUMO-l; Lane 6，30 昭 HeLa cell lysate; Lane 7, 30 昭 HeLa cell lysate 
SUMOylated with His6-SUMO-l; Lane 8, 30 i^g HeLa cell lysate SUMOylation with 
His6-4Cys2-SUMO-l; Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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3.3.3 2As-4Cys labeling in two-dimensional electrophoresis (2-DE) 
As mentioned in section 1.3，2As-4Cys labeling adaptation has been mainly on in-cell 
labeling (Rudner et cd., 2004; Andresen et al, 2004) which its potential use in in-gel 
labeling has not been fully explored. As the 2As-4Cys tag-dye complex is able to 
tolerate the denaturing conditions of SDS-PAGE, its potential use in 2-DE was 
investigated. 2As-4Cys labeling relies on the covalent bonding formed between the 
arsenic molecules of the dye and the thiosulphate (-SH) group of a pair of cysteines on 
the tag. Therefore after the tag-dye complex has been formed, it can tolerate the even 
more drastic conditions in 2-DE. However, there are a few concerns have to be 
considered. In-gel labeling reagents were added directly in the SUMOylation reaction 
mixture prior to 2-DE and therefore, the unknown composition of the reagents, e.g. 
buffer content, may interfere with the isoelectric focusing process. Isoelectric focusing 
process was heavily dependent of the clearance of salts. On the other hand, excess dye 
molecules which were not conjugated to the tag might cause undesirable chemical 
- interaction with the chemical reagents used in the 2-DE experiment. In addition, long 
course of the experiment might reduce the competency of dye performance. Trials with 
appropriate controls assessing the feasibility of application of 2As-4Cys labeling 
system in 2-DE are described in the following sub-sections. 
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3.3.3.1 Detection limit of 4Cys2-SUMO-l in SDS-PAGE 
Detection limit of LumioTM dye labeled 4Cys2-tagged protein in SDS-PAGE was done 
with a titration of 4Cys2-SUMO-l as described in section 3.2.5.3. The U V excited gel 
was compared to the silver stained gel. Results showed that LumioTM labeled SUMO-1 
has yet a slightly lower detection efficiency than silver staining under the condition of 
SDS-PAGE (Fig. 3.3.3.1). A very faint band was detected when 60 ng SUMO-1 protein 
was loaded. The detection limit was determined to be around 100 ng to give a 
significant band which was still weaker than expected. According to the manufacturer's 
protocol, it is capable of detecting 1 pmole of a 4Cys-tagged protein, which would be 
equal to 20 ng of 4Cys2-SUMO-l protein (20 kDa), however according to our 
experiment, this capacity could not be achieved. 
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Figure 3.3.3.1 Comparison of detection limit of in gel His6-4Cys2-SUMO-l LumioTM 
labelling in 12% SDS-PAGE under UV excitation at 302 nm (A); of corresponding silver 
nitrate staining after LumioTM labelling (B). Lane 1-7，different concentrations of 
His6-4Cys2-SUMO-l loaded (Lane 1，6 |xg; Lane 2, 3 ^ ig; Lane 3, 1.5|xg; Lane 4，0.75 i^g; 
Lane 5, 0.38 fig; Lane 6, 0.14 |ig; Lane 7，0.06 jxg); Marker, Invitrogen SeeBlue® Plus 2 
Pre-Stained Standard. 
225 
Chapter III Results 
3.3.3.2 LumioTM labeling in 2-DE 
A number of procedures in the 2-DE including sample clean-up, lEF process to the 
ImmobilineTM strips equilibration with high concentrations of DTT and lAA; and long 
source of 2-DE process, might affect the performance of the LumioTM fluorescence. To 
test upon their effects, various experiments were performed. 
For sample clean-up, the fluorescence of pure 4Cys2-SUMO-l samples running on 
SDS-PAGE with and without prior sample clean-up using the 2-D clean-up kit 
(GEHealthcare) was compared. Results showed that after sample clean-up, the 
fluorescence was diminished (Fig.3.3.3.2). Therefore clean-up procedure was found to 
be undesirable for the tag-dye interaction, possibly the salt removal or the precipitation 
process dissociated the tag-dye interaction. Therefore, sample clean-up is 
recommended to perform prior to LumioTM labeling. 
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(Exposure time: 2s) 
Figure 3.3.3.2 Effect of sample clean up with 2-D clean up kit (GEhealthcare) on 
fluorescent intensity of in gel His6-4Cys2-SUMO-l LumioTM labelling in 12% SDS-PAGE 
under UV excitation at 302 nm. Lanes 1 and 2, 5 |ig of His6-4Cys2-SUMO-l without sample 
clean up; Lanes 3 and 4，5 |ig of His6-4Cys2-SUMO-1 processed by sample clean up. 
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For investigation into the influence of the strip equilibration process, a series of 
dilutions of DTT and lAA in the equilibration buffer were adjusted to test the dye 
performance. The tag-dye complex was incubated with 20, 8, 3 mg/ml DTT and 25，15, 
5 mg/ml lAA for 15 min and followed by SDS-PAGE analysis. The resulting gel was 
viewed under U V excitation (Fig.3.3.3.3). It showed that the fluorescent intensity has 
been greatly diminished in high concentration of DTT (20 mg), which was the usual 
concentration of DTT used in the strip equilibration step. Fluorescent intensity gained 
back along a descending gradient of DTT concentration and was found comparable to 
that of the control when the concentration was decreased to 3 mg/ml (16% control 
concentration). The results agreed with the chemical theory as higher concentration of 
DTT cause competition with the cysteines on the tag and dissociation of the tag-dye 
complex. The same set of experiment was done with the LumioTM enhancer. LumioTM 
enhancer is able to cap cysteines which were not on the 4Cys tag for prevention of 
nonspecific binding by the dye (LumioTM Datasheet, Invitrogen, 2005). The labeling 
efficiency was higher than without adding the enhancer. However, it was not 
‘ recommended to use in 2-DE experiments as the unknown composition of the enhancer 
would interfere with the lEF process. 
228 
Chapter III Results 
On the other hand, lAA showed to completely abolish the fluorescence when present in 
the labeling mixture. The fluorescence was null even when lAA concentration was 
decreased to 5 m M (30% control concentration). The result agreed with prediction as 
lAA is an alkylation agent of cysteines which prevent the dye molecule from attaching 
to it. 
According to the results, lAA was excluded in the equilibration process while DTT was 
reduced to 10 mg/ml (50% control concentration) in order to preserve the fluorescence 
performance. 
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Figure 3.3.3.3 Optimization of DTT and lAA concentration in the in gel 
His6-4Cys2-SUMO-l LumioTM labelling in 12% SDS-PAGE under UV excitation at 302 
nm (A); of corresponding Coomassie® R250 staining after LumioTM labelling (B). Lane 1, 
Control with no DTT or lAA added; Lanes 2-7, without LumioTM enhancer (Lane 2，with 20 
mg/ml DTT; Lane 3, with 8 mg/ml DTT; with 3 mg/ml DTT; Lane 4, with 3mg/ml DTT ； Lane 
5，with 25 mg/ml lAA; Lane 6，with 15 mg/ml lAA; Lane 7，with 5 mg/ml lAA); Lanes 8-13, 
with LumioTM enhancer (Lane 8, with 20 mg/ml DTT; Lane 9，with 8 mg/ml DTT; with 3 
mg/ml DTT; Lane 10, with 3 mg/ml DTT; Lane 11, with 25 mg/ml lAA; Lane 12, with 15 
mg/ml lAA; Lane 13，with 5 mg/ml lAA). All lanes loaded with 5 ^ig His6-4Cys2-SUMO-l. 
Marker, Invitrogen SeeBlue® Plus 2 Pre-Stained Standard. 
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The modified procedures were then applied on an entire run of 2-DE of 5 |ig purified 
4Cys2-SUMO-l with Lumio™ labeling after sample clean-up for examining the 
fluorescence emission and the detection limit. The resulting gel was visualized under 
U V excitation. A fluorescent spot could be noticed which matched both the size and pi 
of 4Cys2-SUMO-l (Fig. 3.3.3.4). However when comparing with a 6 jig 
4Cys2-SUMO-l band on SDS-PAGE in fig.3.3.3.1, a significant diminishment of 
fluorescence was observed. The detection limit resided at a concentration of 500 ng of 
4Cys2-SUMO-l (Fig. 3.3.3.5), which was still weaker than that observed in 
SDS-PAGE. 
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Figure 3.3.3.4 Detection limit of in gel His6-4Cys2-SUMO-l LumioTM labelling in 2-DE 
processed by 7 cm pH4-7 ImmobilineTM drystrip and 12% SDS-PAGE under UV 
excitation at 302 nm (A); of corresponding silver nitrate staining after LumioTM labelling 
(B). The 2-DE was loaded with 5 ^ig His6-4Cys2-SUMO-1. 
A B 
H P SOOng 
(Exposure time: 0.3s) 
Figure 3.3.3.5 Detection limit of in gel His6-4Cys2-SUMO-l LumioTM labelling in 2-DE 
processed by 7 cm pH4-7 I m m o b i l i n e T M drystrip and 12% SDS-PAGE under UV 
excitation at 302 nm (A); of corresponding silver nitrate staining after LumioTM labelling 
(B). The 2-DE was loaded with 500 ng His6-4Cys2-SUMO-l. 
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3.4 DISCUSSION 
Characterization of the biarsenical-tetracysteine labeling method in studying S U M O 
was carried out with the two major application of the fluorescent system: in-cell 
labeling and in-gel labeling. Tetracysteine labeling was first developed by Tsien's 
group in 1998 (Griffin et a/., 1998). It was a breakthrough of fluorescent labeling by the 
novel production of a small, sensitive, specific tag which can be fused with the target 
protein at the genetic level. 
Our study focused on the use of this system on S U M O study, particularly on its use as 
a specific tag for visualization of S U M O and S U M O conjugated proteins in attempt to 
serve as a pilot work for application of a novel fluorescent labeling system on S U M O 
researches. 
- Construction of 4Cys-tagged SUMO-1 was done initially with the tag 
A R E D C C P G C C A R R (4Cysl) (Adams et aL, 2001). On tagging SUMO-1 with 4Cysl, 
the basic properties of SUMO-1 were not critically altered (pi 6.35/Mw 15.05; original 
His6-SUM0-1 pi 6.35/Mw 14.67). The tag is relatively small (12 a.a.) to exert 
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conformational hindrance on the folding of SUMO-1 when attached on the N-terminal. 
The fluorescent performance of 4Cysl-SUMO-1 was investigated by transient 
transfection of pHM6-4Cys 1 -SUMO-1 into HeLa cells. Transfection efficiency was 
high when using 1.2 |ig of D N A and 2.4 [i\ of Lipofectamine® agent; and harvested 
48-hr post-transfection. Cells were labeled by Lumio™ in-cell labeling kit and viewed 
under laser fluorescent spectromicroscope with an FITC filter. It can be observed that 
the background fluorescence in the control without 4Cysl-SUMO-1 transfection was 
very high even when the labeling time has been minimized to 15 minutes with the 
minimum recommended concentration of LumioTM reagent (1 |iM) (Fig. 3.3.1.2). 
Background fluorescence was clearly observed in both the nucleus and spread through 
the cytoplasm. While in the transfected cells, though a significantly higher fluorescent 
intensity in the nucleus was shown under same excitation conditions, high background 
fluorescence persisted. Background fluorescence is generally caused by binding of the 
dye to endogenous cysteine pairs and lipoamide cofactors. Different strategies were 
conducted to minimize the background fluorescence. Thorough washing of full 
‘ medium containing FBS was done prior to staining. The background was able to be 
reduced by addition of 10 |j,M EDT into the labeling mixture, allowing clearer nucleus 
staining of 4Cysl-SUMO-1. 4Cysl-SUMO-1 was localized in the nucleus the same as 
the endogenous SUMO-1 as noticed in the IHC staining of anti-SUMO-1 antibody. 
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Under the same spectromicroscopic conditions, IHC staining gives a better resolution 
of SUMO-1 protein localizations. However, it should be taken into considerations that 
Lumio™ staining gives an in vivo picture of SUMO-1 localization as the staining was 
done in live cells. Lumio™ staining can give the dynamic SUMO-1 localization. This 
is particularly useful for investigations of signaling molecules or chemicals which 
might affect SUMO-1 localization with confocal microscopy, live videos of SUMO-1 
trafficking could be taken. This would be a very valuable studying tool for the 
localization of S U M O and its interacting partners as S U M O is regarded as a tag for 
nuclear transport signal for many proteins (Seeler and Dejean, 2003) and S U M O 
substrate localizations are still of great interests nowadays. 
The membrane-permeable quality of LumioTM reagent allow rapid binding to 4Cys 
motif on the target proteins and thus able to detect the nascent protein at the beginning 
of protein synthesis. Its versatility of having two different emission wavelengths by the 
two different dye molecules FlAsH and ReAsH (LumioTM green and red) can allow 
‘ overlapping studies of a single protein by two critical time points (Rudner et al., 2004). 
This was not tested on S U M O investigations and of value being tested in the future. 
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Despite of the advantages, the background problem must be overcome in order to 
improve the potency of the fluorescent staining. This makes the dye unfavourable for 
labelling of non-abundant cellular proteins. Improvements can only be achieved by 
technical modulation of the dye itself as the background largely comes from 
non-specific interactions with endogenous cellular cysteine pairs (Stroffekova et al., 
2001). Current investigations had been aiming at optimization of flanking sequences of 
the 4Cys motif to give a greater affinity to the dye in attempt to eliminate background 
(Martin et al., 2005). Controls are able to discriminate between backgrounds and 
genuine signals at the present time. On the other hand, this technique was more 
technical demanding than usage of other intrinsic fluorescent proteins (eg. GFP). This 
is because application of 2As-4Cys system requires specific tuning of the labeling dye 
concentration, labeling time and the visualization settings for different proteins. 
The performance of 2As-4Cys fluorescent system in visualization of proteins on 
SDS-PAGE gels was accomplished through production of recombinant 
- 4Cysl-SUMO-1 in E.coli. Purification of His6-4Cysl-SUMO-1 was done with the 
same purification scheme as His6-SUM0-1. Approximately 90% of purity has been 
achieved, which implying the tag has less chemical hindrance for the affinity 
chromatographic methods used. LumioTM in-gel labeling kit was used to label 
235 
Chapter III Discussions 
SUMOylated T D G immediately after the reaction and 4Cys 1 -SUMO-1 -TDG conjugate 
could be clearly observed as a fluorescent band corresponding to the shifted band seen 
in Coomassie® staining. S U M O conjugation was not hindered by the addition of the 
tag both sterically and chemically. This made it valuable for the visualization of S U M O 
conjugates in polyacrylamide gel electrophoresis, as an alternative of immunoblotting 
analysis. Lumio™ staining of S U M O conjugates on gels assures an absolute specificity 
on the 4Cys tag as seen from the gels. Post-SUMOylation labeling was of minimal 
amount of work when comparing to immunoblotting which was considered to be a 
more convenient way to immunoblotting. 
However it remains to be a concern for the detection sensitivity of the 2As-4Cys 
system on proteins with low cellular abundance, particularly in our case, the S U M O 
conjugates in cell lysates. When optimizations were going on, a modified version of 
the 4Cys tag has been published (Martin et al., 2005). Construction of 4Cys-tagged 
SUMO-1 was done subsequently with the new version tag F L N C C P G C C M E P (4Cys2). 
‘ The basic properties of SUMO-1 were not critically altered (pi 6.03/Mw 15.07; 
original His6-SUM0-1 pi 6.35/Mw 14.67) when tagging SUMO-1 with 4Cys2. Same 
in vivo investigations applied on 4Cysl were performed with addition of 10 |j,M EDT. 
The background fluorescence observed was drastically minimized with 
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4Cys2-SUMO-l (Fig.3.3.2.3). Fluorescence was not observed in the control while the 
nucleus was appropriately fluoresced green. The resolution of staining has been greatly 
improved due to a reduction of background staining. A longer exposure of the cells was 
allowed with the background staying clean. 4Cys2-SUMO-l can be readily seen in the 
subnulear structures (Fig,3.3.2.4). This is a promising improvement of the fluorescent 
staining system which required null optimizations after adopting a 4Cys tag with new 
tag sequence. 
Further optimizations could be conducted on reducing the toxicity of the dye on the 
living cells. Currently the labeling of cells would not affect cell morphology within 30 
minutes after addition of LumioTM dye. Toxicity arises when oxidation occurs inside 
the cells owing to binding of excess dye to even a scarce amount of cellular dithiol 
cysteine pairs. This was currently reduced when an appropriate concentration of EDT 
was added during the staining. 2-mercaptoethanol was reported to have a better effect 
on reduction of oxidation effects (Langhorst et al., 2005) while on the other hand, a 
‘ rise in pH was observed in the cells which affects the viability. It has been suggested 
that supplementing the cells with 25 m M HEPES pH 7.4 can successfully prevent the 
problem (Lumio™ Datasheet, Invitrogen, 2005). Nonetheless, it should be noted that 
the fluorescent performance of the 2As-4Cys system varies depend upon individual 
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target protein and the cell type. 
The performance of 4Cys2 tag in-gel was accomplished through production of 
4Cys2-SUMO-l protein in E.coli. Purification of His6-4Cys2-SUMO-l was done with 
the same purification scheme as His6-SUM0-1. Approximately 95% of purity has been 
achieved. 4Cys2-SUMO-l was found to give an approximately 8-fold higher 
fluorescent intensity than 4Cysl-SUMO-1 (Fig.3.3.2.7). In the labeling of the 
4Cys2-SUMO-l conjugates in HeLa lysates, 4Cys2 was able to give an observable 
fluorescence with a 30 |xg lysate load. In order to quantify the detection limit of 
4Cys2-SUMO-l on SDS-PAGE gels, a titration of 4Cys2-SUMO-l was done with 
LumioTM labeling and silver staining. Detection limit was found to be at 60 ng 
(3.8 pmole) of 4Cys2-SUMO-l under U V excitation. 
Finally, investigation of application of 2As-4Cys system in 2-DE was carried out. The 
possible chemical interference with the LumioTM labeling system was verified using 
“ purified 4Cys2-SUMO-l protein. It was observed that sample clean-up caused a 
significant drop of fluorescent intensity. This might be due to the nature of acetone 
precipitation was too stringent for the arsenical-thiosulphate bonding to exist. A second 
reason was the removal of salt from the labeling buffer where the complexes were 
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leaded to a dissociation of bonding by undesirable ionic conditions. Therefore the 
sample clean-up for crude cell lysates was done prior to Lumio™ labeling in later 
experiments to avoid the drop of fluorescent intensity. 
In the strip equilibration step between lEF and SDS-PAGE, high concentrations of 
DTT and lAA were a concern to the tag-dye interaction. With original recommended 
concentrations of DTT and lAA in the 2-DE protocol, fluorescence was diminished 
(Fig.3.3.3.3). The data essentially agree with the fact that DTT was a dithiol reagent 
which competes with the cysteine pairs on the tag for the dye molecule and thus 
reducing available tag-dye complex to fluoresce. The similar occurs with lAA, which 
alkylated the cysteines on the tag preventing them from binding to the dye molecule. It 
was shown that a 6-fold decrease of DTT was needed to establish the full potential 
fluorescence while when the same applied to lAA could not retrieve back the 
fluorescence and thus equilibration with 5 mg/ml DTT concentration for 15 min was 
maintained. lAA equilibration was omitted from the protocol without any significant 
' influence to the 2-DE resolution as it was not obligatory in the recommended protocol. 
These alterations were applied to a 2-DE of purified 4Cys2-SUMO-l on 7-cm pH 4-7 
I m m o b i l i n e T M drystrip and the data shown that the 4Cys2-SUMO - l was able t o 
fluoresce under U V excitation. The SUMO-1 spot was positioned at the correct size 
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and pi in the 2-DE gel (Fig.3.3.3.4). This implied that the small amount of LumioTM 
dye added (0.8 jil) has no negative effect on the lEF process, which was a concern 
before the experiment. However, it should be noted that the detection limit of LumioTM 
staining of 4Cys2-SUMO-l after the 2-DE process has significantly dropped from 60 
ng to 500 ng when compared with SDS-PAGE LumioTM staining. It should be partly 
due to the longer processing time of 2-DE which allows the negative effects 
accumulate. 
A LumioTM labeling 2-DE trial of SUMOylated HeLa cell lysate was finally done on 
13-cm pH 3-10 ImmobilineTM drystrip. Gel was scanned by TyphooniM Trio 
fluorescent scanner and by U V excitation respectively. However, no fluorescence has 
been observed. This negative result may imply the system's inefficiency in revealing 
the SUMOylated proteins which are of very low abundance within the cell lysates. 
Therefore, application of this system on proteomic study of SUMOylation may not be 
better than the existing methods like immunoprecipitation and differential 
‘ CoomassieTM stained gel comparison. Since currently the challenge in proteomic study 
of SUMOylation is to find out the proteins with particularly low cellular abundance 
which cannot be detected using conventional methods (Rosas-Acosta et al., 2004). 
With the modified 2-DE protocol however higher quantity of cell lysates can be loaded 
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on the 2-DE gels to accommodate the limit of the fluorescent labeling system as done 
with Coomassie staining. Nevertheless the biarsenical-tetracysteine labeling system 
was tested in our study for its feasibility and competence in SUMOylation research 
work. Apart from its potential use in 2-DE currently cannot be fulfilled, the approach 
introduced here should assist researchers to study SUMOylation in an alternative way 
both in vitro and in vivo. Further studies are worth to be conducted in optimizing its 




Conclusion and Future Perspectives 
4.1 Conclusion on proteomic study of SUMOylation 
The present study aims at identifying potential S U M O interacting partners in 
HPV-positive human cervical carcinoma by comparative proteomics using HeLa cell 
line. This work has been accomplished by two separate parts with the first part aiming 
at identification of potential SUMOylation substrates by in vitro SUMOylation of 
HeLa cell lysate; and the second part aiming at the identification of effector proteins 
downstreaming S U M O upregulation by in vivo overexpression of SUMO-1 in HeLa 
cells. These data serves as a pilot study for further investigations in the role of S U M O 
in cancer and the relationship between SUMOylation and viral infection. 
‘ In the in vitro study on S U M O substrate, 16 proteins were found to differentially 
expressed between the control and in vitro SUMOylated samples and successfully 
identified by P M F through MALDI-TOF MS/MS analysis. These proteins consist of a 
group of stress response proteins: chaperone associated protein (Hsp70, Hsp27 and 
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Stipl), anti-oxidative proteins (DJ-1, TSA and Prdx 1), metabolic related proteins 
(aldolase A, enolase 1, phosphoglycerate mutase 1 and triosephosphate isomerase) and 
cell cycle regulation protein (nm23A). The other categories of protein include an 
oncoprotein (v-crk CTIO), a tumor suppressor protein (annexin I), a virulence related 
protein (cyclophilin A) and an intermediate filament protein (vimentin) (Table 2.4.1.1). 
The results intriguingly suggest that stress proteins are the major SUMOylation targets 
apart from the transcriptional factors which agree with the fact that S U M O has a role 
of cellular damage repair and at the same time damage prevention. In the result, 
proteins with antagonistic functions like oncoproteins and tumor suppressors are found 
which lead to a prediction of the versatility of SUMOylation. S U M O works on nearly 
universal types of proteins and modulates a convergence of cellular effects such as 
achieving cellular repair and protection. In the present study, two proteins were found 
to potentially relate S U M O to H P V infection: nm23A, a prey protein of HPV-16 E7, 
and cyclophilin A which is also a prey protein mediating higher virulence. Further 
verifications need to be done to confirm the S U M O modification of these identified 
‘ proteins. At present, Prdx 1 was confirmed to be a SUMOylation substrate. 
In the in vivo study on S U M O downstream effector proteins, 21 proteins differentially 
expressed upon S U M O overexpression were successfully identified by P M F through 
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MALDI-TOF MS/MS analysis. These proteins included a group of apoptosis-related 
proteins and cell cycle regulators (Hsp 60 and Hsp70, keratin 8 and 17, XIAP-1, ISG15, 
PDZ-RGS3 and 14-3-3a protein). A second group of proteins (actinyl, tubulinP, 
hepatocyte growth factor 4, PR02619 and keratin 1) were reported to be dysregulated 
in cancers in terms of protein level. Others are a calcium stress response protein 
(calreticulin precursor) and a group of proteins with unknown function or relationship 
with cancer (La4.1, carnitine/acylcarnitine translocase, Ub specific protease 11, an 
unnamed protein product and a hypothetical protein) (Table 2.5.1.1). The results lead to 
a few observations on a group of proteins related to apoptosis (Table 2.6.1) in brief: (1) 
upregulation and downregulation of the proteins in cancers were dependent on their 
regulatory effect on apoptosis; (2) overexpression of S U M O upregulated both 
pro-apoptotic and anti-apoptotic proteins, which agree with the results obtained in the 
in vitro study; (3) all of the proteins were involved in NF-KB activity regulation, this 
provided extra evidence on the existing studies for NF-KB to be a mediator between the 
S U M O effector protein and apoptosis; (4) all of the proteins except Hsp60 and ISG15 
- were involved in the regulation of Akt signaling pathway. 
On the other hand, several proteins were found to relate S U M O to viral cancer 
potentially: Hsp70 was another prey protein essential in virus survival in the host; 
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14-3-3a was aberrantly expressed in immortalized keratinocytes, which may relate 
S U M O to the immortalization of cervical cells. Keratin 17 was reported to be a potent 
marker in HPV-positive cervical carcinomas, while ISG15 de-ISGylation was reported 
to have a role of immunity against viral infection. Lastly, a networking effect between 
these proteins can be observed: keratin 17 binds to 14-3-3a and has aberrant effect on 
Akt pathway while 14-3-3o can be modified by ISG15 which possibly has a role in 
favour of maintenance of virus survival. Verification was currently done on keratin 17， 
which confirmed to be upregulated under S U M O overexpression. 
In summary, the proteomic method allowed narrowing down the target proteins for 
more detail investigations. Proteins identified are of important value by providing a 
starting point for further investigations in the relationship between SUMOylation and 
cancer (or HPV-related cancers). 
4,2 Future perspectives ofproteomic study of SUMOylation 
‘ 4.2.1 In vitro study 
Verifications of the proteins as SUMOylation substrates should be performed by in 
vitro SUMOylation and Western analysis. In depth study of the proteins for locating 
their SUMOylation site can be achieved by mutagenesis studies. On the other hand, 
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functional study on the effects resulting from SUMOylation can be achieved by 
examining changes of their activity upon SUMOylation or examining their cellular 
effect through expressing mutant which are defective to be SUMOylated in cells. 
For Prdx 1，further trials of immunoprecipitation will be carried out to confirm its 
SUMOylation in vivo. Since Prdxl is an anti-oxidant enzyme, the biological function 
of its modification can be studied by characterization of its S U M O conjugation upon 
oxidative stress which can be introduced into HeLa cells using H2O2 Results 
obtained would give new insights in the relationship between oxidative stress and 
S U M O . 
4.2.2 In vivo study 
Verifications of the proteins to confirm their differential expression should be carried 
out by performing Western analysis. Further verification can be done by S U M O gene 
silencing using RNAi. In depth study for verifying effect of S U M O upregulation on the 
- NF-KB and Akt pathways can be attained by examining the expression level of NF-KB, 
Akt and their related proteins (Table 2.6.1) through Western analysis. On the other 
hand, the interesting relationship between 14-3-3a, keratin 17 and ISG 15 can be 
investigated by mutagensis studies. 
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For keratin 17，the above suggested investigations can be done. In addition, the m R N A 
level of keratin 17 can be studied by RT-PCR to determine if the up-regulated 
expression is at the m R N A level. 
4.3 Conclusion of the investigation of biarsencial-tetracysteine (2As'4Cys) system 
application on SUMO study 
This study aims at characterize the potential use of 2As-4Cys fluorescent labeling 
system on S U M O study, which relies on specific and precise detection. Tetracysteine 
was a novel fluorescent tag which can be specifically attached to S U M O by molecular 
engineering. Recombinant plasmids pHM6-4Cys-SUMO-1 and 
pET-28m-4Cys-SUMO-1 have been constructed for this purpose. Investigations were 
separated into two strategies: characterization of the performance of in vivo S U M O 
labeling in live cells, and characterization of the performance of in gel S U M O labeling 
in both SDS-PAGE and 2-DE. Two 4Cys tags with different amino acid sequences 
were tested in our study: 4Cysl and 4Cys2. The 4Cysl tag was found to have high 
- background in in-cell staining of S U M O and was unable to tag SUMO-conjugated 
protein from cell lysate on SDS-PAGE analysis. Efforts have been put in the adoption 
of 4Cys2 upon its release. The performance of 4Cysl was excelled by 4Cys2 in both 
the in cell labeling and in gel labeling of S U M O . 
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In the in cell staining of S U M O , background has been significantly reduced with 
4Cys2, while it could only label total protein at a marginal level even with the addition 
of E D T during staining. However, there were drawbacks with the tag, like cytotoxicity 
and extensive technical optimization compared to the use of intrinsic fluorescent 
proteins like GFP. However it remains to be a valuable tool of studying S U M O 
localization in live cells, which cannot be achieved with ordinary IHC staining. The 
tag's small size was crucial and ideal for S U M O labeling than GFP which is 2-fold 
larger than the S U M O protein, and would possibly pose undesirable steric hindrance 
on its protein interactions. 
In the in gel staining of S U M O , labeling of S U M O conjugates with 4Cys2 was found 
to be successful after in vitro SUMOylation of both T D G and HeLa cell lysate on 
SDS-PAGE gels. The detection limit of purified 4Cys2-SUMO was determined to be 
60 ng. Finally, modifications on 2-DE protocol were performed, the results indicated 
that both D T T and lAA hampered Lumio® labelling，and sample clean-up was 
- unfavorable for the dye-tag binding. According to the results, D T T concentration 
reduced to 3 mg/ml and omission of lAA in the equilibration step are necessary. On the 
other hand, sample clean-up, if required, have to carried out before Lumio® labelling. 
Though several key parameters were optimized, the result of labeling was not 
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satisfactory as the detection limit of purified 4Cys2-SUMO was impaired to 500 ng in 
the 2-DE. An attempt of labeling in vitro SUMOylation HeLa lysate on a 13-cm strip 
gave no fluorescence even with a fluorescent scanner TyphoonTM Trio. 
In conclusion, this present work successfully characterized the potential use of 
2As-4Cys system on the study of S U M O . Apart from its use in 2-DE currently cannot 
be fulfilled, the approach introduced in this report is of special value to assist 
researchers to study SUMOylation in an alternative way both in vitro and in vivo. 
4.4 Future perspectives of the application of 2As-4Cys system application on 
SUMO study 
4.4.1 In cell study 
As the background problem has significantly improved after the adoption of 4Cys2, 
further optimizations could be carried out on reducing the toxicity of Lumio⑧ dye on 
the living cells. 2-mercaptoethanol has been reported to reduce the oxidation effects 
‘ caused by the dye and this can be tried. Supplement of 25 m M HEPES pH7.4 to the 
cells will be added to the protocol in order to antagonize a rise of pH resulted after 
addition of Lumio® dye to raise the cell viability. 
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4.4.2 In gel study 
The fluorescent intensity given by the 2As-4Cys system is dependent of the tag's 
architecture, which can potentially generate a higher affinity for the dye molecule than 
the non-specific cellular cysteine pairs. Optimizations of this chemical nature would 
not be carried out in our study. Nonetheless, higher quantity of cell lysates can be 
loaded in 2-DE experiments to compensate the detection limit of 2-DE Lumio® 
labeling. Finally, further optimizations on the 2-DE protocol can be explored to further 
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" HiyTao .jMttftI,,, ..^^..！., T>T趙�
TA7M:C:fcTGSGCftGCftGCCA7CATCATCATCA7CACAGCAGCGGCCTGGTGC£iGCSCGGCAGCCA•； ATGGCTAGC/rrGAC�了 GGTGGfeCASC/U 
rets lySerSerHiSh tan�！ah ^aHiaHia5»rS»rGlvL»uValProAr|GlySoi'HnratAlo5«rrofrhrGlYGI)fGI'\£U 
丨 tlironibwi 
a t f ^ I HMIM Noti Xhoi msi^UQ XTCCCTCCCCCiJixCMTlCGACClCCCTCCMrAACtTTCCCCCtrifCJ^nCCACCACCACCJlCCACCACCXCTCACJaCCCCCTCnAMrAUlCCCC pei-2la(-| 
KetC lylkrgC iy l^ er 8 luf^ hoG iuLtfwAr l^r9G} nAi oCfdC t yAr^ TKr ArQAI oPt^ oProPtroPz-oProLeuAr-gSerG I yCy-ftCnd ..GG7LGGS*TLCGfcmCGAGCTCCQlCS*CAAGCTTGCGGtCGCACTCG4GCfcCCACCACCACCACCAt7GAGATCC6GCTGCT*ACAAfcGCCC~pEwebTT 
...C ly&rg^^&pProfr&n^er^ er^ er'VolAiipLysLtuAi cAicAtoLttuGluHi sHi aHi shi aHi shi stnd 
RfrrrPr^fcTCrPAATTCGAfSCtCrGTCGACAACrrTrXfiGCtGCiCTCGASCACCACtACf ACCACfACTGARATCCGRrTCCTiACtJtASrCC pTI-PRcl-l 
C loftfQl loA-ofc lnProS»rThrfi»ri lull ^Argl�籐ul y P r o 
flP"贈 I TTtennwator 
0AA*GG(iAGCTG«i67TGGC-GC^GCCACCGCTGAGC<i*TA*CT*CC*TA«CCCTTGGG6CClCT*MCGG67CT7G*GQ6GTTT7nG 
1/ temlrtMx unrrwmWUSjy-a 
pET.28a-c(+) cloning/expression region 
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(b) Vector map and MCS of pHM6 
Comimnts tor pHMC, 5442 nucl»otides 
C MV promotof: bases 20«-863 
T7 prcMix)ter/ixlining siiD： bases 663-^ 82 
ATG initiation codoi： bases 901-903 
HA opitopo tag： bases 904-930 
Muttiple cloning site: bases 931-975 
Poly(His) epitope tag； bases. 976-993 
Sp6 promoter/priming ate： bases 1002-1024 
BGH pofyadcny!tilk)n signal： bases 1043-1257 
n origin； basos 1320-1730 
SV40 pronioifir and Ofigin: Iwsos 1794-2119 
Neoinycin-re5tstai>ce g^w. 2153-2950 
SV40 polyadeitylatton signal： bases 2967-3205 
ColEI origin； bases 3633-4304 
Ampicillin-resiswncG gene; basos 4447-5308 
I 
5 i� 各 著 § i 4 S ^SP6 
/ MammaHan ^ L 
m Expression Victors 
i - J 
pHM6 HA Wirtdlll Kpnl top I fcoRI Not� tor PI M � 
" ATG TAC C C A T A C G A C G T C C C A G A C TAC GCT GGA AGC TTG GOT ACC TCC GCG GAG AAT TCG CGG CCG CTA CAC GTG CAT C A T C A T C A T C A T CAT TAA 
Met Tyr Pro Tyr Asp Val Pro A%p Tyr Aln Gl> S« Leu Gty Tlir Su Alo Gu A川 Ser A r g Pro Leu Hii. Vol Hn Hi t H h Hh Hit HK … 
pMH Hind III KunI Ksf>\ fco Rl BUP\ HA 
CCA AGC TTG GGT ACC TCC GCG GAG AAT TCG CGG CCG CTA CAC GTG TAC C C A T A C GAC GTC C C A GAC TAC GCT TAA 
Pro Sef Leu Gly Tin Scf Aki Glu Asn S « Aig Pro Leu His Val Tyr Pro Tyr Asp Val Pro Asp Tyr A U *" 
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(c) Vector information of pTwo-E 
pTWO Vectors 
• Mjn>m6f HiiG ug, PreScission cie«vdt>ie 
‘pTVVO-g (I>»5e0 on DET-}7b, expression in E-coti) 
• pTWO-B (based on pPASTBAC-l, expression ir. Bacuiovlrus) 
• Untried mwlti|>i« dor、‘ng site 
• r .mpicltir* nsslstance 
• Clone at either tfte Nde or NheJ slt«« plus your choice of 3' (-» yo j r own ?’rop codo"iO 
PreSdssion cleavage leaves 3 amino «dds If donmg at fideJ site {Gph..,) 
pTWO^i multiple cloning site 
‘Please note: if you wtsh to aubcione from pTWO-E uv.o pTWO-8, the EcoRV site cannot t>e 
used »$ It ii (iupiicatcd efsewncre m vector. 
HyU I 
At^ TL'ACTATJUPQSACi/VCCACAACiaCTTTCrt:�：<.•'rAGAWlTAATTTTCTTTAACrrrAACAAGCyUJJvTATACATAAaAl? 
H t! H H B H H X, t V L F C C P jH M k S ‘ 
Hir»dm Kpiftl 8HUBHI SJVJI BCORI tCM^ V 
Not! XJiol 
ckTCAC:ACTGGCOt3CCCCrT^‘C;Abc/^ TtCGp?SJOCT|w«|jUWliGCcijCy^ ««;^ flt\«lCTGAGTTCC5CTCCTCCCACCGC 
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3. Primers used in this study 
Forward primers 
For SUMO-1 with BamHl 
BamH\ 
5'-GGT CGC G G A T C C ATG TCT GAC CAG GAG GCAAAACCT-3 ' 
SUMO-1 
For SUMO-1 with Kpnl 
Kpnl 
5'-AGC TTG G G T A C C ATG TCT GAC CAG GAG GCAAAACCT-3 ' 
S U M O - I 
For 4Cysl-SUMO-l with Ndel 
Nde\ 4Cys1 
5'-GGC AGC CAT ATG GCAAGA GAA GAT TGC TGC CCA GGA TGC TGC GCAAGA CGT 
ATG TCT GAC CAG GAG GCAAAACCT-3 ' 
SUMO-1 
For 4Cysl-SUMO-l with Hindlll 
Hind\\\ 4CysJ 
‘ 5'-GCT GGA AGC TTG GCA AG A GAA GAT TGC TGC CCA GGA TGC TGC GCA AG A CGT 





For SUMO-1 and 4Cysl-SUMO-1 with Notl 
Notl SUMO-1 




4. Nikon TE2000 filter sets spectrums 
(a) FITC/GFP filter set 
丨 I • 
J j� ； _ _ J •_ _ • I� ； _ ^^ ^^ ^^  I •••I� 丨丨，I，�
TTPT「厂 T^^T^厂f n — T — — — 
：：嚷 r p 着 I i I i�；�
40 ——— V~ 4 I I ~ ^ j - — 一 一 - t r 
3。 , — — 一 V — I — • • — … — — — 一 一 … — ‘ — 
“ 1 丨� 1� 丨� 丨� ；�：�
1:1 & I I L 0 0 0 0 0 0 0 -d- \o ^ 
W a v e l e n g t h ( n m ) 
Legend: blue - exciter, green - dichroic, red - emitter. 
(Spectrum from Chroma Ltd., MlOOl) 
(b) RFP filter set 
100 I j 
::：丄：：R—:…:.: 
I j I I 
70 i h \ 
“ V — h A ^ f[ l i T i Z I ] — 1—— . ..1 / 1. -..「 
50 — —• — ^ ~ " I I j | - — f ' { i -
40 - ."j^ - - ^ \ ••••'•' —• J- 4- t- - • - .r 
21 Y 1 Y I� 二 : J ‘ 
- 2。一 ||7"" j v i “ ^ . . 厂 - - - 1 ]... . -. .I. -. .1.「.... 
"LU_/lilii AAi \ T T A I 
O o O o 
1? S s S 
W a v e l e n g t h ( n m ) 
Legend: blue - exciter, green — dichroic, red — emitter. 
(Spectrum from Chroma Ltd., M1043) 
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(c) UV/DAPI/Hoechst filter set 
100�丨 ， j ~ 
！ 90 . L... / i� ：�
30 1 / ,. . -
1 I —— ^ i. i.… _• 
/ • [ “ r.� 卞- j- -
卜 50 乂— - V J ‘ I - "H [-—— 4 
4。厂\ / Y — j - —� 一 十 - ‘ —— 
：：善：L\�判;^：^^ 
恼 " T 3/. - I�本…i� -丄4： L . 
^ i ° 1 
Wavelength (nm) 
Legend: blue — exciter, green - dichroic, red — emitter. 
(Spectrum from Chroma Ltd., #31000v2) 
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5. Akt signalling pathway diagram 
Akt/PKB Signaling 
BCR 
•、RTK ••yntoflrin •^^StU� 份�
严 / V / \ \ \ 
cA Coll， 、JNk* Cardtovasculaf Synt»i««« qJ^ Survival Pathway Homaostasis 
I III I I ••• • Ml II I I I I ••••••••__IM_ •• —ll-.l. ••••• ••丨•••• l _ . •• _, • , •l..ll I I ••• 
0 Knase • Dved Stnxiatory Ibtodtficabon 1 > Transonptcnal S&nrUabon 
Q Phocphatase 1 Dved IrhMory Modificatim I | Transcnpdonai Inhbction 
0 Tranccnplion Factor ——•——• MultKtep Stirrxiatory Mod4lca»on • TranskxaOon 
——•~I lkybtiepkihbilDryMo(A6caton ；^；；^ Separau^nofStAninrtsorCteavagePioducts 
• Tentaive SomUatery McxMcaton 、 
-I TentabvehhbtoryMcxMcaton ^� 一 Jomgof S^iunits 
(Adopted from Cell Signalling Technology®, 
http://www. cellsignaL com/pathways/akt'signalingjsp) 
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6. DNA sequence of SUMOs and 4Cys2 oligonucleotide 
SUMO-1 
A T G T C T G A C C A G G A G G C A A A A C C T T C A A C T G A G G A C T T G G G G G A T A A G A A 
G G A A G G T G A A T A T A T T A A A C T C A A A G T C A T T G G A C A G G A T A G C A G T G A G A T 
T C A C T T C A A A G T G A A A A T G A C A A C A C A T C T C A A G A A A C T C A A A G A A T C A T A 
C T G T C A A A G A C A G G G T G T T C C A A T G A A T T C A C T C A G G T T T C T C T T T G A G G G 
T C A G A G A A T T G C T G A T A A T C A T A C T C C A A A A G A A C T G G G A A T G G A G G A A G 
A A G A T G T G A T T G A A G T T T A T C A G G A A C A A A C G G G G G G T 
SUMO-2 
A T G G C C G A C G A A A A G C C C A A G G A A G G A G T C A A G A C T G A G A A C A A C G A T C 
A T A T T A A T T T G A A G G T G G C G G G G C A G G A T G G T T C T G T G G T G C A G T T T A A G 
A T T A A G A G G C A T A C A C C A C T T A G T A A A C T A A T G A A A G C C T A T T G T G A A C G 
A C A G G G A T T G T C A A T G A G G C A G A T C A G A T T C C G A T T T G A C G G G C A A C C A A 
T C A A T G A A A C A G A C A C A C C T G C A C A G T T G G A A A T G G A G G A T G A A G A T A C 
A A T T G A T G T G T T C C A A C A G C A G A C G G G A G G T 
SUMO-3 
A T G T C C G A G G A G A A G C C C A A G G A G G G T G T G A A G A C A G A G A A T G A C C A C A 
T C A A C C T G A A G G T G G C C G G G C A G G A C G G C T C C G T G G T G C A G T T C A A G A T C 
A A G A G G C A C A C G C C G C T G A G C A A G C T G A T G A A G G C C T A C T G C G A G A G G C 
A G G G C T T G T C A A T G A G G C A G A T C A G A T T C A G G T T C G A C G G G C A G C C A A T C 
A A T G A A A C T G A C A C T C C A G C A C A G C T G G A G A T G G A G G A C G A G G A C A C C A 
T C G A C G T G T T C C A G C A G C A G A C G G A G G T 
4Cvs2 oligonucleotide 
A G C T T G T T C C T G A A C T G T T G T C C C G G C T G C T G C A T G G A G C C T G G A T C C 
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7. Electrophoresis markers 
SeeBlue Plus Pre-Stained Standard, Invitrogen (Cat#LC5925) 
Apparent molecular weights of SeeBlue' 
Plus2 Pre-Stained Standard on a NuPAGE" 
Novex 4-12% Bis-Tiis Gel w/MES 
kDa Proiein; 
\m Myosin 
98 Phosiiborylise B 
62 BSA 
.� Clutjimic dehydmgennfe 
.讲 Alcutu)! dehytliogtMiajie 
Carbaiiic anhydiasf 
17 mmm MyoglohinRe<i 
14 mmmm l.ysuzyilk. 
6 Aproliiiin 
^ insulin B chain 
Portman lOObp D N A ladder, Portman (Cat# DLIOO) 
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